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Abstract 
 
The creation of new molecules useful for therapeutic applications is 
necessary for the screening of large compound libraries, in order to identify 
molecular structures to be selected as new lead compounds for biological 
targets. Diversity-Oriented Synthesis (DOS) concept has been placed as 
new paradigm for the improvement of molecular diversity in the same 
synthetic process, which combines the generation of a functionalized 
precursor with further synthetic elaborations, in order to obtain diverse 
cyclic molecule and variably decorated.  
The aim of this thesis is to apply the principles of the DOS to obtain 
densely functionalized molecular scaffolds from simple building blocks like 
sugars and amino acids derivatives.  
The investigation of the structural diversification of BTAa scaffolds, 
synthesized from tartaric acid and amino acids derivatives, has led to a new 
class of spiro-β-lactams via Staudinger reaction, useful for medicinal 
chemistrya (Scheme 1). The reactivity of L-Ascorbic acid derivatives with 
Glycine acetale, to give a new α-amino acid bicyclic scaffold, Proline 
analogue,b has been then explored (Figure 1). 
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Scheme 1      Figure 1 
 
Secondary cyclic amino acids and in particular morpholine ring have an 
important role in medicinal chemistry. We moved towards a DOS 
approach to generate morpholine scaffolds starting from enantiopure 
compounds like L-Ascorbic acid and amino acids derivatives (Scheme 2). 
The acyclic densely functionalized template gave the 1st generation of 
morpholine scaffolds in which is included the Proline bicyclic analogue of 
above (Scheme 3). 
 
                  
 
 
 
 
 
a A . Trabocchi, C. Lalli, F. Guarna, A. Guarna Eur. J. Org. Chem. 2007, 16, 4594-4599. 
b C. Lalli, A. Trabocchi, F. Guarna, C. Mannino, A. Guarna Synthesis 2006, 18, 3122. 
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Lactone aminolysis using LiNTf2  as catalyst (see below) gave the 2
nd 
generation. Functional-group-pairing reactions allowed to obtain molecules 
of 3rd generationc (Scheme 4).  
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During the development of the 2nd generation we were interested in finding 
an efficient method for synthesizing molecules through the aminolysis of 
lactones. 
 
 
 
 
c A. Guarna, A. Trabocchi, G. Menchi, C. Lalli, F. Sladojevich, N. Cini Heterocyclic compounds containing the 
morpholine nucleus their preparation and use. WO2008/129004, October 30th 2008. 
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In this contest an aminolysis of lactones process, LiNTf2-catalyzed,
d with 
stoichiometric quantities of amine, was developed (Scheme 5). 
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Scheme 5 
 
Multicomponent reactions are another powerful process to obtain diversity 
and complexity in a rapid way. They allow to combine in only one synthetic 
operation at least three elements to give densely functionalized products. In 
the context of a collaboration program with Dr. Jieping Zhu from ICSN, 
CNRS of Gif-sur-Yvette (France), a new four-component reaction has 
been developed for the synthesis of heterocyclic scaffolds oxa-bridged, 
with four points of diversity, useful for medicinal chemistry (Scheme 6). 
 
 
 
       
Scheme 6 
 
 
 
 
 
 
 
 
 
d C. Lalli, A. Trabocchi, G. Menchi, A. Guarna Synlett 2008, 2, 189-192. 
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Peptidomimetics and Diversity-
Oriented Synthesis 
 
The creation of new molecules useful for therapeutic applications is 
necessary for the screening of large compound libraries, in order to identify 
molecular structures to be successively selected as new lead compounds 
with respect to biological targets. Modern methods for stereoselective 
organic synthesis have increased the efficiency with which small molecules 
can be prepared.1 During last years organic synthesis has taken advantage of 
solid-phase synthetic techniques,2 as demonstrated by the high number of 
papers and patents in the field. Solid phase organic synthesis increases 
dramatically the diversity and number of small molecules available for 
medical and biological applications and it has provided to synthesize not 
only single target compounds but also collections of structurally 
differentiated compounds.  Differently decorated heterocyclic compounds 
and functionalizable with reactive groups for immobilization on solid 
supports are very useful for this new kind of synthetic strategy. During last 
decade, drug discovery focused on the generation of combinatorial libraries 
of ad hoc designed molecules. Unfortunately, most common synthetic 
methods in combinatorial chemistry are based on the generation of libraries 
through simple functionalization of a given molecule, often of cyclic or 
polycyclic nature, thus limiting the achievement of molecules carriers of 
high molecular diversity within the same synthetic process. More recently 
the concept of Diversity-Oriented Synthesis3 has been placed as a new 
paradigm for the improvement of molecular diversity in the same synthetic 
process, which combines the generation of a densely functionalized 
                                                                        
1 P. S. Farmer in Drug Design (Ed.: E. J. Ariens), Academic Press, New York, 1980, 119–143 
2 (a) R. B. Merrifield, J. Am. Chem. Soc. 1963, 85, 2149. (b) C. C. Leznoff and J. Y. Wong, Can. J. 
Chem. 1972, 50, 2892. (c) F. Camps, J. Castells, M. J. Ferrando, J. Font, Tetrahedron Lett. 1971, 12, 
1713. (d) F. Camps, J. Castells, J. Pi, An. Quim. 1974, 70, 848. (e) A. Patchornik and M. A. Kraus, J. 
Am. Chem. Soc. 1970, 92, 7857. (f) J. I. Crowley and H. Rapoport, J. Am. Chem. Soc. 1970, 92, 6363. (g) 
V. Yedida and C. C. Leznoff, Can. J. Chem. 1980, 58, 1140. 
3 Schreiber, S.L. Science 2000, 287, 1964-1968. 
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precursor with further synthetic elaborations, in order to obtain a large 
array both of diverse cyclic molecules and variably decorated with 
functional groups. 
 
 
 
1.1. Peptidomimetics 
 
During the last three decades a huge number of biologically active peptides 
has been discovered and characterized. As a consequence of interaction with 
their membrane-bound receptors, these peptides acting as hormones, 
neurotransmitters and neuromodulators influence cell-cell communication and 
control a series of vital functions such as metabolism, immune defense, 
digestion, respiration, behavior. Many physiological processes are governed by 
protein-protein interactions, thus peptides are of special interest as targets in 
drug discovery and in the biomedical field, and the number of native and 
modified peptides used as therapeutics is ever increasing. Many bioactive 
peptides have been prepared in large scale and tested both in pharmacology and 
clinic, thus allowing the development of new therapies for a variety of 
pathologies. However, the use of peptides as therapeutics is limited due to 
several factors:4 low metabolic stability towards proteolysis, poor absorption 
after oral ingestion, rapid excretion, undesired effects caused by potential 
interaction of relatively flexible peptides with several receptors. Besides all these 
drawbacks, biomedical research is now oriented towards the development of 
peptidomimetics.5 In this approach peptides and proteins are considered as leads 
for the discovery of other classes of compounds, more than potential 
therapeutics.   
Peptidomimetics are small molecules having the same structural or functional 
features of the native peptides, such that they bind to enzymes or receptors 
with higher affinity than starting peptide. During last years peptidomimetics 
have shown great interest both in organic and medicinal chemistry. They are 
more selective and efficient than native peptides, they show greater oral 
bioavailability and biological activity is prolonged due to lower enzymatic 
degradation.6 
The discovery of new peptidomimetics is crucial, as peptides are not 
‘optimal drugs’ due to low metabolic stability, low oral bioavailability, high 
flexibility resulting in poor selectivity and difficulty in reaching the target. 
                                                                        
4 A. Giannis, T. Kolter, Angew. Chem. Int. Ed. Engl. 1993, 32, 1244-1267. 
5 J. Gante, Angew. Chem. Int. Ed. Engl. 1994, 33, 1699-1720. 
6 (a) R.M.J. Liskamp Recl. Trav. Chim. Pays-Bas 1994, 113, 1. (b) G.L. Olson, D. R. Bolin, M. P. 
Bonner, M. Bös, C. M. Cook, D. C. Fry, B. J. Graves, M. Hatada, D. E. Hill, M. Kahn, V. S. 
Madison, V.K. Rusiecki, R. Sarabu, J Sepinwall, G. P. Vincent, M. E. Voss J. Med. Chem. 1993, 36, 
3039-3049. 
I n t r o d u c t i o n  
 
 
 3
The generation of peptidomimetics is basically focused on the knowledge 
of electronic and conformational features of the native peptide and its 
receptor or active site of an enzyme. Peptidomimetics may be subdivided 
into three classes depending on their structural and functional 
characteristics: 
1. Structural mimetics or type I mimetics: these compounds show an 
analogy of a local topography with the native substrate, and they 
carry all the functionalities responsible of the interaction with an 
enzyme or a receptor in a well-defined spatial orientation.  
2. Functional mimetics or type II mimetics: in these molecules the 
analogy with the native compound is based on the interaction with 
the target receptor or enzyme, without apparent structural 
analogies. 
3. Structural-functional mimetics or type III mimetics: an example is a 
scaffold having a structure different from the substrate, in which all 
the functional groups needed for biological interactions are 
mounted in a well-defined spatial orientation. 
 
 
 
1.2. From Target-Oriented 
Synthesis (TOS) to Diversity-
Oriented Synthesis (DOS) 
 
Synthetic organic chemistry aims to gain access to small molecules for 
medical and biological applications using three general approaches.  
 
The first approach uses Target-Oriented Synthesis (TOS). Target-
oriented synthesis has a long history in organic chemistry. The targets are 
natural products or drugs. Natural compounds can be identified in screens 
of extract mixtures, isolated, and then structurally characterized. Once the 
structure has been identified, it can become a target for chemical synthesis. 
Beginning in 1960s, a systematic method to plan syntheses of target 
molecules, named retrosynthetic analysis, was devised.7 Synthetic pathways 
in TOS are linear and convergent, and they are planned in the reverse-
synthetic direction by using retrosynthetic planning, which aims to move in 
the direction of complex → simple  (Figure 1.1). 
                                                                        
7 (a) E. J. Corey, X.-M. Cheng The Logic of Chemical Synthesis (Wiley, New York, 1989). (b) E. J. Corey 
Angew. Chem. 1991, 103, 469. (c) E. J. Corey Angew. Chem. Int. Ed. Engl. 1991, 30, 455  (Nobel 
Lecture). (d) E. J. Corey Pure. Appl. Chem. 1967, 14, 19. (e) E. J. Corey, W. T. Wipke Science 1969, 166, 
178. (f) E. J. Corey Q. Rev. Chem. Soc. 1971, 25, 455. 
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Retrosynthetic analysis has been used in the synthetic planning of many 
target compounds of value in medicine and biology. It is also used in solid 
phase synthesis, in particular in the synthesis of ‘focused libraries’.8 
 
 
 
 
Figure 1.1. Beginning with a complex target the analysis leads to the 
identification of simple starting materials.9 
 
 
The second approach uses either combinatorial chemistry. The 
instrument of combinatorial chemistry is the solid phase synthesis and it 
has become largely used only in recent years.10 Solid phase syntheses have 
been performed in parallel, so similar reactions are performed, but the 
structures of the building blocks in key fragment-coupling steps are varied. 
Solid phase, parallel synthesis is an example of what is commonly referred 
to as combinatorial synthesis and is most commonly used to synthesize a 
focused library. A second variation of solid phase synthesis is the split-and-
pool strategy of synthesis.11 The aim in medicinal and combinatorial 
chemistry is to access diversity to some degree, and usually involves 
synthesizing analogues of a given target structure. This can be 
accomplished efficiently using a solid-phase synthesis approach to append 
different sets of building blocks to a common molecular skeleton.12 If this 
common skeleton contains multiple reactive sites with potential for 
orthogonal functionalization, the powerful technique of split-pool synthesis 
can be used to access all possible combinations of building blocks 
efficiently. 
 
 
The third approach uses Diversity-Oriented Synthesis (DOS). 
Diversity-Oriented Synthesis is not aimed at one particular target, and 
retrosynthetic analysis can therefore not be applied directly. It is instead 
                                                                        
8 (a) P. H. H. Hermkens, H. C. J. Ottenheijm, D. Rees Tetrahedron 1996, 52, 4527. (b) R. E. Dolle, K. 
H. Nelson Jr. J. Combinatorial Chem. 1999, 1, 235. 
9 D. A. Evans, J. V. Nelson J. Am. Chem. Soc. 1980, 102, 774. 
10 (a) B. A. Bunin, J. A. Ellman J. Am. Chem. Soc. 1992, 114, 10997. (b) R. J. Simon et al., Proc. Natl. 
Acad. Sci. U.S.A. 1992, 89, 9367. (c) S. H. DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6909. 
11 (a) R. A. Houghten et al., Nature 1991, 354, 84. (b) K. S. Lam et al., Nature 1991, 354, 82. 
12 (a) R. E. Dolle, J. Comb. Chem. 2000, 2, 383. (b) R. E. Dolle J. Comb. Chem. 2001, 3, 477. (c) R. E. 
Dolle J. Comb. Chem. 2002, 4, 369. 
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aimed at a collection of many compounds having structural complexity and 
diversity. In DOS, where the structural complexity of the individual 
compounds and the structural diversity of the overall collection are 
maximized, synthesis pathways are branched and divergent, and they are 
planned in the forward-synthetic direction by using forward-synthetic 
analysis (Figure 1.2). 
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Figure 1.2.  Beginning with a simple building block, the analysis provides a 
synthetic pathway leading to a large collection of structurally complex and 
diverse compounds.13 
 
 
 
1.3. Diversity-Oriented 
Synthesis (DOS): principles 
 
Forward-synthetic planning aims to move in the direction of simple 
and similar → complex and diverse. Complexity is important because many 
biological processes are critically dependent on protein-protein interactions, 
and many small molecules are able to disrupt these interactions. The basic 
subunit of forward-synthetic planning is the transformation of a collection 
of substrates into a collection of products by performing a number of 
chemical reactions together in the forward-synthetic direction. The key 
element is the  chemical reactivity common to a collection of compounds 
that makes them all potential substrates for the same reaction. When a 
diversity-oriented synthesis is planned, complexity-generating reactions are 
most valuable for accessing complexity in an efficient manner. Moreover, 
identification of pairwise relationships, where the product of one 
complexity-generating reaction is the substrate for another, can lead to 
highly complex products with just a few synthetic steps (3-5 steps). An 
                                                                        
13 D. S. Tan, M. A. Foley, M. D. Shair, S. L. Schreiber J. Am. Chem. Soc. 1998, 120, 8565. 
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example of the application of these concepts is reported in Scheme 1.1.14 
The Ugi four-component coupling reaction can be used to assemble a 
complex product from simple starting materials in a single step. If those 
simple starting materials are selected to include both a diene and a 
dienophile, then the product of this first complexity-generating reaction is a 
substrate for another, namely an intramolecular Diels–Alder reaction. After 
bisallylation an additional complexity-generating reaction, namely a ring-
opening/ring-closing metathesis can generate a highly complex polycyclic 
molecular skeleton.  
 
NH2
O
CHO
CN
HO2C
O
H
N Ar
N
OHN
O
O
NH
O
Ar
O N
O
HN
O
HN O
Ar
KHMDS
Br
O N
O
N
O
N O
Ar
N N MesMes
Ru
Cl
Cl
PCy3
Ph N
O
N
O
O
N
O
Ar  
 
Scheme 1.1. Three-step synthesis of a complex polycyclic ring system using 
complexity-generating reactions. 
 
In DOS, where there is not a target structure, the problem of diversity is 
subdivided into three diversity elements: appendages, stereochemistry and 
molecular skeletons.15 
  
• Appendage Diversity 
The simplest diversity-generating process involves the use of coupling 
reactions to attach different appendages to a common molecular skeleton. 
It’s a complexity-generating reaction to yield a single, complex molecular 
skeleton having several attachment points followed by a series of diversity-
generating appending processes to attach all possible combinations of 
building blocks to this common skeleton. This one-synthesis/one-skeleton 
                                                                        
14 (a) K. Paulvannan, Tetrahedron Lett. 1999, 40, 1851. (b) D. Lee, J.K. Sello, S. L. Schreiber, Org. Lett. 
2000, 2, 709. 
15 S. L. Schreiber, M. D. Burke Angew. Chem. Int. Ed. 2004, 43, 46-58. 
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approach is general and capable of generating hundreds, thousands, or even 
millions of distinct small molecules in just three to five steps.  
An interesting example is a complexity-generating, consecutive 
transesterification–cycloaddition reaction used to generate, in one step, the 
tetracyclic skeleton (i) with suitable functional groups for further 
elaboration through a series of diversity-generating appending processes.13 
A Sonogashira coupling reaction was first used to append a diverse 
collection of alkyne building blocks (BB1) to the iodoaryl moiety of (i) to 
generate the collection of more diverse products (ii). These products have a 
common electrophilic lactone moiety so they are substrates for another 
appending process, an amine-mediated lactone-opening reaction that 
generated a collection of new products (iii). They all share a common 
nucleophilic secondary hydroxy group, thus making them all substrates for 
a third appending process, the coupling with a collection of carboxylic acid 
building blocks (BB3). This generate the complete matrix of building blocks 
(iv) in a highly efficient manner (Scheme 1.2). 
 
 
 
Scheme 1.2. Complexity-generating synthesis of compounds derived from 
Shikimic Acid. 
 
• Stereochemical Diversity 
Stereochemical diversity increases the number of relative orientations of 
potential macromolecule-interacting elements in small molecules. It can 
best be achieved by using stereospecific reactions that proceed with 
enantio- or diastereoselectivity. Since diversity-generating processes involve 
the transformation of a collection of substrates into a collection of 
products, it is critical that the processes used to generate new stereogenic 
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centers are both selective and general.16 The collective transformation of 
chiral substrates into products having increased stereochemical diversity 
requires powerful reagents that can override substrate bias and deliver 
diastereomeric products with very high selectivity.17 
 
• Skeletal Diversity 
There are two different strategies for planning DOS pathways that generate 
skeletal diversity.  
The first strategy, using different reagents, transform a common substrate 
with the potential for diverse reactivity into a collection of products having 
distinct molecular skeletons (Figure 1.3 A).18  
In the second strategy diverse skeletons of small molecules can be accessed 
by transforming a collection of substrates having different appendages that 
pre-encode skeletal information (called σ elements) into a collection of 
products having distinct molecular skeletons using common reaction 
conditions (Figure 1.3 B).19  
 
 
 
Figure 1.3 A and B. Two general approaches for planning synthesis 
pathways that generate skeletal diversity. 
 
 
 
 
 
 
                                                                        
16 (a) W. S. Knowles, M. J. Sabacky Chem. Commun. 1968, 1445. (b) T. P. Dang, H. B. Kagan Chem. 
Commun. 1971, 481. (c) W. S. Knowles, M. J. Sabacky, B. D. Vineyard, D. J. Weinkauff J. Am. Chem. 
Soc. 1975, 97, 2567. 
17 (a) K. B. Sharpless Chem. Scr. 1985, 25, 71. (b) S. Masamune, W. Choy, J. S. Petersen, L. R. Sita 
Angew. Chem. 1985, 97, 1. (c) S. Masamune, W. Choy, J. S. Petersen, L. R. Sita Angew. Chem. Int. Ed. 
Engl. 1985, 24, 1. (d) S. Y. Ko, A.W. M. Lee, S. Masamune, L. A. Reed III, K. B. Sharpless, F. J. 
Walker Science 1983, 220, 949. 
18 D. Lee, J. Sello, S. L. Schreiber J. Am. Chem. Soc. 1999, 121, 10648. 
19 M. D. Burke, E. M. Berger, S. L. Schreiber Science 2003, 302, 613. 
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1.4. The Build/Couple/Pair 
(B/C/P) strategy 
 
Some recent efforts in diversity synthesis provide a systematic and 
general process for obtaining a dense matrix of stereochemically and 
skeletally diverse products in a small number of synthetic transformations. 
This three-phase strategy is called Build/Couple/Pair (B/C/P):20  
• Build: asymmetric synthesis of chiral building blocks containing 
orthogonal sets of functionality for subsequent coupling and 
pairing steps; this process when combined with the ‘Couple’ phase 
provides the basis for stereochemical diversity.  
• Couple: intermolecular coupling reactions without stereochemical 
consequences or with complete control of all possible 
stereochemical outcomes. 
• Pair: intramolecular coupling reactions that join pairwise 
combinations of functional groups incorporated in the ‘build’ phase 
(what Porco and co-workers have termed functional-group-pairing 
reactions21); this process provides the basis for skeletal diversity 
(Figure 1.4). 
 
Couple
Build
coupling functional group
pairing functional group
pairing functional group
functional
group
pairing
Pair
 
 
Figure 1.4. Generation of stereochemical diversity with the 
Build/Couple/Pair strategy. 
 
In the build phase building blocks are synthesized. Chiral building blocks 
can be prepared by using either enantio- and diastereoselective reactions or 
compounds from the ‘chiral pool’. Chiral building blocks ideally are 
                                                                        
20 T. E. Nielsen; S. L. Schreiber Angew. Chem.  Int. Ed. 2008, 47, 48-56. 
21 E. Comer, E. Rohan, L. Deng, J. A. Porco Org. Lett. 2007, 9, 2123 – 2126. 
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synthesized in every possible stereoisomeric form. To minimize the 
number of synthetic steps, functional groups needed for subsequent 
coupling and pairing reactions should be embedded within these building 
blocks, although, additional steps have been performed immediately after 
the coupling process. 
In the couple phase intermolecular coupling reactions are performed, 
which join the building blocks and result in compounds with a dense array 
of functional groups that can undergo intramolecular reactions in distinct 
pairwise combinations.  
In the pair phase intramolecular coupling reactions are performed and 
compounds with diverse skeletons are obtained. For this purpose, the 
power of modern synthesis, especially the functional group preferences of 
different transition metals, can be exploited to achieve a dense 
combinatorial matrix of functional group pairings in the cyclization 
reactions.22 Functional groups used in the subsequent pairing reactions 
should be strategically positioned so as to allow as many ring-closing modes 
as possible. Selective coupling of pairs of functional groups 
(‘chemoselectivity’) in functional-group-pairing reactions may be achieved 
by several different strategies. Three categories of functional group 
couplings are: 
1) polar/polar (amine/ester to form a lactam);  
2) nonpolar/nonpolar (alkene/alkene ring-closing metathesis to generate a 
cycloalkene); 
3) polar/nonpolar (alcohol/alkyne cycloacetalization enabled by 
alkynophilic metal activation).  
In conclusion the B/C/P strategy will yield small molecules with increased 
probability of success in the discovery, optimization, and manufacturing 
phases of drug-discovery research. Public databases that provide access to 
the results of these researchs are expected to provide the means to evaluate 
the performance of compounds from different origins, including from 
pathways by the B/C/P strategy.  
 
                                                                        
22 (a) N. Kumagai,G. Muncipinto, S. L. Schreiber Angew. Chem. 2006, 118, 3717 – 3720. (b) N. 
Kumagai,G. Muncipinto, S. L. Schreiber Angew. Chem. Int. Ed. 2006, 45, 3635 – 3638. 
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Aim of this thesis work 
 
2.1. BTAa, BTS and BTKa:  previous works  
 
During last years our interest in the development of heterocycles and 
constrained amino acids for peptidomimetic chemistry has focused on 
developing heterocyclic scaffolds using amino acids and sugars derivatives 
as building blocks.23 In particular has been developed a new class of 3-aza-
6,8-dioxabicyclo[3.2.1]octane scaffolds named Bicycles from Tartaric acid 
and Amino acids (BTAa). As reported in the first paper about BTAa,24 they 
satisfy all the requirements needed for the development of 
peptidomimetics: 
• easy synthetic procedures in few steps, starting from commercially 
available compounds in both enantiomeric forms 
• stereochemical control in every step 
• high number of functions for molecular diversity 
Successively the synthesis of a BTS scaffold has been achieved, in which a 
polar group is present in position 4, as a consequence of the use of serine 
as amino acid.25 
A new sub-class of BTAa, developed more recently, presents as a common 
feature an aromatic substituent in position 5. These new compounds, 
named Bicycles from Tartaric acid and Keto-amine (BTKa), are obtained 
from the condensation of tartaric acid derivatives and aromatic amino 
ketones.26 In this case the possibility of expanding the diversification is 
                                                                        
23 For an account, see: A. Trabocchi, G. Menchi, F. Guarna, F. Machetti, D. Scarpi, A. Guarna Synlett 
2006, 3, 331-353. 
24 A. Guarna, A. Guidi, F. Machetti, G. Menchi, E. G. Occhiato, D. Scarpi, S. Sisi, A. Trabocchi J. 
Org. Chem. 1999, 64, 7347-7364. 
25 N. Cini, F. Machetti, G. Menchi, E. G. Occhiato, A. Guarna Eur. J.  Org. Chem. 2002, 873-880. 
26 A. Guarna, I. Bucelli, F. Machetti, G. Menchi, E. G. Occhiato, D. Scarpi, A. Trabocchi Tetrahedron  
2002, 58, 9865–9870. 
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given by the high number of aromatic amino ketones, commercially 
available or easy to obtain. 
Recently, we moved from tartaric acid to sugars as building blocks 
for new versatile scaffolds with complete control of the stereochemistry. In 
particular, it was possible to generate new enantiopure bicyclic amino acids, 
such as γ- or δ-amino acids as reverse turn inducers by use of erythrose 
derivatives, and bicyclic Proline mimetics starting from Serine and 
Glyceraldehyde derivatives as reported for the synthesis of α-,27 β-28 and γ/δ 
-amino acids29 as well as tricyclic scaffolds containing the 4-hydroxyproline 
nucleus30 and [4.2.1]- and [5.2.1]-sized heterocyclic analogues31 (Figure 2.1). 
 
 
 
Figure 2.1. New class of 3-aza-6,8-dioxabicyclo[3.2.1]octane scaffolds from 
amino acids and tartaric acid or sugars derivatives. 
 
The keys steps in the synthesis of such BTAa are a coupling of the building 
blocks obtained from the chiral pool, namely an amidation, to give a 
densely functionalized acyclic template and an intramolecular 
transacetalization to give the biclyclic scaffold. In this approach the two 
building blocks react with all their functionalities to give the bicyclic 
structure. Further manipulations on the R group can lead to structural 
diversification, so to new structures. 
Now, what happens if we change approach? Can we imagine just to allow 
only one cyclization, to obtain a morpholine ring? In this new approach not 
all the functionalities would be already implicated in the cycle so that there 
                                                                        
27 (a) A. Trabocchi, N. Cini, G. Menchi, A. Guarna Tetrahedron Lett. 2003, 44, 3489–3492. (b) 
Trabocchi, A.; Menchi, G.; Rolla, M.; Machetti, F.; Bucelli, I.; Guarna, A. Tetrahedron 2003, 59, 5251. 
28 E. Danieli, A. Trabocchi, G. Menchi, A. Guarna Eur. J. Org. Chem. 2005, 4372–4381. 
29 A. Trabocchi, G. Menchi, M. Rolla, F. Machetti, I. Bucelli, A. Guarna Tetrahedron 2003, 59, 5251–
5258. 
30 A. Trabocchi, M. Rolla, G. Menchi, A. Guarna Tetrahedron Lett. 2005, 46, 7813–7816. 
31 (a) D. Scarpi, D. Stranges, A. Trabocchi, A. Guarna Tetrahedron 2006, 7, 1575–1582. (b) D. Scarpi, 
D. Stranges, L. Cecchi, A. Guarna Tetrahedron 2004, 60, 2583–2591. 
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would be space for a more vast investigation of the molecular 
diversification. In particular it would be possible to operate, according to 
the principles of the Diversity-Oriented Synthesis, a skeletal diversification 
obtained with a differentiating pairing process. 
 
 
 
2.2. Topics discussed in this thesis work  
 
Nowadays there is an ever-increasing need for versatile scaffolds to be 
applied in peptidomimetic design. The attempt to satisfy this demand 
produced the previous work and as consequence this thesis work.  
How to prepare collections of molecules with molecular diversity in a rapid 
and efficient way? In this thesis work we will demonstrate that DOS 
chemistry is a powerful concept for the development of new highly diverse 
chemical entities. 
Starting from the background we first explored the structural 
diversification, so we tried to obtain new structures from known ones: the 
investigation of the diversification of BTAa scaffolds has led to a new class 
of spiro-β-lactams useful for medicinal chemistry.  
We explored the reactivity of L-Ascorbic acid derivatives with amino acids 
to give a new α-amino acid bicyclic scaffold, Proline analogue, as 
consequence of the previous works involving the coupling of amino acids 
and sugars derivatives. This new scaffold results in a structure ‘BTAa-like’, 
but in this case the couple phase consists in a nucleophylic substitution SN2 
to give the densely functionalized acyclic template, that undergoes 
intramolecular transacetalization to give the biclyclic scaffold. 
Then we moved towards a DOS approach to generate morpholine 
scaffolds starting from the same starting materials, just operating in 
different reaction conditions (pair phase). In the first generation of 
morpholine compounds is also included the bicyclic Proline analogue of 
above. During the development of the second generation of these 
heterocycles for chemical diversity, we were interested in finding an easy 
and efficient method to synthesize molecules through the aminolysis of 
lactones, and in particular we were interested in achieving the reaction 
using stoichiometric quantities of reactants. In this contest a work about 
aminolysis lactones LiNTf2-catalyzed is placed. The second generation has 
been submitted to further manipulation and a third generation of complex 
bi- and tricyclic molecules has been obtained. 
Multicomponent reactions are another powerful process to obtain diversity 
and complexity in a rapid way. They allow to combine in only one synthetic 
operation at least three elements to give highly functionalized products. In 
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the context of a collaboration program with Dr. Jieping Zhu from ICSN, 
CNRS of Gif-sur-Yvette (France), a new four-component reaction for the 
synthesis of heterocyclic scaffolds useful for medicinal chemistry was 
developed. 
In summary, in this Ph.D. thesis the following topics will be discussed: 
• Diastereoselective synthesis of highly constrained spiro-β-lactams 
via Staudinger reaction using an unsymmetrical bicyclic (BTAa) 
ketene. The spiro-β-lactams formation is commonly used for 
constraining the torsion angles for the development of constrained 
β-turn mimetics.  
• Synthesis of an α-amino acid from L-Ascorbic acid, considered as 
bicyclic mimetic of Proline, particularly suited for peptidomimetic 
chemistry on solid-phase. 
• Diversity-oriented synthesis of morpholine based scaffolds from L-
Ascorbic acid and amino acids, to give a 1st, 2nd and 3rd generation 
of complex bi- and tricyclic molecules. 
• LiNTf2-catalyzed aminolysis of lactones with stoichiometric 
quantities of amines, specifically, as a part of the program towards 
the development of heterocycles for chemical diversity. 
• Development of a novel multicomponent reaction with 
functionalized α-isocyanoacetates to give highly functionalized oxa-
bridged heterocycles. 
 
The applications of such heterocycles are in the field of medicinal and 
peptidomimetic chemistry. BTAa, BTS and BTKa have been proved to be 
dipeptide isosteres when inserted in peptide chains and they have been 
used as reverse turn inducers; the bicyclic mimetic of Proline could be 
applied in the same field. Morpholine scaffolds have been incorporated in 
polypeptides. Spiro-β-lactams have antiviral and antibacterial properties, 
they have been subjected to biological evaluation as antibiotics and β-
lactamase inhibitors. Finally the oxa-bridged heterocycles should find 
applications in a large number of fields for the synthesis of libraries of 
medicinally important heterocycles of this type. 
 
 
PART  I I  
Diversity-Oriented Synthesis of 
heterocyclic scaffolds 
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Diastereoselective synthesis of 
highly constrained Spiro-β-
Lactams via Staudinger Reaction 
using an unsymmetrical bicyclic 
ketene*  
 
Control of the topological arrangement of the residues that 
constitute the pharmacophore in peptidomimetics is accomplished by the 
use of molecular scaffolds.63 Organic chemistry uses modern synthetic 
techniques to make structurally diverse scaffolds to use as peptidomimetic 
templates, including cyclic, polycyclic and spiro compounds varying in ring 
size and in their level of functionalization. In particular, lactam or bicyclic 
lactam formation is commonly used for constraining the torsion angles for 
the synthesis of peptidomimetics,64 and β-lactams have been extensively 
used as synthetic intermediates in organic synthesis (the β-lactam synthon 
                                                                        
* Trabocchi, A.; Lalli, C.; Guarna, F.; Guarna, A. Eur. J. Org. Chem. 2007, 16, 4594-4599. 
63 G. L. Olson, D. R. Bolin, M. Pat Bonner, M. Bos, C. M. Cook, D. C. Fry, B. J. Graves, M. Hatada, 
D. E. Hill, M. Kahn, V. S. Madison, V. K. Rusiecki, R. Sarabu, J. Sepinwall, G. P. Vincent, M. E. 
Voss, J. Med. Chem. 1993, 36, 3039–3049. 
64 (a) M. J. O’Donnell, Org. Lett. 2004, 6, 1629–1632. (b) R. Krelaus, B. Westermann, Tetrahedron Lett. 
2004, 45, 5987–5990. (c) R. M. Freidinger, J. Med. Chem. 2003, 46, 5554–5566. (d) K. Dolbeare, G. F. 
Pontoriero, S. K. Gupta, R. K. Mishra, R. L. Johnson, J. Med. Chem. 2003, 46, 727–733. (e) T. 
Hoffmann, R. Waibel, P. Gmeiner, J. Org. Chem. 2003, 68, 62–69. (f) L. Colombo, M. Di Giacomo, 
V. Vinci, M. Colombo, L. Manzoni, C. Scolastico, Tetrahedron 2003, 59, 4501–4513. (g) E. Artale, G. 
Banfi, L. Belvisi, L. Colombo, M. Colombo, L. Manzoni, C. Scolastico, Tetrahedron 2003, 59, 6241–
6250. (h) S. Hanessian, H. Sailes, A. Munro, E. Therrien, J. Org. Chem. 2003, 68, 7219–7233. (i) Z. 
Feng, W. D. Lubell, J. Org. Chem. 2001, 66, 1181–1185. (j) M. Cristau, C. Devin, C. Oiry, O. Chaloin, 
M. Amblard, N. Bernad, A. Heitz, J.-A. Fehrentz, J. Martinez, J. Med. Chem. 2000, 43, 2356–2361. (k) 
A. D. Abell, J. Gardiner, J. Org. Chem. 1999, 64, 9668–9672. (l) S. Hanessian, G. McNaughton-Smith, 
H.-G. Lombart, W. D. Lubell, Tetrahedron 1997, 53, 12789–12854. (m) K. Kim, J.-P. Dumas, J. P. 
Germanas, J. Org. Chem. 1996, 61, 3138–3144. 
Chapter 
3 
D i a s t e r e o s e l e c t i v e  s y n t h e s i s  o f  s p i r o - β - l a c t a m s   
v i a  S t a u d i n g e r  r e a c t i o n  
 16
method),65 thus providing a very useful route to a number of α- and β-
amino acid derivatives and peptides. The application of spiro-β-lactams in 
peptidomimetic chemistry is well-documented, and relevant examples 
include the development of constrained β-turn mimetics.66 Spiro-β-lactams 
have also received attention in medicinal chemistry owing to their antiviral 
and antibacterial properties,67 as well as recognized activity as cholesterol 
absorption inhibitors.68 Among the strategies developed for the 
construction of β-lactams,69 the reaction of acyl chlorides with imines 
(known as the Staudinger reaction)70 constitutes one of the most popular 
procedures. Also, several syntheses of spiro-β-lactams have been described 
in the literature,71 and in recent years many researchers have accomplished 
the synthesis of spiro-β-lactams through cycloaddition reactions employing 
different ketenes and imines.72  
 
In recent years, our interest in the development of heterocycles and 
constrained amino acids for peptidomimetic chemistry has focused on the 
                                                                        
65  (a) I. Ojima, Acc. Chem. Res. 1995, 28, 383–389. (b) E. Juaristi, V. Soloshonok in Synthesis of β-
Amino Acids and Their Derivatives from β-Lactams: An Update, Wiley, 2005, pp. 477–493. 
66 E. Alonso, F. Lopez-Ortiz, C. del Pozo, E. Peratta, A. Macias, J. Gonzalez, J. Org. Chem. 2001, 66, 
6333–6338. For pioneering work on β-lactam-based β-turns, see: (a) C. Palomo, J. M. Aizpurua, A. 
Benito, R. Galarza, U. K. Khamrai, J. Vazquez, B. de Pascual-Teresa, P. M. Nieto, A. Linden, Angew. 
Chem. Int. Ed. 1999, 38, 3056–3058. (b) C. Palomo, J. M. Aizpurua, A. Benito, J. I. Miranda, R. M. 
Fratila, C. Matute, M. Domercq, F. Gago, S. Martin-Santamaria, A. Linden, J. Am. Chem. Soc. 2003, 
125, 16243–16260. 
67 (a) J. W. Skiles, D. McNeil, Tetrahedron Lett. 1990, 31, 7277–7280. (b) J. C. Sheehan, E. Chacko, Y. 
S. Lo, D. R. Ponzi, E. Sato, J. Org. Chem. 1978, 43, 4856–4859 and references cited therein. 
68 (a) G. Wu, W. Tormos, J. Org. Chem. 1997, 62, 6412–6414. (b) L.-Y. Chen, A. Zarks, S. 
Chackalamamil, S. Dugar, J. Org. Chem. 1996, 61, 8341–8343. 
69 (a) T. T. Tidwell, Eur. J. Org. Chem. 2006, 563–576. (b) M. Benaglia, M. Cinquini, F. Cozzi, Eur. J. 
Org. Chem. 2000, 563–572. (c) O. Dirat, C. Koulovsky, M. Manduit, Y. Langlois, Pure Appl. Chem. 
2000, 72, 1721–1737. (d) T. Kawabata, Rev. Hetereoatom Chem. 2000, 33–58. (e) E. G. Mata, Curr. 
Pharm. Des. 1999, 5, 955–964. (f) Y. Yamamoto, N. Asao, N. Tsukuda ‘Asymmetric Synthesis of β-
Amino acids and β-Lactam Derivatives via Conjugate addition of Metal Amides’ in Advances in 
Asymmetric Synthesis (Ed.: A. H. Hassner), JAI Press, Stamford, CT, 1998, vol. 3. (g) T. E. Muller, M. 
Beller, Chem. Rev. 1998, 98, 675–704. (h) M. P. Doyle, Pure Appl. Chem. 1998, 70, 1123–1128. 
70 C. Palomo, J. M. Aizpurua, I. Ganboa, M. Oiarbide, Eur. J. Org. Chem. 1999, 3223–3235 and 
references cited therein. 
71 (a) P. D. Croce, R. Ferraccioli, C. La Rosa, Tetrahedron 1999, 55, 201–210. (b) S. Anklam, J. 
Liebscher, Tetrahedron 1998, 54, 6369–6384. (c) J. Fetter, F. Bertha, M. Kajtar-Paredy, A. Sapi, J. 
Chem. Res. (S) 1997, 118–119. (d) L.-Y. Chen, A. Zaks, S. Chackalmannil, S. Dugar, J. Org. Chem. 1996, 
61, 8341–8343. (e) H. Aoyama, H. Sagae, A. Hosomi, Tetrahedron Lett. 1993, 34, 5951–5952. (f) A. W. 
Guest, J. H. Bateson, Tetrahedron Lett. 1993, 34, 1799–1802. (g) S. Le Blanc, J. P. Pete, O. Piva, 
Tetrahedron Lett. 1992, 33, 1993–1996. (h) I. Ishibashi, N. Nakamura, T. Sato, M. Takeuchi, M. Ikeda, 
Tetrahedron Lett. 1991, 32, 1725–1728. (i) M. K. Sharma, T. Durst, Tetrahedron Lett. 1990, 31, 3249–
3252. (j) M. Ikeda, T. Uchino, H. Ishibashi, Y. Tamura, M. Ikeda, J. Chem. Soc. Chem. Commun. 1984, 
758–759. 
72 (a) B. Alcaide, P. Almendros, R. Rodriguez-Acebes, Chem. Eur. J. 2005, 11, 5708–5712. (b) B. 
Alcaide, P. Almendros, T. M. Campo, R. Rodriguez-Acebes, Tetrahedron Lett. 2004, 45, 6429–6431. 
(c) G. Cremonesi, P. D. Croce, C. L. Rosa, Tetrahedron 2004, 60, 93–97. (d) A. Macias, E. Alonso, C. 
del Pozo, A. Venturini, J. Gonzalez, J. Org. Chem. 2004, 69, 7004–7012. (e) A. Macias, E. Alonso, C. 
del Pozo, J. Gonzalez, Tetrahedron Lett. 2004, 45, 4657–4660. (f) E. Alonso, C. del Pozo, J. Gonzalez, 
J. Chem. Soc. Perkin Trans. 1 2002, 571–576. (g) P. D. Croce, C. L. Rosa, Tetrahedron: Asymmetry 1999, 
10, 1193–1199. (h) J. C. Sheehan, E. Chacko, Y. S. Lo, D. R. Ponzi, E. Sato, J. Org. Chem. 1978, 43, 
4856–4859. 
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synthesis of bicyclic 3-aza-6,8-dioxabicyclo[3.2.1]octane scaffolds as γ/δ-
amino acids.23 We were interested in further exploring the skeletal diversity 
of such constrained scaffolds by generating polycyclic spiro compounds 
through the Staudinger reaction with different types of imines. Our aim 
was to generate compounds possessing diverse scaffolds to which different 
functional groups could be fixed in a stereodefined 3D topological 
arrangement. 
Derivatives 3.2 and 3.3, obtained from bicyclic Bn-BTG(O)-OMe 
3.1 (BTG: Bicycles from Tartaric acid and Glycin derivatives), were used to 
assess the yield and selectivity resulting from the reaction of the 
corresponding BTAa-derived ketene with selected imines (Table 3.1). 
Ketenes are commonly generated from acyl chlorides, and the use of 
Mukaiyama’s salt for in situ generation of the reactive species, even in 
solid-phase chemistry, has also been reported.73,74 Both methodologies were 
thus explored to verify the reactivity of the unsymmetrical bicyclic ketene at 
the 7-position of the scaffold with respect to the imine at different 
temperatures and with different solvent systems (Scheme 3.1). 
 
 
 
Scheme 3.1. Methodologies explored for the formation of the ketene: from 
acyl chloride and from Mukaiyama’s salt. 
 
 
Hydrolysis of 3.1 with potassium trimethylsilanolate (TMSOK) in 
anhydrous THF furnished corresponding carboxylic acid 3.2 in quantitative 
yield (Scheme 3.1). Activation of the carboxylic function of the BTG 
                                                                        
73 (a) S. Matsui, Y. Hashimoto, K. Saigo, Synthesis 1998, 1161–1166. (b) G. I. Georg, P. M. Mashava, 
X. Guan, Tetrahedron Lett. 1991, 32, 581–584. (c) R. L. Funk, M. M. Abelman, K. M. Jellison, Synlett 
1989, 36–37. (d) S. G. Amin, R. D. Glazer, M. S. Manhas, Synthesis 1979, 210–213. 
74 C. M. L. Delpiccolo, A. Fraga, E. G. Mata, J. Comb. Chem. 2003, 5, 208–210. 
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scaffold by means of Mukaiyama’s salt, followed by reaction of either imine 
3.I or 3.VII (see Table 3.1) in anhydrous CH2Cl2, resulted in the formation 
of corresponding amides 3.5. This was a consequence of the hydrolysis of 
the iminium salt that resulted from the condensation of the activated acid 
with the corresponding imine (Scheme 3.2).  
Replacement of CH2Cl2 with toluene as the solvent and a change in the 
order of addition of the reagents to the reaction mixture resulted in the 
same amide byproducts. The effect of temperature was also investigated, 
but no improvement in the reactivity was obtained in refluxing chloroform 
or toluene solutions of the reactive Mukaiyama’s adduct with imine 3.I 
(Table 3.1). Thus, the use of Mukaiyama’s salt with bicyclic carboxylic acid 
3.2 could not lead to the preferential formation of the corresponding spiro-
β-lactam after conrotatory ring closure, because hydrolysis of the 
intermediate N-acyl iminium species was favoured under all the conditions 
tested, leading to amide byproducts 3.5. 
 
 
 
Scheme 3.2. Spiro-β-lactams are obtained when a solution of acyl chloride 
in toluene is added to a refluxing toluene solution of the imine. The amide 
3.5 is also obtained in some cases, and it is the only product starting from 
the Mukaiyama’s salt. 
 
Therefore, more reactive acyl chloride derivative 3.3 was used to obtain 
title spiro-β-lactams 3.4. The addition of preformed acyl chloride 3.3 to a 
refluxing CH2Cl2 solution of the imine and triethylamine (TEA) resulted in 
poor conversion to spiro-β-lactam 3.4 after a reaction time of 18 h. 
However, spiro-β-lactam 3.4 was obtained after a reaction time of 24 h by 
adding a solution of acyl chloride 3.3 in toluene to a refluxing toluene 
solution of the imine and TEA (method 1) (Scheme 3.2). When the 
reaction was conducted at lower temperatures, the reverse approach was 
used, which consisted of the preformation of the ketene by allowing the 
acyl chloride to react with TEA, followed by the addition of the imine 
species (method 2). The reaction was explored with imines derived from α-
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amino esters, benzylamine and aromatic amines and gave different results 
in terms of yield and diastereoselectivity, as shown in Table 3.1. 
 
 
Entry Imine R’       R    Product  Yield(%)  cis/trans 
 
1       3.I       Ph    CH(CH2Ph)CO2Me  3.6      33           1.4:1 
2       3.II     Ph    CH2Ph   3.7      66           1:1.2 
3       3.III    Ph    p-CH3Ph   3.8      14           15:1 
4       3.IV    Ph    p-NO2Ph   3.9      -           - 
5       3.V     Ph    p-OMePh   3.10      39          10:1 
6       3.VI    p-NO2Ph   p-CH3Ph   3.11      24          20:1 
7       3.VII  p-OMePh   p-CH3Ph   3.12      59          >50:1 
8       3.VIII p-BrPh    p-CH3Ph   3.13         33          7:1 
 
 
Table 3.1. Selected examples of spiro-β-lactams 3.4 with general formulas 
as in Scheme 3.2: reactions were all conducted in toluene at 110°C by using 
method 1. 
 
The nucleophilicity of the amine derivatives comprising the imine 
proved to influence the yield, as the conversion proceeded in the order 
benzyl > amino ester ≈ aryl. In particular, substitution on the aniline ring 
influenced the reactivity, as p-NO2-aryl-N-substituted imine 3.IV (Table 
3.1, entry 4) failed to react with the bicyclic ketene, probably as a result of 
the unfavourable electronic effects in the Staudinger reaction, whereas p-
OMe-aryl-N-substitution (Table 3.1, entry 5) gave the highest yield of the 
benzaldehyde-derived aryl imines (Table 3.1, entries 3–5). Also the nature 
of the aromatic aldehyde-derived moiety agreed with the hypothesis that an 
electron-rich imine could improve the yield of the corresponding spiro-β-
lactam, as p-NO2-aryl-C-substitution gave 3.11 in 24% yield, whereas p-
OMe-aryl-C-substitution yielded corresponding spiro compound 3.12 in 
59% yield (Table 3.1, entries 6 and 7, respectively).  
In the latter case (Table 3.1, entry 7), the order of addition of the 
reagents proved to influence the ratio of 3.4/3.5 as a consequence of the 
hydrolysis of the intermediate iminium species. Specifically, method 1 
proved to give the spiro-β-lactam even at 60°C, whereas method 2, 
consisting of the preformation of the ketene followed by imine addition, 
resulted in a 1:1 mixture of spiro-β-lactam 3.4/amide byproduct 3.5 
(Scheme 3.2). In terms of stereoselectivity, imine 3.I (derived from 
benzaldehyde and phenylalanine methyl ester; Table 3.1, entry 1) gave a 
mixture of two compounds as a result of poor diastereoselectivity, as did 
imine 3.II (derived from benzylamine; Table 3.1, entry 2). However, 
aromatic imines 3.III–3.VIII gave in all cases a major stereoisomer. Spiro-
β-lactam formation by using benzylamine-derived imine 3.II (Table 3.1, 
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entry 2) was further investigated as a function of the reaction temperature. 
In this case, method 2, involving preformation of the ketene, was found to 
be crucial for achieving corresponding spiro compound 3.7. Interestingly, 
we observed an effect of the temperature on the diastereomeric ratio, as 
shown in Table 3.2. 
 
 
Entry Temperature (°C)  Yield (%)  cis/trans 
 
1 0    22   2.7:1 
2 20    14   2.2:1 
3 60    24   1:1 
4 80    19   1.1:1 
5 110    66   1:1.2 
  
 
Table 3.2. Effect of the temperature on the diastereoisomeric ratio of spiro-
β-lactams 3.7 as in Table 3.1, entry 2: reactions were all conducted by using  
method 2. 
 
 Specifically, when moving from 110 to 0°C we observed a slight increase 
in the stereoselectivity and a shift towards the preferential formation of one 
of the two diastereoisomers (Figure 3.1).  
 
                        
 
Figure 3.1. 1H NMR signal of 5-H of compound 3.7 resulting from the 
reaction of 3.3 with imine 3.II. The reactions were carried out at 110°C, 
80°C and 20°C. 
 
 
 
 
 
The structure of the two stereoisomers was assigned by NOESY 
experiments of the mixture resulting from the reaction at 20°C (Table 3.2, 
entry 2). In the major stereoisomer, a strong NOE signal was observed 
between 1-H of the bicyclic compound and 4’-H of the azetidine ring, 
110°C 80°C 20 
ci s
t r a ns
°C 
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which suggests that spiro-β-lactam 3.7 with the general structure of cis-3.4 
as in Scheme 3.2 was obtained as the major compound at temperatures 
below 60°C. X-ray and NMR spectroscopic analysis of compound 3.12 
revealed information about the structure of the major diastereoisomer. 
NOESY experiments agreed with the X-ray crystal structure of 3.12 as 
shown in Figure 3.2,75 as demonstrated by a NOE crosspeak between 4’-H 
of the azetidine ring and 1-H of the bicyclic scaffold, and also by a weak 
NOE crosspeak between the CH2 protons at N-3 and the 4’-p-OMePh 
hydrogen atoms (Figure 3.3). 
 
 
 
Figure 3.2. X-ray structure of compound 3.12 with thermal ellipsoids at 
50% probability. For table see experimental section chapter 8.3. 
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Figure 3.3. Selected NOE contacts for compound 3.12. 
 
The mechanism of the reaction is widely thought to involve 
nucleophilic attack of the imine on the ketene species to give a zwitterionic 
intermediate, which undergoes a subsequent conrotatory ring closure to 
generate the spiro-β-lactam species. In agreement with similar substrates 
                                                                        
75 CCDC-641203 contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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reported in the literature,41(f) diastereoisomer cis-3.12 (Scheme 3.2) would 
thus have resulted from initial attack of the imine species on the bicyclic 
ketene in the anti orientation with respect to the O-6 oxygen atom of the 
scaffold, followed by a preferential outward conrotatory ring closure of the 
O-6 substituent favoured by a torquoelectronic effect (Figure 3.4). 
 
 
 
Figure 3.4. Proposed mechanism for the stepwise Staudinger reaction. 
 
This effect has been demonstrated to be very pronounced for ketenes 
bearing a heteroatom adjacent to the carbon–carbon double bond,41(f) thus 
agreeing with the high stereoselectivity observed in our compounds derived 
from aromatic imines. The minor stereoisomer could result from syn attack 
of the imine species to give the trans compound as shown in Figure 3.4. 
This hypothesis is supported by the absence of NOESY peaks either 
between 4’-H of the azetidine ring and 1-H of the bicyclic scaffold, thus 
excluding the other possible cis stereoisomer, or between the CH2 protons 
at N-3 and the 4’-aryl hydrogen atoms, thus excluding the other possible 
trans structure. The loss of stereoselectivity in the case of benzyl- and 
phenylalanine-derived imines may take account of the higher 
conformational freedom due to the lack of conjugation within the imine 
with respect to the aromatic ones. 
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In conclusion the synthesis of highly constrained spiro-β-lactams 
from a bicyclic ketene was achieved by the Staudinger reaction. The 
outcome of the reaction indicated that the aromatic imines are best choice 
for the generation of a new molecular architecture bearing aromatic 
functional groups, as in this case the reaction proceeded with high 
stereoselectivity to produce the corresponding cis spiro-β-lactams as the 
major compounds. Both aliphatic- and amino acid derived imines provided 
mixtures of cis- and trans spiro-β-lactams in variable amounts. Given the 
potential structural diversity of the ketene bicyclic scaffold,23 this method is 
of interest for the generation of densely functionalized molecular scaffolds 
having restricted conformational freedom and a stereodefined 3D 
topological array of the substituents. Optimized reaction conditions may be 
applied for the subsequent generation of polycyclic spiro-β-lactams as 
peptidomimetics for biomedical research. 
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Bicyclic Proline analogue from L-
Ascorbic acid* 
 
Nowadays there is an ever-increasing need for versatile scaffolds, 
including new amino acid templates, to be applied in peptidomimetic 
design.45 Among the various approaches for mimicking peptide structures,46 
numerous mimetics and analogues of Proline have been developed and 
applied in the synthesis of biologically active compounds,47 expecially with 
the aim of modulating the cis/trans isomerism of acyl-proline bonds, and 
producing proline-like reverse turn inducers.48  
Since the development of first examples of 3-aza-6,8-
dioxabicyclo[3.2.1]octane-based scaffolds (BTAa, see Figure 4.1), 
functionalities have been introduced at positions 3, 4, 5 and 7,23 whereas 
position 2 remained largely unexplored, occupied only by C=O, C=S, or 
CH2 groups. In particular, the possibility of generating scaffolds with 
differently positioned carboxy groups (Figure 4.1, A-C) has been recently 
                                                                        
* C. Lalli, A. Trabocchi, F. Guarna, C. Mannino, A. Guarna Synthesis 2006, 18, 3122–3126. 
45 A. Trabocchi, F. Guarna, A. Guarna Curr. Org. Chem. 2005, 9, 1127. 
46 See for example: S. Hanessian, G. McNaughton-Smith, H. -G. Lombart, W. D. Lubell Tetrahedron 
1997, 53, 12789. 
47 (a) D. Damour, F. Herman, R. Labaudinière, G. Pantel, M. Vuilhorgne, S. Mignani Tetrahedron 
1999, 55, 10135. (b) Q. Wang, M. –E. Tran Huu Dau, N. A. Sasaki, P. Potier Tetrahedron 2001, 57, 
6455. (c) L. Demange, J. Cluzeau, A. Ménez, C. Dugave Tetrahedron Lett. 2001, 42, 651. (d) M. V. 
Gorichko, O. O. Grygorenko, I. V. Komarov Tetrahedron Lett. 2002, 43, 9411. (e) A. Dahlgren, J. 
Bråualt, I. Kuaenström, I. Nilsson, D. Musil, B. Samuelsson Bioorg. Med. Chem. 2002, 10, 1567. (f) X. 
J. Wang, S. A. Hart, B. Xu, M. D. Mason, J. R. Goodell, F. A. Etzkorn J. Org. Chem. 2003, 68, 2343. 
(g) I. O. Donkor, R. Korukonda, T. L. Huang, L. Le Cour Jr Bioorg. Med. Chem. Lett. 2003, 13, 783. 
(h) G. Jeannotte, W. D. Lubell J. Org. Chem. 2004, 69, 4656. (i) Y. –T. Liu, J. K. Wong, M. Tao, R. 
Osterman, M. Sannigrahi, V. M. Girijavallabhan, A. K. Saksena Tetrahedron Lett. 2004, 45, 6097. 
48 (a) K. Kym, J. P. Germanas J. Org. Chem. 1997, 62, 2847. (b) L. Halab, W. D. Lubell J. Org. Chem. 
1999, 64, 3312. (c) L. Halab, W. D. Lubell J. Am. Chem. Soc. 2002, 124, 2474. (d) T. K. Chakraborty, 
A. Ghosh, S. K. Kumar, A. C. Kunwar J. Org. Chem. 2003, 68, 6459. (e) W. –J. Zhang, A. Berglund, J. 
L. –F. Kao, J. –P. Couty, M. C. Gershengorn, G. R. Marshall J. Am. Chem. Soc. 2003, 125, 1221. (f) S. 
Chierici, M. Jourdan, M. Figuet, P. Dumy Org. Biomol. Chem. 2004, 2, 2437. 
Chapter 
4 
B i c y c l i c  P r o l i n e  a n a l o g u e  f r o m  L - A s c o r b i c  a c i d  
 
 25
pursued, in order to expand the scope of peptidomimetic chemistry within 
this class of bicyclic scaffolds. For this approach new synthetic strategies 
have been necessary, using different building blocks from the chiral pool.27 
 
 
  
Figure 4.1. General formula of BTAa scaffolds (top) and isomeric bicyclic 
amino acids A-D, with A and D as proline mimetics. 
 
Recently, we moved from tartaric acid to sugars as building blocks 
for new versatile scaffolds in enantiopure form with complete control of 
the stereochemistry.27 In particular, it was possible to generate new 
enantiopure bicyclic amino acids, such as γ- or δ-amino acids as reverse 
turn inducers by use of erythrose derivatives,27(b) and bicyclic proline 
mimetics starting from Serine and Glyceraldehyde derivatives.27(a) We 
reasoned that starting from L-Ascorbic acid derivative 4.1 (Scheme 4.1), we 
could afford a new set of scaffolds bearing a substituent at position 2 
(Figure 4.1, D). L-Ascorbic acid has appeared in literature as a valuable 
source of chiral building blocks for the preparation of enantiopure β-
lactams49 and L-hexoses.50 Moreover, the use of such an inexpensive starting 
material is an advantage in multigram-scale organic synthesis. 
Thus, starting from triflate 4.2, obtained from the protected L-
Ascorbic acid derivative 4.149,51 compound 4.4 was obtained in 99% yield by 
nucleophilic substitution with aminoacetaldehyde dimethylacetal 4.3 at 
room temperature and overnight stirring (Scheme 4.1). Further protection 
as Fmoc-urethane 4.5, wich was obteined with 9-fluorenylmethyl 
chloroformate in 1,4-dioxane as solvent, whereas N-(9-
fluorenylmethoxycarbonyloxy)succinimide did not yield any product. Then, 
Fmoc-derivative 4.5 was subjected to acid cyclization at 0°C, according to 
reported procedures,27 to afford the methyl ester of scaffold 4.6. 
                                                                        
49 C. C. Wei, S. De Bernardo, J. P. Tengi, J. Borgese, M. Weigele J. Org. Chem. 1985, 50, 3462. 
50 L. Ermolenko, A. Sasaki J. Org. Chem. 2006, 71, 693. 
51 A. Tanaka, K. Yamashita Synthesis 1987, 570. 
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Surprisingly, the corresponding carboxylic acid 4.6 was obtained as major 
product by concomitant deprotection of the carbomethoxy group, and the 
conversion to acid 4.6 went to completion when the reaction was 
conducted at 25°C. Since the preparation of 4-endo-carboxylic scaffolds 
proved to be problematic and low yielding, as previously reported (see 
Figure 4.1, structure A),27(a) the facile synthesis of 4.6, with the carboxylic 
group in endo position, provides a more complete collection of bicyclic 
amino acids for application in peptidomimetic chemistry. 
 
O
N O
HO2C
Fmoc
OO
TfO
CO2Me
H2N
OMe
OMe4.3
4.4
OO
HN
CO2Me
MeO
MeO
OO
N
CO2Me
MeO
MeO
Fmoc
Fmoc-Cl
2,6-lutidine TFA
4.5 4.6
Tf2O
py
OO
HO
CO2Me
L-Ascorbic acid
4.1
4.2
ref. 49
59%
99%
DIPEA
97% 46%
3 steps
 
 
Scheme 4.1. Synthesis of a bicyclic α-amino acid with an endo-carboxy 
group from L-Ascorbic acid. 
 
Formal inversion of the configuration at the C-2 stereocenter of 
compound 4.6 gives 4.13, the corresponding diastereomer of 4.6, carrying 
the carboxy group in 2-exo position (Scheme 4.2). Thus, treatment of L-
Ascorbic acid derivative 4.1 with chloroacetic acid and triphenylphosphine, 
as previously reported,50 produced the corresponding ester-derivative 4.7 
with inversion of configuration at C-2 (Scheme 4.2). Subsequent hydrolysis 
with sodium hydrogen carbonate in place of triethylamine gave 4.8, the 
stereoisomer of 4.1, which was converted to the corresponding triflate 
derivative 4.9 in 53% yield. The reaction of triflate 4.9 with acetal 4.3 gave 
adduct 4.10, a diastereoisomer of 4.4, with inversion of configuration at C-
2. Successively, Fmoc protection by the same procedure used to prepare 
4.5 yielded 4.11, which was subsequently cyclized by treatment with 
trifluoroacetic acid. Interestingly, in this case, the reaction provided the 
bicyclic scaffold as methyl ester derivative 4.12 (Scheme 4.2), since the 
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concomitant hydrolysis failed to occur, probably because of the axial 
orientation of the carbomethoxy group. This led to the hypothesis that the 
facile hydrolysis to give compound 4.12 might occur through the urethane 
carbonyl group providing anchimeric assistance to the equatorial 
carbomethoxy group. Compound 4.12 could be obtained in excellent yield 
when the cyclization time was prolonged from 16 hours (35% yield) to 48 
hours (81% yield). 
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Scheme 4.2. Synthesis of a bicyclic α-amino acid with an exo-carboxy group 
from L-Ascorbic acid. 
 
Hydrolysis of 4.12 proved to be problematic, and different methods were 
tried. Specifically, basic hydrolysis with lithium hydroxide did not yield α-
amino acid 4.13 in significant amounts, and partial Fmoc-deprotection of 
4.12 was observed. Hydrolysis with a dioxane-water system at room 
temperature for 48 hours gave 4.13 with 19% conversion, and a similar 
result (17%) was achieved when ester 4.12 was treated with 4 M aqueous 
hydrogen chloride in acetonitrile. However, when ester 4.12 was refluxed in 
the same aqueous hydrogen chloride-acetonitrile system for 16 hours, acid 
4.13 was obtained in satisfactory yield (75%) (Scheme 4.2).  
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In conclusion, a new bicyclic α-amino acid was synthesized in a 
three-steps procedure starting from an L-Ascorbic acid derivative, 
producing amino acid derivative 4.6 directly after acid cyclization. In 
addition, inversion of configuration at the carbon atom bearing the triflate 
group of the L-Ascorbic acid derivative allowed the synthesis the 
corresponding diastereomeric bicyclic amino acid 4.13, wich has the 
carboxy group in the 2-exo configuration. These two new bicyclic Proline 
analogues may thus find application in peptidomimetic research, and, in 
particular, are suited for solid-phase organic and peptide synthesis by the 
Fmoc-protocol. 
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Diversity-Oriented Synthesis of 
Morpholine-based scaffolds* 
 
In the field of medicinal chemistry the synthesis of cyclic amino 
acids have attracted considerable interest, particularly for the 
peptidomimetic applications.5 Secondary cyclic amino acids have been 
extensively used in biomedical research, and their insertion in biologically 
active peptides has been documented in the course of the years. In 
particular, the morpholine ring is found in numerous bioactive molecules, 
such as inhibitors of TACE,52 of MMP and TNF, and within the structure 
of the potent VLA-4 antagonist.53 Moreover, morpholine has been 
successfully inserted in the heterocyclic structure of tricyclic 
benzodiazepines,54 of 6-methylidene-penem as β-lactamase inhibitors55 of β-
carbolines as IKK-2 inhibitors, of 6,8-fused bicyclic peptidomimetics as 
interleukin-1β converting enzyme inhibitors,56 and in the structure of 
benzoxazepines as stimulators of AMPA receptor, which demonstrates the 
high interest in the biomedical field towards this heterocycle and the 
molecules containing it.  
                                                                        
* Guarna, A.; Trabocchi, A.; Menchi, G.; Lalli, C.; Sladojevich, F.; Cini, N. Heterocyclic compounds 
containing the morpholine nucleus their preparation and use. WO2008/129004, October 30th 
2008. 
52 J. I. Levin, J. M. Chen, L. M. Laakso, M. Du, X. Du, A. M. Venkatesan, V. Sandanayaka, A. Zask, 
J. Xu, W. Xu, Y. Zhang, J. S. Skotnicki Bioorg. Med. Chem. Lett. 2005, 15, 4345-4349. 
53 J. Chiba, N. Machinaga, T. Takashi, A. Ejima, G. Takayama, M. Yokoyama, A. Nakayama, J. J. 
Baldwin, E. McDonald, K. W. Saionz, R. Swanson, Z. Hussain, A. Wong Bioorg. Med. Chem. Lett. 
2005, 15, 41-45. 
54 J. M. Matthews, A. B. Dyatkin, M. Evangelisto, D. A. Gauthier, L. R. Hecker, W. J. Hoekstra, F. 
Liu, B. L. Poulter, K. L. Sorgi, B. E. Maryanoff Tetrahedron: Asymmetry 2004, 15, 1259-1267. 
55 A. M. Venkatesan, A. Agarwal, T. Abe, H. Ushirogochi, I. Yamamura, M. Ado, T. Tsuyoshi, O. 
Dos Santos, Y. Gu, F. -W. Sum, Z. Li, G. Francisco, Y. –I. Lin, P. J. Petersen, Y. Yang, T. Kumagai, 
W. J. Weiss, D. M. Shlaes, J. R. Knox, T. S. Mansour J. Med. Chem. 2006, 49, 4623-4637. 
56 S. V. O’Neil, Y. Wang, M. C. Laufersweiler, K. A. Oppong, D. L. Soper, J. A. Wos, C. D. Ellis, 
M.W. Baize, G. K. Bosch, A. N. Fancher, W. Lu, M. K. Suchanek, R. L. Wang, B. De, T. P. Demuth  
Bioorg. Med. Chem. Lett. 2005, 15, 5434-5438. 
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The scope of this project is to obtain morpholine scaffolds from 
simple building blocks like sugars and amino acids derivatives according 
with the principles of the Diversity-Oriented Synthesis (Figure 5.1). 
 
 
 
Figure 5.1. ‘Diversity-oriented synthesis involves the deliberate, simultaneous and 
efficient synthesis of more than one target compound in a diversity-driven approach to 
answer a complex problem’ (David R. Spring)57 
 
 
 
5.1. Heterocyclic compounds containing 
morpholine nucleus 
 
Our attention is focused on the generation of morpholine-based 
heterocyclic scaffolds, using building blocks selected from the chiral pool, 
taking into account the existence of two functionalities acting as 
nucleophile and electrophile. The compounds of general formula I can be 
achieved from a two steps synthetic process using precursors easily 
obtainable as enantiopure compounds (Scheme 5.1). In particular the 
building blocks taken into account are amino acids and the L-Ascorbic acid 
derivatives, this already described in Chapter 4. 
 
                                                                        
57 D. R. Spring Org. Biomol. Chem. 2003, 1, 3867. 
D i v e r s i t y - O r i e n t e d  S y n t h e s i s  o f   
M o r p h o l i n e - b a s e d  s c a f f o l d s  
 
 31
 
 
Scheme 5.1. Two-steps synthetic process for the synthesis of morpholine 
scaffolds. 
 
Such new type of compounds, cyclic or bicyclic in structure, can be 
successively functionalized in different positions and transformed in other 
compounds containing the morpholine ring through subsequent reactions, 
as known in literature, thus functioning as core structure for the generation 
of a wide array of new compounds with high level of molecular diversity 
(Scheme 5.2). 
 
 
 
Scheme 5.2. Structures obtained by manipulations of the morpholine core. 
 
We are interested in α-amino aldehydes derived from natural amino acids as 
nucleophiles, and L-Ascorbic acid-derived protected threonate derivative as 
electrophile. In the build phase the amino acids and sugar derivatives are 
obtained from natural products. In particular the amino acids derivatives 
are synthesized by reduction of the carboxylic group to aldehyde and 
successively protection as dimethylacetals A. The sugar moiety is the 
threonate derivative B, obtained as reported49,50 from L-Ascorbic acid in 
three steps (see Chapter 4) (Figure 5.2). While for the amino acid moiety we 
have taken into account only natural amino acids of L-serie, in the case of 
D i v e r s i t y - O r i e n t e d  S y n t h e s i s  o f   
M o r p h o l i n e - b a s e d  s c a f f o l d s  
 
 32
the L-Ascorbic acid derivatives we have synthesized two diastereoisomers 
(aR,bS) and (aS,bS) respectively (see Chapter 4) (Figure 5.2). 
 
 
 
Figure 5.2. Selected building blocks for the coupling step. 
 
In the coupling phase we allowed the electrophile B bearing the hydroxyl 
group to react with the nucleophile A bearing the amine. Building block B 
was coupled with α-amino acid-derived A via SN2 to give the corresponding 
adduct C as the highly functionalized acyclic precursor (Figure 5.3). 
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Figure 5.3. Acyclic precursor for the cyclization step. 
 
Compound B with (aR,bS) configuration (molecule 4.2 see Chapter 4) has 
been coupled by nucleophilic substitution with: 
• the Glycine derived aminoacetaldehyde dimethylacetal 4.3 to give 
the acyclic precursor 4.4 (see Chapter 4)58 (Scheme 5.3). 
• the 4-OH-Proline-derived acetal precursor 5.1 to give the acyclic 
precursor 5.3 (Scheme 5.3). 
• the Asp-(Ot-Bu)-derived acetal precursor 5.2 to give the acyclic 
precursor 5.4 (Scheme 5.3). 
 
                                                                        
58 C. Lalli, A. Trabocchi, F. Guarna, C. Mannino, A. Guarna Synthesis 2006, 18, 3122–3126. 
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Scheme 5.3. Selected acyclic precursors for the cyclization step obtained 
with: Glycine derived aminoacetaldehyde dimethylacetal, 4-OH-Proline-
derived acetal, Asp-(Ot-Bu)-derived acetal. 
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5.1.1. 1st generation scaffolds 
 
Intramolecular reactions provide the cyclization of intermediate C 
to the morpholine scaffold to give the first degree of skeletal diversity 
around the morpholine nucleus (Scheme 5.4). 
 
 
 
Scheme 5.4. 1st generation scaffolds: general structures. 
 
 
The intermediate 4.4 could be derivatized at the nitrogen atom and 
cyclized, or could be directly cyclized and then functionalized at the 
nitrogen atom, to give hemiacetal IIA or acetal IIB with 6M HCl at 80°C 
or SOCl2 in MeOH respectively (Scheme 5.5). Acylation of the nitrogen 
atom of the acyclic precursor, followed by cyclization in refluxing toluene 
with a catalytic amount of p-TSA resulted in the bicyclic oxazine IIC, due 
to the contemporaneous cyclization and elimination of a molecule of 
MeOH (Scheme 5.5). Finally the cyclization in TFA gives the bicyclic 
scaffold 4.6 (see chapter 4)58 (Scheme 5.5). 
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Scheme 5.5. 1st generation derived from the coupling of compound B with 
(aR,bS) configuration, with Gly derivative. 
 
 
 
Figure 5.4. X-ray structure of compound 5.14 (IIB with R=Bn) with 
thermal ellipsoids at 50% probability. For Tables see experimental section 
chapter 8.5. 
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The cyclization of 5.3 and 5.4 with SOCl2 in MeOH resulted 
respectively in the tricyclic compound 5.23 and in the bicyclic molecule 
5.24, having the side chain group as a methyl ester (Scheme 5.6). 
 
 
 
Scheme 5.6. 1st generation scaffolds: morpholine-lactones derived from 4-
OH-Pro and Asp-(Ot-Bu). 
 
 
Figure 5.5. X-ray structure of compound 5.23 with thermal ellipsoids at 
50% probability. For Tables see experimental section chapter 8.5. 
 
Investigation by X-ray crystallography analysis of compounds 5.14 
and 5.23 revealed the propensity of α anomer to crystallize. 
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Interestingly, by using building block B with (aS,bS) configuration 
(molecule 4.9 see Chapter 4) for the coupling with Glycine derived 
aminoacetaldehyde dimethylacetal 4.3, different 1st generation scaffolds 
were achieved (Scheme 5.7). Compound 5.25 was obtained upon treatment 
of 4.10 with SOCl2 in MeOH, whereas reaction of the N-protected acyclic 
adduct in pure TFA resulted in the corresponding bicyclic scaffold 4.12, as 
also previously reported for the compound 4.6 (see chapter 4)58 (Scheme 
5.7). 
 
 
 
Scheme 5.7. Different 1st generation derived from the coupling of 
compound B with inversion of configuration at C-2, (aS,bS) configuration, 
with Gly derivative. 
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5.1.2. 2nd generation scaffolds 
 
Lactone aminolysis of molecules of structure IIB with different 
amines using LiNTf2 as catalyst59 (see chapter 5), gave 2
nd generation 
compounds of structure IIIA (Scheme 5.8).  
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Scheme 5.8. 2nd generation scaffolds: aminolysis of morpholine-lactones. 
 
The results obtained for the aminolysis of the morpholine-lactones are 
reported in Table 5.1. 
 
Entry R2 R6 R7 Yield(%) Compound 
1 Bz H CH2Ph 93 5.26 
2 Bz H CH2CH=CH2 97 5.27 
3 Bz H CH2C≡CH 93 5.28 
4 Bz H -CHCH2CH2 86 5.29 
5 Bz -CH2(CH2)3CH2- 85 5.30 
6 CO-o-IPh       H   CH2Ph       97 5.31 
 
Table 5.1. Aminolysis of the morpholine-lactones. 
 
 
The morpholine core could be further decorated, in fact the common 
nucleophilic hydroxy group makes the structures obtained, substrates for a 
third appending process, the alkylation at the hydroxyl group or the 
acylation with a collection of carboxylic acid building blocks, to give 
structures IIIB (Scheme 5.9). 
 
                                                                        
59 C. Lalli, A. Trabocchi, G. Menchi, A. Guarna  Synlett 2008, 2, 189-192. 
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Scheme 5.9. Further manipulations: scaffold decoration. 
 
The possibility of a different 2nd generation from the hemiacetal IIA was 
also explored and the corresponding benzyl derivatives through 
trichloroacetimidate intermediates were obtained (Scheme 5.10). This kind 
of reactivity demonstrates the possibility of loading on resin of these 
morpholine structures, that are suited for solid-phase organic and peptide 
synthesis by the Fmoc-protocol. 
 
 
 
Scheme 5.10. 2nd generation scaffolds: manipulation of the morpholine-
hemiacetal. 
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5.1.3. 3rd generation scaffolds 
 
The 3rd generation is obtained by manipulation of the 2nd one, in 
particular the processes involved are again intramolecular reactions that 
provide other cycles to be closed. 
When IIB was acylated with BrCH2COBr, aminolysis with benzylamine 
gave directly 5.38 (Scheme 5.11); acylation with o-I-benzoyl chloride 
provided the intermediate for Cu-catalyzed cyclization to give tricyclic 5.39 
(Scheme 5.11) and Mitsunobu reaction gave tricyclic lactam 5.40 (Scheme 
5.11). 
  
 
 
 
 
N
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5.405.29  
 
Scheme 5.11. Further cyclizations: 3rd generation. 
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5.1.4. Summary of the structures 
 
The structures reported in Figure 5.6 are obtained with the strategy 
discussed (see experimental section chapter 8.5). 
 
N
O
O
O
R5
R2
R2 = H, Bz, Fmoc, Cbz, Ac, Bn, CH2-o-NO2Ph,
COCH2Br, CO-o-NO2Ph, CO-o-IPh,
CO-o-BrPh, SO2-p-ClPh, CH(CO2Me)-p-MePh
R5 = OH, OMe
N
O
O
OR2
R2 = Bz, Cbz
N
O
O
O
O
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N
H
O
O
O
O
MeO2C
N
O
O
CO2HFmoc
N
H
O
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O
CO2Me
1st generation  
 
 
 
Figure 5.6. Morpholine-based scaffolds obtained with complexity-
generating synthesis. 
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In conclusion DOS chemistry is a powerful concept for the 
development of new highly diverse chemical entities. We applied this 
approach in the generation of morpholine-containing molecular scaffolds 
for peptidomimetic chemistry by using bifunctional building blocks 
deriving from α-amino acids and L-Ascorbic acid in a pairwise approach, 
followed by subsequent generation of complex bi- and tricyclic molecules.  
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LiNTf2-Catalyzed aminolysis of 
lactones with stoichiometric 
quantities of amines* 
 
Lactone aminolysis is a common transformation which allows direct 
conversion to the corresponding amides, and it is a highly attractive 
transformation in modern organic synthesis, although it generally requires 
harsh conditions,60 which are limiting factors expecially in scale-up 
procedures. Moreover, excess of amine is generally used to guarantee 
proper conversion and reaction rate, making the direct aminolysis not 
feasible especially when the amines are not readily available.61 Several 
methods have been reported in the literature for facilitating the reaction of 
lactones with amines,62 and the use of the Weinreb reagents coming from 
the reaction of trimethylaluminium with an amine, or the use of 2-
hydroxypyridine have been considered as being the most popular.63 
Recently, Shimizu reported on the use of Me2AlCl–HN(OMe)Me as an 
                                                                        
* C. Lalli, A. Trabocchi, G. Menchi, A. Guarna  Synlett 2008, 2, 189-192. 
60 M. J. Robins, S. Sarker, M. Xie, W. Zhang, M. A. Peterson Tetrahedron Lett. 1996, 37, 3921–3924 
61 (a) J. H. Musser, P. F. VonVoightlander, J. Szmuszkovicz Heterocycles 1986, 24, 155–159. (b)G. 
Blay, L. Cardona, B. Garcia, C. L. Garcia, J. Pedro Tetrahedron Lett. 1994, 35, 931–934. 
62 (a) A. Basha, M. Lipton, S. M. Weinreb Tetrahedron Lett. 1977, 4171–4174. (b) J. I. Levin, E. Turos, 
S. M. Weinreb Synth. Commun. 1982, 12, 989–993. (c) M. F. Lipton, A. Basha, S. M. Weinreb Org. 
Synth. 1979, 59, 49. (d) D. R.  Sidler, T. C. Lovelace, J. M. McNamara, P. J. Reider J. Org. Chem. 1994, 
59, 1231–1233. (e) W. M. Liu, D. D. Xu, O. Repic, T. J. Blacklock Tetrahedron Lett. 2001, 42, 2439–
2441. (f) J. M. Williams, R. B. Jobson, N. Yasuda, G. Marchesini, U. H. Dolling, E. J. J. Grabowski 
Tetrahedron Lett. 1995, 36, 5461– 5464. (g) K. Iseki, D. Asada, Y. Kuroki J. Fluorine Chem. 1999, 97, 
85–89. 
63 See for example: (a) Jr. J. Rebek, R. Beerli Tetrahedron Lett. 1995, 36, 1813–1816. (b) M. Shibasaki, 
S. Nakamura Tetrahedron Lett. 1994, 35, 4145–4148. (c) D. A. Evans, S. W. Kaldor, T. K. Jones, J. 
Clardy, T. J. Stout  J. Am. Chem. Soc. 1990, 112, 7001–7031. (d) R. S. Garigipati, D. M. Tschaen, S. M. 
Weinreb J. Am. Chem. Soc. 1985, 107, 7790–7792. 
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efficient amidating agent.64 As lactone aminolysis is commonly carried out 
in multi-step synthesis, there is an interest for versatile activators which 
could be of great benefit, expecially where stoichiometric amounts of 
valuable building blocks have to be used. 
Recently, Cossy and coworkers reported the application of LiNTf2 as an 
efficient activator towards regioselective ring opening of epoxides with a 
variety of nucleophiles including amines.65 This process was adopted by our 
group as a tool to synthesize intermediate compounds in the gram scale.28 
We reasoned that a similar effect could exist with respect to oxygen atoms 
of lactones, as a consequence of activation of the carbonyl group towards 
nucleophilic aminolysis, thus opening the route towards a general and facile 
method for the ring opening of lactones of different ring size with amines 
belonging to different classes.  
Specifically, as a part of a program towards the development of 
heterocycles carrying of chemical diversity, we were interested in finding an 
easy and efficient method for synthesizing molecules through the 
aminolysis of lactones,66 and in particular we were interested in achieving 
the reaction using stoichiometric quantities of the reactants (see chapter 5).  
After the initial observation that the addition of sub-stoichiometric 
quantities of LiNTf2 could catalyze the aminolysis of γ-butyrolactone 6.1, 
we started investigating the best conditions to achieve optimal conversion 
using allylamine 6.2 (Scheme 6.1), specifically by tuning the solvent and the 
temperature, and monitoring the reaction time until completion. 
 
O O H
N
OH
O
LiNTf2 0.5 eq.
Allylamine 6.2
1 eq.
CHCl3
70 °C, 40 h6.1 6.3  
 
Scheme 6.1. Model reaction with γ-butyrolactone and allylamine. 
 
Among the three main solvent systems tested, namely THF, EtOH and 
chloroform, the corresponding control experiments were also carried out at 
refluxing temperatures, to have reference data about the yields without 
LiNTf2 (Table 6.1, entries 1-4, respectively). Reactions conducted in EtOH 
at 80°C in a sealed vial showed a 43% and 62% yield after 17 and 40 h, 
respectively (Table 6.1), whereas THF and chloroform produced the title 
amido alcohol in 37% and 52% yield, respectively. Addition of LiNTf2 in 
THF did not yield any improvement (entry 5), as the reaction outcome 
dropped to 12%, indicating this solvent is not compatible with the lithium 
                                                                        
64 (a) T. Shimizu, K. Osako, T. Nakata Tetrahedron Lett. 1997, 38, 2685–2688. (b) N. Murakami, T. 
Nakajima, M. Kobayashi Tetrahedron Lett. 2001, 42, 1941–1943. 
65 J. Cossy, V. Bellosta, C. Hamoir, J. –R. Desmurs Tetrahedron Lett. 2002, 43, 7083–7086. 
66 A. Guarna, A. Trabocchi, G. Menchi, C. Lalli, F. Sladojevich, N. Cini Heterocyclic compounds 
containing the morpholine nucleus their preparation and use. WO2008/129004, October 30th 
2008. 
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salt-catalyzed aminolysis. The reaction in EtOH and in the presence of 
LiNTf2 indicated a small effect of the catalyst, as a similar yield as the 
control experiment was achieved at lower temperature (Table 6.1, entry 6 
compared to entry 2). We next turned our attention to halogenated 
solvents, as these were reported being the systems of choice in the 
aminolysis of epoxides,65 probably due to their low coordinating effect 
towards the catalyst, thus resulting in a lower interference in the process. 
Dichloromethane was tested at different temperatures (entries 7-9), giving 
at 40°C yields similar to EtOH, with no additional improvement by 
prolonging the reaction time from 17 to 72 h (entries 8-9). Also, the 
addition of 10% 1,1,1,3,3,3-hexafluoroisopropanol produced the same 
result as of pure dichloromethane, indicating no beneficial effect to the 
reaction (entry 10). These preliminary experiments suggested the solvent to 
play a role in the reaction, and that an aprotic solvent with a high polar 
character might allow the lithium salt to work optimally in activating the 
carbonyl group towards the ring opening aminolysis. In fact, chloroform 
showed a marked improvement with respect to dichloromethane, as when 
the reaction was carried out at refluxing temperature, the yield was raised to 
83% (entry 12). Finally, the best conditions were achieved by prolonged 
reaction of γ-butyrolactone and allylamine in stoichiometric amounts in 
chloroform at 85°C for 40 h, giving a clean product in quantitative yield 
(entry 13). Further attempts to lower both the temperature and the catalyst 
load resulted in lower yield (entry 14-16). Whenever incomplete reaction 
was observed, the crude mixture contained only the starting material and 
the title product, without significant amount of degraded material. 
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 Entry Solvent  T(°C) t(h) LiNTf2(eq)  Yield(%) 
 
 1 THF   85a 24 0  37 
 2 EtOH   95 a 17 0  43 
 3 EtOH   95 a 40 0  62 
 4 CHCl3   85
 a 40 0  52 
 5 THF   50 17 0.5  12 
 6 EtOH   50 17 0.5  62 
 7 CH2Cl2   20 17 0.5  33 
 8 CH2Cl2   40 17 0.5  58 
 9 CH2Cl2   40 72 0.5  60 
      10 CH2Cl2-HFIP(9:1) 20 17 0.5  38 
 11 ClCH2CH2Cl  20 17 0.5  48 
 12 CHCl3   85
 a 17 0.5  83 
 13 CHCl3   85
 a 40 0.5  99 
 14 CHCl3   20 17 0.5  43 
 15 CHCl3   85
 a 40 0.2  62 
 16 CHCl3   85
 a 40 0.1  60 
 
 a Oil-bath temperature corresponding to reflux condition in the sealed vial. 
 
Table 6.1. Aminolysis of γ-butyrolactone with 1 eq of allylamine in a sealed 
vial. 
 
As a hypothesized mechanism relating to the activating role of LiNTf2 
towards lactone aminolysis, the coordinating effect of the lactone carbonyl 
group was considered. Thus, the interaction of the strong electron 
withrawing lithium salt with the C=O bond would increase the electrophilic 
character of the carbonyl carbon atom towards nucleophilic addition of the 
amine, resulting in higher yield to the corresponding hydroxy amide. 
We next investigated the generality of the process by performing the 
reaction with lactones varying in ring-size and in substitution pattern, and 
also using amines of different steric and nucleophilic character. Ring-
opening of γ-butyrolactone was explored with secondary amines, and while 
piperidine gave quantitative yield, the bulky diisopropylamine did not yield 
any product, suggesting the relevance of steric hindrance (Table 6.2, entries 
2-3). Also, the nucleophilic character of the amine influenced the reaction 
conversion, as benzylamine and butylamine gave 100% yield, whereas 
aromatic p-anisidine gave the adduct in only 11% yield and the 
corresponding lactam resulting from subsequent cyclization of the hydroxy 
amide in 12% yield (entry 6). 
Surveying ring size of lactones indicated 4-6 membered rings to proceed in 
almost quantitative yields (entries 7-8), and also ε-caprolactone reacted 
under these conditions to furnish the corresponding product in 53% yield 
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(Table 6.2, entry 9). The presence of unprotected functional groups, and in 
particular of hydroxylic functions, proved to influence negatively the 
outcome of the reaction (entries 12-13), probably by interfering with the 
lithium salt. In particular, unprotected erythronolactone 6.20 failed to react, 
giving the adduct in only 6% yield (entry 13), whereas the corresponding 
isopropylidene derivative 6.22, having the two hydroxyls embedded in the 
dioxolane ring, reacted cleanly to produce the adduct in 93% yield (entry 
14). Similarly, α-benzyloxy-γ-butyrolactone 6.24 reacted quantitatively 
(entry 15), compared to the corresponding unprotected α-hydroxy-γ-
butyrolactone 6.18, which furnished the amido alcohol in 46% yield (entry 
12), thus corroborating the importance of having protic functional groups 
protected. In all cases, the amides resulting from aminolysis of the 
corresponding lactones where easily purified by standard flash 
chromatography. 
 
 
 Entry Amine  Lactone    Product          Yield(%) 
1 allylamine 6.2 6.1 6.3      99 
2 piperidine 6.1      6.4     100 
3 diisopropyl- 6.1  -            - 
amine 
4 benzylamine 6.1           6.5     100 
5 butylamine 6.1           6.6     99 
6 p-methoxy- 6.1              6.7     11a 
  aniline 
7 6.2  6.8     6.9      100 
8 6.2  6.10       6.11       95 
9 6.2  6.12       6.13      53 
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10 6.2        6.14  6.15       80 
11 6.2      6.16  6.17        64 
12 6.2  
O O
OH 6.18    6.19       46 
13 6.2            6.20   6.21       6 
14 6.2   6.22     6.23        93 
15 6.2       6.24 6.25      99 
16 6.2       6.26  6.27      80 
 
 a The corresponding butyrolactam 6.7bis was also obtained in 12% yield. 
 
Table 6.2. Various Lactones and Amines tested. 
 
Finally, preliminary investigations indicated this catalytic system to 
work with even more inactivated carboxylic esters, as the amidation of Boc-
Ala-OMe with allylamine in the presence of 0.5 eq of LiNTf2 under 
standard conditions furnished the corresponding Boc-alanine allylamide in 
52%, whereas only starting reagents were obtained in the corresponding 
control experiment without the lithium salt. Similar results were obtained 
for the synthesis of protected hydroxamic acids from lactones, as the 
reaction of γ-butyrolactone with O-benzylhydroxylamine resulted in 45% 
yields under standard conditions compared to 0% of the control 
experiment, thus indicating the possibility of preparing N-hydroxamic acids 
from lactones by this method. 
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In conclusion, we report a mild and effective method for the 
aminolysis of lactones with stoichiometric quantities of amines, which 
consists on the use of LiNTf2 as an activator of the carbonyl function of 
the lactone. The method was developed using chloroform as solvent, and 
the generality of the reaction was demonstrated with selected amines and 
lactones, indicating the importance of avoiding steric hindrance and of the 
protection of protic functional groups for optimal conversions. The 
method was also tested for the reaction of an allylamine with the methyl 
ester of Boc-alanine, and for the lactone aminolysis of γ-butyrolactone with 
protected hydroxylamine, indicating the possibility of a more general 
application of LiNTf2-catalyzed reactions on lactones and esters. 
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Modulating the reactivity of α-
Isocyanoacetates: novel Four-
Component Reaction for 
heterocyclic scaffolds synthesis 
 
The reactions involving more than two reagents in a one-pot 
process to give a product incorporating the majority of the atoms of the 
reactants are called MultiComponent Reactions (MCRs). The MCRs are 
powerful processes to give molecular complexity and to generate more than 
two chemical bonds, with the advantage of selectivity, convergence and 
atom economy. The starting materials are generally commercially available 
or simple to synthesize. The synthesis of α-amino acid via α-aminonitrile 
developed by Strecker in 1850 is considered the first multicomponent 
reaction.67 Then the synthesis of heterocycles were developed by Hantzsch68 
and a lot of examples are known in literature until the first four-component 
reaction to give access to natural products.69 
The most employed MCR involves an isonitrile (IMCR, Isocyanide-based 
MultiComponent Reaction) and this is due to the particular reactivity of the 
isonitrile able to react with the nucleophiles and the electrophiles. The first 
multicomponent reaction involving an isonitrile was developed by Passerini 
in 1921,70 then Ugi described the most important four-component reaction 
                                                                        
67 (a) A. Strecker Justus Liebig Ann. Chem. 1850, 75, 27. (b) A. Strecker Justus Liebig Ann. Chem. 1850, 
91, 349. 
68 (a) A. Hantzsch  Justus Liebig Ann. Chem. 1882, 215, 1. (b) A. Hantzsch  Ber.Dtsch. Chem. Ges. 1890, 
23, 1474. 
69 (a) H. T. Bucherer, W. Steiner  J. Prakt. Chem. 1934, 140, 24. 
70 (a) M. Passerini  Gazz. Chim. Ital. 1921, 51, 126. (b) M. Passerini  Gazz. Chim. Ital. 1921, 51, 181. (c) 
M. Passerini  Gazz. Chim. Ital. 1922, 52, 432. 
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involving an amine, an aldehyde, a carboxylic acid and an isonitrile71 
(Scheme 7.1). 
 
R1CO2H R2CHO R3NC
P-3CR
R1 O
O R2 H
N
O
R3
R1CO2H R2CHO R3NC
U-4CR
R1 N
O R2 H
N
O
R3
R4NH2
R4  
 
Scheme 7.1. The three-component Passerini reaction (P-3CR) and the four-
component Ugi reaction (U-4CR) involving isonitriles. 
 
Recently a new multicomponent synthesis of 5-aminooxazoles has been 
reported using an aldehyde, an amine and an α-isocyanoacetamide72 
(Scheme 7.2). 
 
R1CHO R2R3NH
CN
NR5R6
O
R4
N
O
NR5R6
R4
R1
NR2R3
 
 
Scheme 7.2. Three-component synthesis of 5-aminooxazoles with an α-
isocyanoacetamide. 
 
As has been demonstrated the interesting property of these isonitriles 
consists in the acidity of the α-proton, due to electron-withdrawing group 
in α position like an ester or a nitrile. The chemistry of methyl α-
isocyanoacetate73 was investigated thoroughly in the 1970s, mainly by the 
research groups of Schllkopf and Matsumoto.74,75,76 By taking advantage of 
                                                                        
71 (a) I. Ugi, R. Meyer  Angew. Chem. 1958, 70, 702. (b) I. Ugi, R. Meyer  Chem. Ber. 1960, 93, 239. (c) I. 
Ugi, R. Meyer  Angew. Chem. 1959, 71, 386. (d) I. Ugi, C. Steinbruckner  Angew. Chem. 1960, 72, 267. 
72 (a) X. Sun, P. Janvier, G. Zhao, H. Bienayme, J. Zhu J. Org. Chem. 2001, 3, 877. (b) X. Sun, P. 
Janvier, G. Zhao, H. Bienayme, J. Zhu J. Am. Chem. Soc. 2002, 124, 2560. 
73 (a) D. Hoppe Angew. Chem. 1974, 86, 878–893. (b) D. Hoppe Angew. Chem. Int. Ed. Engl. 1974, 13, 
789–804. (c) U. Schllkopf Angew. Chem. 1977, 89, 351–360. (d) U. Schllkopf Angew. Chem. Int. Ed. 
Engl. 1977, 16, 339–348. (c) S. Marcaccini, T. Torroba Org. Prep. Proced. Int. 1993, 25, 141–208. 
74For selected examples of metal-mediated C-H activation of α-isocyanoacetates for the synthesis of 
heterocycles, see: (a) T. Saegusa, Y. Ito, H. Kinoshita, S. Tomita J. Org. Chem. 1971, 36, 3316–3323. 
(b) H. Takaya, S. Kojima, S. Murahashi Org. Lett. 2001, 3, 421–424. (c) Y. Ito, M. Sawamura, T. 
Hayashi J. Am. Chem. Soc. 1986, 108, 6405–6406. (d) A. Tongi, S. D. Pastor J. Org. Chem. 1990, 55, 
1649–1664. (e) T. Hayashi, E. Kishi, V. A. Soloshonok, Y. Uozumi Tetrahedron Lett. 1996, 37, 4969–
4972. (f) Y.-R. Lin, X.-T. Zhou, L.-X. Dai, J. Sun J. Org. Chem. 1997, 62, 1799–1803. (g) R. Grigg, M. 
I. Lansdell, M. Thornton-Pett Tetrahedron 1999, 55, 2025–2044. (h) S. Kamijo, C. Kanazawa, Y. 
Yamamoto J. Am. Chem. Soc. 2005, 127, 9260–9266. (i) C. Kanazawa, S. Kamijo, Y. Yamamoto J. 
Am. Chem. Soc. 2006, 128, 10662–10663. 
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the higher acidity of the α-phenyl-α-isocyanoacetate, Orru and co-workers 
recently developed an elegant three-component synthesis of imidazolines 
(Scheme 7.3).75  
 
 
 
Scheme 7.3. Three-component synthesis of imidazolines described by Orru 
and co-workers. 
 
The presence of the phenyl group is essential for this one-pot process. The 
phenyl group was thought to render the α CH position acidic enough to be 
deprotonated by a weak base. In general, the exploitation of the 
nucleophilicity of the α carbon atom and the electrophilicity of the divalent 
carbon atom of the isocyanide for the effective construction of C-C and C-
N bonds characterized the known chemistry of α-isocyanoacetates.73-76  
In connection with some project developed in Zhu group aimed at the 
development of novel multicomponent reactions77,78 with functionalized 
isocyanides as a key component,79,80,81 they became interested in the 
reactivity profile of hitherto unknown methyl α-(p-nitrophenyl)-α-
isocyanoacetate (Scheme 7.4). The nitro group is strategically incorporated 
into the phenyl ring to render the α C-H bond even more acidic, so that it 
can be deprotonated by weaker bases. Whereas the ready formation of the 
carbanion is the key consideration in the development of the three-
component reaction described by Orru and co-workers, we expected that 
                                                                                                                                                                              
75 (a) R. S. Bon, C. Hong, M. J. Bouma, R. F. Schmitz, F. J. J. De Kanter, M. Lutz, A. L. Spek, R. V. 
A. Orru Org. Lett. 2003, 5, 3759–3762. (b) R. S. Bon, B. Van Vliet, N. E. Sprenkels, R. F. Schmitz, F. 
J. J. De Kanter, C. V. Stevens, M. Swart, F. M. Bickelhaupt, M. B. Groen, R. V. A. Orru J. Org. Chem. 
2005, 70, 3542–3553. 
76 For an alternative reaction pathway, see: M. Suzuki, K.-I. Nunami, T. Moriya, K. Matsumoto, N. 
Yoneda J. Org. Chem. 1978, 43, 4933–4935. 
77 For recent reviews, see: (a) C. Hulme, V. Gore Curr. Med. Chem. 2003, 10, 51–80. (b) R. V. A. 
Orru, M. De Greef Synthesis 2003, 1471–1499. (c) A. Jacobi vonWangelin, H. Neumann, D. 
Gordes, S. Klaus, D. StrJbing, M. Beller Chem. Eur. J. 2003, 9, 4286–4294. (d) V. Nair, C. Rajesh, A. 
U. Vinod, S. Bindu, A. R. Sreekanth, J. S. Mathen, L. Balagopal Acc. Chem. Res. 2003, 36, 899–907. (e) 
J. Zhu Eur. J. Org. Chem. 2003, 1133–1144. (f) G. Balme, E. Bossharth, N. Monteiro Eur. J. Org. 
Chem. 2003, 4101–4111. (g) C. Simon, T. Constantieux, J. Rodriguez Eur. J. Org. Chem. 2004, 4957–
4980. (h) P. Tempest Curr. Opin. Drug Discovery Dev. 2005, 8, 776–788. (i) A. D mling Chem. Rev. 2006, 
106, 17–89. 
78 For a monograph, see: Multicomponent Reactions (Eds.: J. Zhu, H. BienaymK), Wiley-VCH, 
Weinheim, 2005. 
79 For α-isocyanoacetamide, see: (a) X. Sun, P. Janvier, G. Zhao, H. BienaymK, J. Zhu Org. Lett. 
2001, 3, 877–880. (b) P. Janvier, X. Sun, H. BienaymK, J. Zhu J. Am. Chem. Soc. 2002, 124, 2560–
2567. (c) P. Janvier, M. Bois-Choussy, H. BienaymK, J. Zhu Angew. Chem. 2003, 115, 835–838. (d) P. 
Janvier, M. Bois-Choussy, H. BienaymK, J. Zhu Angew. Chem. Int. Ed. 2003, 42, 811–814. 
80 For ortho-isocyanobenzamide, see: D. Bonne, M. Dekhane, J. Zhu Org. Lett. 2005, 7, 5285–5288. 
81 For α-isocyanoacetic acid, see: (a) D. Bonne, M. Dekhane, J. Zhu Org. Lett. 2004, 6, 4771–4774. (b) 
D. Bonne, M. Dekhane, J. Zhu J. Am. Chem. Soc. 2005, 127, 6926–6927. 
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the carbanion derived from the isocyanoacetate would display decreased 
nucleophilicity, as it is highly stabilized. Consequently, its reaction with a 
polar double bond, such as that of an imine, would be initiated by the 
nucleophilicity of the divalent carbon atom of the isocyanide and lead to 
different heterocycles.82,83 The development of a three-component synthesis 
of 5-methoxyoxazoles and a four-component synthesis of furopyrrolones 
on the basis of the unique reactivity of methyl α-(p-nitrophenyl)-α-
isocyanoacetate has been reported84 (Scheme 7.4).  
 
CN CO2Me R2R3NH
R1CHO
NO2
toluene
toluene
TEA
R4ClOC
NO2
O
N
OMe
R3R2N
R1
N
O
OMe
R4O
R2
R1  
 
Scheme 7.4. Multicomponent synthesis of 5-methoxyoxazoles and 
furopyrrolones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        
82 (a) A. D mling, I. Ugi Angew. Chem. 2000, 112, 3300–3344. (b) A. D mling, I. Ugi Angew. Chem. Int. 
Ed. 2000, 39, 3168–3210. 
83 For recent innovative development of Ugi-type reactions, see: (a) L. El KaLm, L. Grimaud, J. 
Oble Angew. Chem. 2005, 117, 8175–8178 Angew. Chem. Int. Ed. 2005, 44, 7961–7964. (b) L. El 
KaLm, M. Gizolme, L. Grimaud, J. Oble Org. Lett. 2006, 8, 4019–4021. (c) G. B. Giovenzana, G. C. 
Tron, S. D. Paola, I. G. Menegotto, T. Pirali Angew. Chem. 2006, 118, 1117–1120. (d) G. B. 
Giovenzana, G. C. Tron, S. D. Paola, I. G. Menegotto, T. Pirali Angew. Chem. Int. Ed. 2006, 45, 
1099–1102. 
84 D. Bonne, M. Dekhane, J. Zhu Angew. Chem.Int. Ed. 2007, 46, 2485. 
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This work proposes the three-component synthesis of 5-
ethoxyoxazoles and the four-component synthesis of heterocycles oxa-
bridged. 
Compounds 7.2 were synthesized readily by a nucleophilic substitution 
reaction (SNAr) between the commercially available α-isocyanoacetate 7.1 
and fluoro derivatives I-V under basic conditions, in a different way Zhu 
and co-workers85 previously developed for the monoalkylation of 7.1 
(Scheme 7.5).  
 
CN CO2Et
F
Cs2CO3, DMSO
r.t, 16h
7.1
CN CO2Et
7.2
R R
I-V  
 
Scheme 7.5. Synthesis of ethyl α-isocyanoacetates 7.2 by a nucleophilic 
substitution reaction (SNAr) between 7.1 and fluoro derivatives I-V under 
basic conditions. 
 
The isonitriles synthesized are reported in Figure 7.1, the yields are good 
(53-72%) as shown in Table 7.1. 
 
N
CN CO2Et CN CO2Et
O2N
CN CO2Et
CO2Me
CN CO2Me
NO2
CN CO2Et
CN
7.3 7.4 7.5
7.6 7.7
 
 
Entry Alkylating Yield(%) Product 
1 1-F-4-NO2benzene (I) 63 7.3 
3 Me-4-F-benzoate (II) 58 7.4 
4 4-F-benzonitrile (III) 53 7.5 
5 4-F-pyridine (IV) 72 7.6 
6 1-F-2-NO2benzene (V) 66 7.7 
 
Figure 7.1 and Table 7.1. α-isocyanoacetates 7.3-7.7 synthesized.  
 
 
                                                                        
85 (a) C. Housseman, J. Zhu Synlett 2006, 1777–1779. (b) R. Beugelmans, A. Bigot, J. Zhu Tetrahedron 
Lett. 1994, 35, 5649–5652. 
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Detailed NMR spectroscopic studies indicated that these isocyanates exist 
as the ester and not in the enol form in common organic solvents. To 
evaluate the chemical reactivity of these isonitriles it was examined the 
three-component reaction with morpholine and cyclohexanal and other 
aldehydes. Condensation of the aldehyde with the amine affords the 
iminium ion (Scheme 7.6). The addition of the isocyanide to the iminium 
ion provides the nitrilium intermediate, which undergoes cyclization to 
afford the 5-ethoxyoxazole86 (Scheme 7.6).  
 
 
 
Scheme 7.6. Three-component synthesis of 5-ethoxyoxazoles: proposed 
mechanism. 
 
 
 
 
 
 
 
 
 
 
 
                                                                        
86 For recent reviews on the chemistry of oxazoles, see: (a) V. S. C. Yeh Tetrahedron 2004, 60, 11 995–
12042. (b) J. Zhong Nat. Prod. Rep. 2005, 22, 186–229. 
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In Figure 7.2 are reported the isocyanoacetate, the amines and the 
aldehydes used for this three-component reaction. 
 
CHOCHO
N
H
O
CHO
CHO
N
CN
Amine Aldehydes
Isonitrile
CO2Et CHO
CHO
i ii iii
iv v vi7.6  
 
Figure 7.2. Isocyanoacetate, amines and aldehydes used for the three-
component reaction for the synthesis of 5-ethoxyoxazole. 
 
This reaction is performed in toluene at r.t. for 16h (Scheme 7.7) and the 
yields are in every case good (50-81%) as shown in Table 7.2. 
 
 
 
Entry R1 Yield (%) Product 
1 Cyclohexyl (i) 81 7.8 
2 Hexyl (ii) 54 7.9 
3 Phenyl (iii) 50 7.10 
4 Benzyl (iv) 53 7.11 
5 Isopropyl (v) 61 7.12 
6 Cinnamyl (vi) 54 7.13 
 
Scheme 7.7. and Table 7.2. Development of three-component reaction: 
synthesis of 5-ethoxyoxazole with different aldehydes. 
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One shortcoming of this three-component reaction is that it 
provides only one point of diversity, at least three changing also amines and 
isonitriles. To further illustrate the utility of the α-isocyanoacetates (7.2) in 
the development of novel multicomponent reactions for heterocycle 
synthesis, the chemical transformation of the 5-ethoxyoxazole was next 
investigated by taking advantage of the functionalities of the 5-
ethoxyoxazoles. 5-ethoxyoxazole is known to be an active diene that readily 
undergoes Diels–Alder reactions with a range of dienophiles.87 In literature 
is reported the cycloaddition of an oxazole with an alkene,88 for pyridine 
synthesis via oxa-bridged intermediate. The 5-ethoxyoxazole presents a 
secondary amine that could be acylated with an α,β-insaturated acyl 
chloride and an azadiene moiety that could be involved in an intramolecular 
aza-Diels-Alder reaction (Scheme 7.8). 
 
 
 
Scheme 7.8. Synthesis of oxa-bridged intermediate from 5-ethoxyoxazoles 
and α,β-insaturated acyl chlorides via intramolecular aza-Diels-Alder 
reaction. 
 
When a solution of oxazole, TEA and (E)-ethyl 4-chloro-4-oxobut-2-
enoate in toluene was stirred at 110°C for 20 min, the oxa-bridged 
intermediate was obtained in a mixture of two saparable diastereoisomers. 
The stereochemistry can be deduced from the mechanism and from NMR 
studies. The coupling constant between Ha and Hb for each diastereoisomer 
is 4.2 Hz like in a trans relationship, and the strain of the oxa-bridged 
imposes a cyclization amide-exo, ester-endo giving only two of the four 
possible diastereoisomers (Figure 7.3). 
 
                                                                        
87 For reviews on the Diels–Alder reaction of oxazoles with alkynes, see: (a) M. Y. Karpeiskii, V. L. 
FlorentOev Russ. Chem. Rev. 1969, 38, 540–546. (b) P. A. Jacobi in Adv. in Heterocyclic Nat. Prod. Syn., 
Vol. 2 (Ed.:W. H. Pearson), 1992, pp. 251 – 298; for examples of the cycloaddition of 5-
aminooxazoles with alkynes, see: (c) P. Janvier, H. BienaymK, J. Zhu Angew. Chem. 2002, 114, 4467–
4470. (d) ) P. Janvier, H. BienaymK, J. Zhu Angew. Chem. Int. Ed. 2002, 41, 4291–4294. (d) A. Fayol, 
J. Zhu Angew. Chem. 2002, 114, 3785–3787. (e) A. Fayol, J. Zhu Angew. Chem. Int. Ed. 2002, 41, 3633–
3635. 
88 (a) G. Y. Kondrat’eva Chem. Abstr. 1958, 52, 6345. (b) M. Karpeiskii Russ. Chem. Rev. 1969, 38, 540. 
(c) A. Hassner, B. Fischer Heterocycles 1993, 35, 1441. 
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Figure 7.3. 1H NMR of one diastereoisomer of 7.14. 
 
If the same reaction is performed with (Z)-ethyl 4-chloro-4-oxobut-2-
enoate a mixture of two diastereoisomers is obtained and the relationship 
between the two protons Ha and Hb is always trans-like, this indicates that 
the cyclization is again endo-exo and not exo-exo as expected. This is due to 
an interaction between the carbonyl of the amide and the CO2Et group and 
the consequence is an epimerization of the intermediate exo-exo to give the 
endo-exo product (Figure 7.4). 
 
 
Figure 7.4. Unfavourable interaction in the expected product exo-exo:  
epimerization of this intermediate to give the endo-exo product. 
 
 
Ha 
Hb 
J = 4.2 Hz 
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The sequence of reactions proposed is one-pot and involves the 
formation of the 5-ethoxyoxazole and a two domino process involving an 
acylation and an aza-Diels-Alder reaction with the same yields with respect 
of the three-component reaction.  
The scope of this four-component reaction was examined by using three α-
isocyanoacetates, three aldehydes, five primary amines and three α,β-
insaturated acyl chlorides (Figure 7.5).  
 
 
CN CO2Et
O2N
CN CO2Et
CO2Me
CN CO2Et
CN
Isonitriles
CHOCHO
Aldehydes
CHO
Amines
NH2
NH2 NH2
NH2 MeO2C NH2
Acyl chlorides
Cl
O
CO2Et
CO2EtCl
O
Cl
O
7.4 7.5
7.7
i ii iii
a
b
c
 
 
 
Figure 7.5. Isocyanoacetates, amines, aldehydes and α,β-insaturated acyl 
chlorides used for the four-component reaction for the synthesis of oxa-
bridge heterocycles. 
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This reaction is performed in toluene at r.t. for 4-16h, depending on the 
reactivity of the isocyanate (Scheme 7.9), then the acyl chloride is added 
and the mixture is refluxed 20min; and the yields are in every case good 
(45-68%) as shown in Table 7.3. 
 
NC
O
OR1
O
R2
NH2
N
O
O
R'3
N
O
R1
R2
Cl
O
2. toluene
20min 110°C
R3
R
R
1. toluene
4-16h
r.t.-60°C
 
 
Entry R R1 R2 R3 Yield(%) Mix 
1 (7.14) p-CO2Me Cy Bn (Z)-CO2Et 68 13:1 
2 (7.15) p-CO2Me Ph Bn (Z)-CO2Et 57 1.8:1 
3 (7.16) p-CO2Me Ph Bn (E)-CO2Et 58 1.8:1 
4 (7.17) p-CO2Me eptanal butyl (Z)-CO2Et 65 2:1a 
5 (7.18) p-CO2Me Ph Bn (E)-Ph 61 2.5:1 
6 (7.19) p-CN Cy Bn (E)-CO2Et 54 20:1 
7 (7.20) p-CN Cy Gly (Z)-CO2Et 45b 6:1 
8 (7.21) o-NO2 Cy Bn (Z)-CO2Et 57 >50:1 
9 (7.22) o-NO2 Cy butyl (E)-CO2Et 54 >50:1 
10(7.23) o-NO2 Cy butyl (E)-Ph 65 10:1 
aseparated 
 bconversion incomplete isolated oxazole 
 
Sheme 7.9 and Table 7.3. Development of four-component reaction with 
functionalized isocyanides with different aldehydes, amines and α,β-
insaturated acyl chlorides. 
 
 
In conclusion a novel four-component reaction is proposed. The 
investigation of the reactivity of α-isocyanoacetates provide the formation 
of an oxa-bridged heterocyclic scaffold, highly functionalized, with four 
points of diversity. This four-component reaction exploites the formation 
of 5-ethoxyoxazoles that can undergo aza-Diels-Alder reaction in a very 
diastereoselective way, providing only the amide-exo, ester-endo product. 
These kind of new scaffolds should therefore find applications in a large 
number of fields for the synthesis of libraries of medicinally important 
heterocycles of this type.89  
                                                                        
89 (a) B. H. Lipshutz Chem. Rev. 1986, 86, 795–819, and references therein. (b) M. Chapdelaine,WO 
Patent 2005/100351A1, 2005 [Chem. Abstr. 2005, 143, 422508]. 
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Conclusions 
 
In this thesis work it has been described about new achievements in the 
field of development of peptidomimetic scaffolds via Diversity-Oriented 
Synthesis. In particular new synthetic methodologies have been developed and 
libreries of densely functionalized compounds are obtained for screening, in 
order to identify molecular structures to be selected as lead compounds for 
biological targets.  
In Chapter 3, it has been described about the possibility 
of obtain structural diversification starting from known 
structures like BTAa. In particular the synthesis of highly 
constrained spiro-β-lactams via Staudinger reaction, 
starting from a bicyclic ketene Bn-BTG(O)-OMe 
derived, is achieved. The aromatic imines are the best choice for the generation 
of spiro-β-lactams, in fact in this case the reaction proceeded with high 
stereoselectivity to produce the corresponding cis spiro-β-lactams as major 
compounds. Both aliphatic- and amino acid derived imines provided mixtures 
of cis- and trans spiro-β-lactams. Given the potential structural diversity of the 
bicyclic ketene, this method is of interest for the generation of densely 
functionalized molecular scaffolds having restricted conformational freedom. 
The optimization of the reaction conditions may allow the generation of 
polycyclic spiro-β-lactams as peptidomimetics for biomedical research. 
In Chapter 4, a new strategy for the development of bicyclic analogues of 
Proline was illustrated, which allowed to obtain Fmoc-amino acids readily 
available for solid phase synthesis of new modified reverse turn peptides. The 
use of L-Ascorbic acid and Glycine derivatives was explored to obtain a new α-
amino acid bicyclic scaffold. The coupling of the building blocks by SN2 
achieved a densely functionalized acyclic intermediate that undergoes 
cyclization in the standard conditions (trifluoroacetic acid) providing the 
scaffold carrying the carboxylic group in 2-endo and in 2-exo position. The 
preparation of 4-endo-carboxylic scaffolds proved to be problematic and low 
yielding, as previously reported, so the facile synthesis of this Proline analogue 
with the carboxylic group in 2-endo position, provides a more complete 
collection of bicyclic amino acids for application in peptidomimetic chemistry. 
The exo-diastereoisomer is more difficult to obtain, the cyclization by treatment 
with trifluoroacetic acid provided the bicyclic scaffold as methyl ester derivative, 
probably because of the axial orientation of the carbomethoxy group. This lead 
to the hypothesis that the facile hydrolysis of the 2-endo diastereoisomer might 
occur through the urethane carbonyl group providing anchimeric assistance to 
the equatorial carbomethoxy group.  
Structural 
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In Chapter 5 the DOS approach has been applied to 
the generation of morpholine-containing molecular 
scaffolds for peptidomimetic chemistry. The build 
phase consists in the synthesis of the building blocks 
from chiral pool: bifunctional building blocks deriving from α-amino acids and 
L-Ascorbic acid were coupled. The pair phase allowed to obtain morpholine-
lactones, a first degree of skeletal diversity around the morpholine nucleus. In 
this 1st generation of morpholine compounds is included also the bicyclic 
Proline analogue of above. The aminolysis of the lactones gave a 2nd generation 
of morpholine scaffolds that then could be further modified to obtain complex 
bi- and tricyclic molecules (3rd generation) like diketopiperazine, 
benzodiazepyne and lactam. During the development of this 2nd generation we 
were interested in finding an easy and efficient method to operate the 
aminolysis of lactones, and in particular we were interested in achieving the 
reaction using stoichiometric quantities of reactants. In this contest the studies 
about aminolysis lactones LiNTf2-catalyzed are placed.    
In Chapter 6 is reported a mild method for the aminolysis of lactones with 
stoichiometric quantities of amines, which consists on the use of LiNTf2 as an 
activator of the carbonyl function of the lactone. The scope of the reaction has 
been investigated with selected amines and lactones and the generality of the 
reaction is demonstrated, except for amines with steric hindrance and lactones 
presenting non-protected protic functional groups. The method was also tested 
for the reaction of the methyl ester of Boc-alanine with allylamine, and for the 
lactone aminolysis of γ-butyrolactone with protected hydroxylamine, indicating 
the possibility of a more general application of LiNTf2-catalyzed reactions on 
lactones and esters. 
In Chapter 7 the development of a novel multicomponent reaction with α-
isocyanoacetates to give highly functionalized oxa-bridged heterocycles is 
proposed. Multicomponent reactions are a powerful process to obtain diversity 
and complexity in a rapid way. In the context of a collaboration program with 
Dr. Jieping Zhu from ICSN, CNRS of Gif-sur-Yvette (France), a new four-
component reaction for heterocyclic scaffolds synthesis, useful for medicinal 
chemistry, was developed. The sequence of reactions proposed is the formation 
of a 5-ethoxyoxazole starting from α-isocyanoacetates and a two domino 
process involving an acylation and an aza-Diels-Alder reaction. The scope of 
this four-component reaction was examined by using three α-isocyanoacetates, 
three aldehydes, five primary amines and three α,β-insaturated acyl chlorides. 
Oxa-bridged heterocyclic scaffolds, highly functionalized, with four points of 
diversity were synthesized. The aza-Diels-Alder reaction is highly 
diastereoselective, providing only the amide-exo, ester-endo product. These kind 
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of new scaffolds should find applications in a large number of fields for the 
synthesis of libraries of medicinally important heterocycles of this type. 
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Experimental Section 
8.1. General 
 
Melting points are uncorrected. Chromatographic separations were 
performed on silica gel using flash-column techniques; Rf values refer to TLC 
carried out on 25-mm silica gel 60 F254 plates with the same eluant indicated for 
column chromatography.  
1H and 13C NMR spectra were recorded with a Varian Gemini  200 (and 50.33 
MHz, respectively with a Varian Gemini 200) or a Varian Mercury Plus 400 
instrument using CDCl3  DMSO or CD3OD solutions. EI mass spectra were 
carried out at 70 eV ionizing voltage using a QMD 1000 Carlo Erba Shimadzu 
spectrometer. IR spectra were recorded with a Perkin Elmer FT-IR-881 
spectrophotometer. Elemental analyses were obtained with a Perkin-Elmer 
2400/2 C analyzer. A JASCO DIP-370 instrument was used for polarimetric 
determinations.  
THF was distilled from Na/benzophenone. CH2Cl2 was distilled from CaH2. 
All reactions requiring anhydrous conditions were performed in oven-dried 
glassware.  
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8.2. Abbreviations 
 
°C   Degrees Celsius 
Å   Ångström 
Ac   Acetyl 
Ar   Aromatic group, not phenyl 
Atm   Standard Atmosphere 
Bn   Benzyl 
Boc   di-tert-butyl dicarbonate 
bs   broad signal 
Bu   Butyl 
C   cyclo / concentration 
Cat   catalyst 
Cbz   Carboxybenzyl 
CH2Cl2   Dichloromethane 
COSY   COrrelation SpectroscopY 
d   doublet 
dd   doublet of doublets 
DIAD   diisopropyl azodicarboxylate 
DMAP   4-dimethylaminopyridine 
DMF   dimethylformamide 
DMSO   dimethylsulfoxide 
EDG   Electron Donating Group 
eq   equivalents 
ESI   ElectroSpray Ionization 
Et   Ethyl 
Et2O   Diethyl ether 
EtOAc   Ethyl Acetate 
EtOH   Ethanol 
EWG   Electron Withdrawing Group 
Fmoc   9H-fluoren-9-yl-methoxycarbonyl 
g   gram 
h   hour(s) 
HPLC   High Performance Liquid Chromatography 
Hz   Hertz 
i   iso 
IR   InfraRed 
M   molar 
m   meta 
m   multiplet 
m/z   mass-to-charge ratio 
Me   Methyl 
MeOH   Methanol 
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mg   milligram 
MHz   MegaHertz 
min   minute 
mL   millilitre 
µL   microlitre 
mmol   millimole 
mol   mole 
M.p.   melting point 
MS   molecular sieves / mass spectrometry 
n   normal, straight chain 
nm   nanometre 
NMR   Nuclear Magnetic Resonance 
NOE   Nuclear Overhauser Effect 
Nu   nucleophile 
o   ortho 
p   para 
Ph   Phenyl 
Pr   Propyl 
ppm   parts per million 
q   quartet 
quat   quaternary 
R   any alkyl group 
Ref   reference 
r.t.   room temperature 
s   singlet 
t    triplet (NMR) / tertiary 
T   temperature 
t-Bu  tert-butyl 
TFA   Trifluoroacetic acid 
THF   Tetrahydrofuran 
TLC   Thin Layer Chromatography 
TMS   trimethylsilyl 
Ts   p-toluenesulfonyl 
p-TSA    p-toluene sulfonic acid 
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8.3. Experimental Section of 
Chapter 3 
 
(1R,5S,7R)-3-Benzyl-2-oxo-6,8-dioxa-3-
azabicyclo[3.2.1]octane-7-carbonyl Chloride 
 
 
  
Bn-BTG(O)-OMe 3.1 was dissolved in anhydrous THF to give a 0.1 M 
solution, and TMSOK (1.5 eq) was added in one portion. After stirring 
1.5h at room temperature, the mixture was diluted with EtOAc, washed 
with 5% KHSO4 and brine and dried with Na2SO4. Evaporation of the 
organic phase gave pure acid 3.2 in 95% yield. 1H NMR (200 MHz, CDCl3): 
δ = 7.36–7.18 (m, 5 H, Ph), 5.92 (d, J = 2.2 Hz, 1 H, 5-H), 5.12 (s, 1 H, 1-
H), 4.96 (s, 1 H, 7-H), 4.56 (s, 2 H, CH2-Ph), 3.39 (dd, J = 12.4 Hz, J = 2.4 
Hz, 1 H, 4-H), 3.14 (d, J = 12.0 Hz, 1 H, 4-H) ppm. To a solution of acid 
3.2 (1 eq) in dry CH2Cl2 (0.7 M) was slowly added a solution of oxalyl 
chloride (5 M, 3 eq) in dry CH2Cl2, and a drop of dry DMF was then added. 
The mixture was stirred at room temperature under a nitrogen atmosphere 
for 15h, and the solvent was then concentrated in vacuo to give the 
corresponding acyl chloride 3.3, which was immediately used in the 
Staudinger reaction. 
 
 
General Procedure for the Synthesis of Spiro Compounds 3.6–
3.13 
(Method 1): A solution of the proper imine (1.1 eq) and dry TEA (1.5 eq) 
in dry toluene (0.2 M) was heated to reflux under a nitrogen atmosphere; a 
mixture of Bn-BTG(O)-Cl (250 mg, 0.89 mmol, 1 eq) in dry toluene (0.4 
M) was then added. The mixture was stirred at 110°C under a nitrogen 
atmosphere for 16h, and it was then washed with saturated aqueous 
NaHCO3 and brine. The organic layer was dried with Na2SO4, filtered and 
concentrated in vacuo to give a dark oil. The pure products were afforded 
after purification by flash chromatography (petroleum ether/EtOAc, 1:1). 
 
 
Diastereoselective 
synthesis of spiro-β-
lactams 
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General Procedure for the Synthesis of Spiro Compound 3.7 
(Method 2): A solution of Bn-BTG(O)-Cl (250 mg, 0.89 mmol, 1 eq) and 
dry TEA (1.5 eq) in dry toluene (0.4 M) was stirred at the desired 
temperature under a nitrogen atmosphere for 10min, and a solution of 
imine (1.1 eq) in dry toluene (0.2 M) was then added. The mixture was 
stirred at the desired temperature under a nitrogen atmosphere for 15h, and 
it was then washed with saturated aqueous NaHCO3 and brine. The 
organic layer was dried with Na2SO4, filtered and concentrated in vacuo to 
give a dark oil, which was purified by flash chromatography (petroleum 
ether/ EtOAc, 1:1). 
 
 
Methyl 2-((1’R,3R/S,4R,5’S)-3’-benzyl-2,2’-dioxo-4-phenyl-6’,8’-
dioxa-3’-azaspiro[azetidine-3,7’-bicyclo[3.2.1]octane]-1-yl)-3-
phenylpropanoate 
 
 
 
White solid, 150 mg, 33% yield. 1H NMR (400 MHz, CDCl3) 3:2 mixture of 
diastereomers A and B: δ = 7.40–7.19 (m, 15 H, Ph, A+B), 5.59 (d, J = 2.4 
Hz, 1 H, 5-H, A), 5.32 (d, J = 2.4 Hz, 1 H, 5-H, B), 4.94 (s, 1 H, 1-H, A), 
4.89 (d, J = 15.1 Hz, CH2, A), 4.88 (s, 2 H, 4’-H, A+B), 4.82 (s, 1 H, 1-H, 
B), 4.74 (d, J = 15.3 Hz, 1 H, CH2, B), 4.52 (m, 1 H, α-H, B), 4.50 (d, J = 
15.3 Hz, 1 H, CH2, B), 4.05 (m, 1 H, α-H, A), 3.91 (d, J = 14.7 Hz, 1 H, 
CH2, A), 3.79 (s, 3 H, OCH3, B), 3.71 (s, 3 H, O CH3, A), 3.56 (dd, J = 
14.0, J = 11.9 Hz, 1 H, β-H, A), 3.30 (dd, J = 14.0 Hz, J = 4.6 Hz, 1 H, β-H 
A), 3.18 (m, 2 H, 4-H, B), 3.15 (m, 1 H, β-H, B), 3.13 (dd, J = 12.4 Hz, J = 
3.0 Hz, 1 H, 4-H, B), 3.05 (dd, J = 12.7 Hz, J = 2.4 Hz, 1 H, 4-H, A), 3.00 
(dd, J = 14.4 Hz, J = 9.6 Hz, 1 H, β-H, B), 2.45 (d, J = 14.0 Hz, 1 H, 4-H, 
A) ppm. 13C NMR (50 MHz, CDCl3) mixture of diastereomers A and B: δ 
= 169.2 (s, A), 168.2 (s, B), 164.5 (s, A), 163.3 (s, B), 136.8 (s, A), 136.6 (s, 
B), 135.3 (s, A), 134.7 (s, B), 134.0 (s, A), 132.7 (s, B), 129.3 (d), 129.2 (d), 
128.9 (d), 128.8 (d), 128.7 (d), 128.5 (d), 128.3 (d), 128.2 (d), 127.9 (d), 
127.7 (d), 127.6 (d), 127.2 (d), 127.1 (d), 100.5 (d, B), 100.1 (d, A), 92.5 (s, 
A), 91.9 (s, B), 79.6 (d, A), 76.8 (d, B), 70.9 (d, A), 62.9 (d, B) 58.9 (d), 57.9 
(d), 57.1 (d), 52.9 (q), 50.7 (d, A), 50.6 (d, B), 48.6 (d, A), 48.4 (d, B), 36.2 (t, 
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B), 35.6 (d, A) ppm. MS: m/z (%) = 512 (3) [M]+, 307 (48), 268 (11), 160 
(76), 148 (21), 117 (13), 91 (100). IR (CDCl3): ν = 3072, 2931, 1792, 1743, 
1664, 1493, 1458 cm–1. 
 
 
(1’R,3R/S,4R,5’S)-1,3’-dibenzyl-4-phenyl-6’,8’-dioxa-3’-azaspiro 
[azetidine-3,7’-bicyclo[3.2.1]octane]-2,2’-dione 
 
 
 
White solid, 258 mg, 66% yield. 1H NMR (400 MHz, CDCl3) mixture of 
diastereomers A and B: δ = 7.48–7.07 (m, 15 H, Ph, A+B), 5.68 (d, J = 2.6 
Hz, 1 H, 5-H, B), 5.42 (d, J = 2.3 Hz, 1 H, 5-H, A), 4.98 (s, 1 H, 4’-H, B), 
4.97 (d, J = 14.2 Hz, 1 H, CH2, A), 4.96 (s, 1 H, 4’-H, A), 4.84 (d, J = 15.2 
Hz, 1 H, CH2, A), 4.83 (d, J = 14.7 Hz, 1 H, CH2, B), 4.82 (s, 1 H, 1-H, B), 
4.78 (d, J = 14.8 Hz, 1 H, CH2, B), 4.55 (s, 1 H, 1-H, A), 4.45 (d, J = 14.8 
Hz, 1 H, CH2, A), 3.99 (d, J = 14.8 Hz, 1 H, CH2, B), 3.97 (d, J = 14.7 Hz, 
1 H, CH2, B), 3.94 (d, J = 14.7 Hz, 1 H, CH2, A), 3.22 (dd, J = 12.5 Hz, J = 
2.4 Hz, 1 H, 4-H, A), 3.18 (dd, J = 12.5 Hz, J = 2.7 Hz, 1 H, 4-H, B), 3.10 
(dd, J = 12.5 Hz, J = 2.3 Hz, 1 H, 4-H, A), 2.54 (d, J = 12.3 Hz, 1 H, 4-H, 
B) ppm. 13C NMR (50 MHz, CDCl3) mixture of diastereomers A and B: δ = 
166.8 (s, B), 164.6 (s, B), 164.5 (s, A), 163.6 (s, A), 135.3 (s, A), 134.7 (s, B), 
134.4 (s, B), 134.3 (s, A), 133.8 (s, B), 132.8 (s, A), 128.9 (d), 128.8 (d), 
128.7 (d), 128.6 (d), 128.5 (d), 128.4 (d), 128.3 (d), 128.2 (d), 128.0 (d), 
127.8 (d), 127.7 (d), 127.6 (d), 100.6 (d, B), 100.1 (d, A), 93.2 (s, B), 92.6 (s, 
A), 79.5 (d, A), 76.7 (d, B), 68.1 (d, B), 62.3 (d, A), 50.8 (t, A), 50.5 (t, B), 
48.6 (t, A), 48.4 (t, B), 44.6 (t, 2 C) ppm. MS: m/z (%) = 440 (7) [M]+, 307 
(63), 292 (17), 216 (15), 160 (75), 148 (27), 132 (22), 91 (100), 65 (25). IR 
(CDCl3): ν = 3055, 2923, 1767, 1676, 1496, 1455 cm
–1. 
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(1’R,3R,4R,5’S)-3’-benzyl-4-phenyl-1-p-tolyl-6’,8’-dioxa-3’-azaspiro 
[azetidine-3,7’-bicyclo[3.2.1]octane]-2,2’-dione 
 
N
O
OO
N
O
Bn
cis major
3.8  
 
Yellow solid, 55 mg, 14% yield. M.p. 86–89°C. [α]25D = –84.44 (c = 0.7, 
CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ = 7.33–7.03 (m, 14 H, Ph), 5.70 (d, 
J = 2.6 Hz, 1 H, 5-H), 5.40 (s, 1 H, PhCHN), 5.09 (s, 1 H, 1-H), 5.04 (d, J 
= 14.6 Hz, 1 H, CH2Ph), 4.03 (d, J = 14.3 Hz, 1 H, CH2Ph), 3.41 (dd, J = 
12.4 Hz, J = 2.6 Hz, 1 H, 4-H), 2.64 (d, J = 12.4 Hz, 1 H, 4-H), 2.23 (s, 3 
H, CH3) ppm. 
13C NMR (CDCl3): δ = 164.6 (s, C=O), 163.7 (s, C=O), 
134.6 (s, Ph), 134.5 (s, Ph), 133.9 (s, Ph), 132.9 (s, Ph), 129.5 (d, 2 C, Ph), 
128.9 (d, 2 C, Ph), 128.8 (d, Ph), 128.6 (d, 2 C, Ph), 128.5 (d, 2 C, Ph), 128.1 
(d, Ph), 127.2 (d, 2 C, Ph), 117.7 (d, Ph), 100.1 (d, C-5), 92.2 (s, C-7), 76.9 
(d, PhCHN), 62.5 (d, C-1), 50.9 (t, C-4), 48.9 (t, CH2Ph), 21.1 (q, CH3) 
ppm. MS: m/z (%) = 440 (8) [M]+, 307 (19), 195 (41), 160 (51), 91 (100), 65 
(18). IR (CDCl3): ν = 3067, 2928, 1760, 1673 cm
–1. C27H24N2O4 (440.5): 
calcd. C 73.62, H 5.49, N 6.36; found C 73.59, H 5.48, N 6.34. 
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(1’R,3R,4R,5’S)-3’-benzyl-1-(4-methoxyphenyl)-4-phenyl-6’,8’-dioxa-
3’-azaspiro[azetidine-3,7’-bicyclo[3.2.1]octane]-2,2’-dione 
 
 
 
Yellow solid, 158 mg, 39% yield. M.p. 94–97°C. [α]25D = –124.98 (c = 0.8, 
CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ = 7.35–7.23 (m, 12 H, Ph), 6.85–
6.81 (m, 2 H, Ph), 5.75 (d, J = 2.6 Hz, 1 H, 5-H), 5.41 (s, 1 H, PhCHN), 
5.12 (s, 1 H, 1-H), 5.08 (d, J = 14.6 Hz, 1 H, CH2Ph), 4.05 (d, J = 14.7 Hz, 
1 H, CH2Ph), 3.78 (s, 3 H, OCH3), 3.30 (dd, J = 12.1, J = 2.6 Hz, 1 H, 4-
H), 2.67 (d, J = 12.1 Hz, 1 H, 4-H) ppm. 13C NMR (50 MHz, CDCl3): δ = 
164.7 (s, C=O), 163.4 (s, C=O), 156.5 (s, Ph), 134.6 (s, Ph), 132.9 (s, Ph), 
129.9 (s, Ph), 128.9 (d, Ph), 128.6 (d, Ph), 128.5 (d, Ph), 128.0 (d, Ph), 127.2 
(d, Ph), 119.0 (d, Ph), 114.3 (d, Ph), 100.1 (d, C-5), 92.3 (s, C-7), 76.9 (d, 
PhCHN), 62.6 (d, C-1), 55.5 (q, OCH3), 50.9 (t, C-4), 48.9 (t, CH2Ph) ppm. 
MS: m/z (%) = 456 (25) [M]+, 307 (23), 211 (66), 196 (33), 160 (75), 148 
(18), 91 (100), 77 (17), 65 (13). IR (CDCl3): ν = 3081, 2921, 1758, 1672, 
1513 cm–1. C27H24N2O5 (456.5): calcd. C 71.04, H 5.30, N 6.14; found C 
71.06, H 5.32, N 6.13. 
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(1’R,2R,3R,5’S)-3’-benzyl-2-(4-nitrophenyl)-1-p-tolyl-6’,8’-dioxa-3’-
azaspiro[azetidine-3,7’-bicyclo[3.2.1]octane]-2’,4-dione 
 
N
O
OO
N
O
Bn
O2N
cis major
3.11  
 
Yellow solid, 104 mg, 24% yield. M.p. 97–100°C. [α]25D = –121.72 (c = 
0.95, CH2Cl2). 
1H NMR (200 MHz, CDCl3): δ = 8.08 (d, J = 8.4 Hz, 2 H, 
Ar), 7.42–7.05 (m, 11 H, Ph), 5.74 (d, J = 2.20 Hz, 1 H, 5-H), 5.46 (s, 1 H, 
PhCHN), 5.11 (s, 1 H, 1-H), 4.81 (d, J = 14.3 Hz, 1 H, CH2Ph), 4.25 (d, J = 
14.3 Hz, 1 H, CH2Ph), 3.35 (dd, J = 12.1, J = 2.6 Hz, 1 H, 4-H), 2.74 (d, J 
= 12.4 Hz, 1 H, 4-H), 2.28 (s, 3 H, CH3) ppm. 
13C NMR (50 MHz, CDCl3): 
δ = 164.5 (s, C=O), 163.8 (s, C=O), 148.0 (s, Ph), 140.5 (s, Ph), 135.0 (s, 
Ph), 134.5 (s, Ph), 133.5 (s, Ph), 129.8 (d, Ph), 129.0 (d, Ph), 128.9 (d, Ph), 
128.4 (d, Ph), 128.0 (d, Ph), 123.9 (d, Ph), 117.5 (d, Ph), 100.4 (d, C-5), 92.4 
(s, C-7), 76.9 (d, PhCHN), 61.5 (d, C-1), 51.0 (t, C-4), 49.2 (t, CH2Ph), 21.1 
(q, CH3) ppm. MS: m/z (%) = 485 (5) [M]
+, 352 (13), 261 (23), 240 (30), 
148 (32), 91 (100), 65 (15). IR (CDCl3): ν = 3053, 2947, 1765, 1673, 1525 
cm–1. C27H23N3O6 (485.5): calcd. C 66.80, H 4.78, N 8.66; found C 66.83, H 
4.80, N 8.69. 
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(1’R,2R,3R,5’S)-3’-benzyl-2-(4-methoxyphenyl)-1-p-tolyl-6’,8’-dioxa-
3’-azaspiro[azetidine-3,7’-bicyclo[3.2.1]octane]-2’,4-dione 
 
N
O
OO
N
O
Bn
MeO
cis major
3.12  
 
Yellow solid, 247 mg, 59% yield. M.p. 99–101°C. [α]25D = –103.63 (c = 
0.95, CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ = 7.34–7.02 (m, 11 H, Ph), 
6.85–6.80 (m, 2 H, Ph), 5.72 (d, J = 2.6 Hz, 1 H, 5-H), 5.34 (s, 1 H, 
PhCHN), 5.07 (s, 1 H, 1-H), 4.98 (d, J = 14.6 Hz, 1 H, CH2Ph), 4.05 (d, J = 
14.6 Hz, 1 H, CH2Ph), 3.79 (s, 3 H, OCH3), 3.26 (dd, J = 12.4 Hz, J = 2.6 
Hz, 1 H, 4-H), 2.68 (d, J = 12.4 Hz, 1 H, 4-H), 2.26 (s, 3 H, CH3) ppm. 
13C 
NMR (50 MHz, CDCl3): δ = 164.6 (s, C=O), 163.9 (s, C=O), 159.8 (s, Ph), 
134.8 (s, Ph), 134.3 (s, Ph), 134.1 (s, Ph), 129.6 (d, Ph), 128.9 (d, Ph), 128.6 
(d, Ph), 128.0 (d, Ph), 124.7 (s, Ph), 117.7 (d, Ph), 114.1 (d, Ph), 100.2 (d, C-
5), 92.2 (s, C-7), 76.9 (d, PhCHN), 62.2 (d, C-1), 55.3 (q, OCH3), 50.9 (t, C-
4), 48.9 (t, CH2Ph), 21.2 (q, CH3) ppm. MS: m/z (%) = 470 (7) [M]
+, 337 
(74), 225 (54), 190 (73), 161 (22), 91 (100), 65 (24). IR (CDCl3): ν = 3063, 
2926, 1759, 1671, 1515 cm–1. C28H26N2O5 (470.5): calcd. C 71.47, H 5.57, N 
5.95; found C 71.47, H 5.55, N 5.96. 
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Crystallographic data are reported. 
 
   Table 1.  Crystal data and structure refinement for 12. 
  
  
      Identification code   12 
  
      Empirical formula           C28 H26 N2 O5 
  
      Formula weight              470.51 
  
      Temperature                 293(2) K 
  
      Wavelength                  0.71069 A 
  
      Crystal system, space group Orthorhombic, P 21 21 21 
  
      Unit cell dimensions        a=6.770(1)A  alpha=90.00(1)deg. 
                                  b=18.915(3)A beta=90.00(1)deg. 
                                  c=19.146(2)A gamma=90.00(1)deg. 
  
      Volume                      2451.7(6) A^3 
  
      Z, Calculated density       4,  1.275 Mg/m^3 
  
      Absorption coefficient      0.088 mm^-1 
  
      F(000)                      992 
  
      Crystal size                ? x ? x ? mm 
  
      Theta range for data collection 4.27 to 22.45 deg. 
  
      Limiting indices           -7<=h<=7, -20<=k<=20, -19<=l<=20 
  
      Reflections collected/unique 6552/3019[R(int)=0.0443] 
  
      Completeness to theta = 22.45 97.4 % 
  
      Refinement method          Full-matrix least-squares on F^2 
  
      Data/restraints/parameters   3019/0/316 
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      Goodness-of-fit on F^2       0.731 
  
      Final R indices[I>2sigma(I)] R1=0.0401,wR2=0.0661 
  
      R indices (all data)         R1 = 0.1180,wR2=0.0844 
  
      Absolute structure parameter 0.7(16) 
  
      Largest diff. peak and hole  0.119 and -0.131 e.A^-3 
  
        
Table 2.  Atomic coordinates ( x 10^4) and equivalent 
isotropic 
         displacement parameters (A^2 x 10^3) for 12. 
   U(eq) is defined as one third of the trace of the      
orthogonalized Uij tensor. 
         ________________________________________________________________ 
  
                      x           y           z         U(eq) 
         ________________________________________________________________ 
  
          N(1)      3739(7)     8936(2)     1545(3)     73(1) 
          N(2)      4760(7)     9887(3)     3944(3)     89(2) 
          O(1)      8068(5)     6392(2)     3137(2)     90(1) 
          O(2)      2240(5)     8927(2)     3096(2)     82(1) 
          O(3)       423(5)     9324(2)     1597(2)     99(1) 
          O(4)      1370(6)    10087(2)     3213(2)    103(1) 
          O(5)      6441(5)    10450(2)     3088(2)    107(1) 
          C(1)      4949(8)     8991(3)     2183(3)     71(2) 
          C(2)      3095(8)     9318(3)     2539(3)     70(1) 
          C(3)      8518(7)     7653(3)     2930(2)     71(2) 
          C(4)      5775(8)     8307(3)     2445(2)     62(1) 
          C(5)      4701(7)     7692(3)     2454(3)     75(2) 
          C(6)      7426(8)     7042(3)     2922(3)     70(2) 
          C(7)      7689(8)     8276(3)     2693(2)     72(2) 
          C(8)      5503(8)     7059(3)     2679(3)     78(2) 
          C(9)      4930(9)    10156(3)     3303(4)     80(2) 
          C(10)     2043(9)     9206(3)     1836(3)     80(2) 
          C(11)     3161(9)    10063(3)     2826(3)     83(2) 
          C(12)     4230(11)    8710(3)      863(4)     74(2) 
          C(13)     6125(10)    8501(3)      709(4)     86(2) 
          C(14)     2943(10)    9546(3)     4185(3)    100(2) 
          C(15)     7274(9)     9415(4)     4794(4)     79(2) 
          C(16)     5168(14)    8294(3)     -501(4)     96(2) 
          C(17)     3295(12)    8496(3)     -318(4)     97(2) 
          C(18)     6570(10)    8280(3)       30(4)     95(2) 
          C(19)     2817(9)     8714(3)      356(4)     92(2) 
          C(20)     7260(8)     8748(5)     4506(3)     96(2) 
          C(21)    10098(7)     6313(3)     3342(3)    116(2) 
          C(22)     1526(9)     9447(4)     3582(4)     98(2) 
          C(23)     8353(10)    9528(4)     5391(4)     95(2) 
          C(24)     6245(8)    10033(3)     4476(3)    102(2) 
          C(25)     9428(11)    9003(6)     5697(4)    122(2) 
          C(26)     5678(9)     8053(3)    -1235(3)    137(2) 
          C(27)     8305(13)    8208(4)     4823(4)    120(2) 
          C(28)     9347(11)    8352(5)     5411(5)    121(2) 
         
_____________________________________________________________ 
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Table 3.  Bond lengths [A] and angles [deg] for 12. 
_____________________________________________________________ 
 
  N(1)-C(10)                1.375(6) 
  N(1)-C(12)                1.413(6) 
  N(1)-C(1)                 1.475(5) 
  N(2)-C(9)                 1.333(6) 
  N(2)-C(24)                1.458(6) 
  N(2)-C(14)                1.464(6) 
  O(1)-C(6)                 1.367(5) 
  O(1)-C(21)                1.437(4) 
  O(2)-C(2)                 1.420(5) 
  O(2)-C(22)                1.438(6) 
  O(3)-C(10)                1.208(5) 
  O(4)-C(22)                1.406(6) 
  O(4)-C(11)                1.422(5) 
  O(5)-C(9)                 1.235(6) 
  C(1)-C(4)                 1.496(6) 
  C(1)-C(2)                 1.556(6) 
C(1)-H(1)                 0.9800 
  C(2)-C(11)                1.514(6) 
  C(2)-C(10)                1.538(7) 
  C(3)-C(6)                 1.372(6) 
  C(3)-C(7)                 1.381(5) 
C(3)-H(3)                 0.9300 
  C(4)-C(5)                 1.371(6) 
  C(4)-C(7)                 1.381(6) 
  C(5)-C(8)                 1.384(5) 
C(5)-H(5)                 0.9300 
C(6)-C(8)                 1.383(6) 
C(7)-H(7)                 0.9300 
C(8)-H(8)                 0.9300 
C(9)-C(11)                1.516(7) 
C(11)-H(11)               0.9800 
C(12)-C(19)               1.363(6) 
C(12)-C(13)               1.375(6) 
C(13)-C(18)               1.399(6) 
C(13)-H(13)               0.9300 
C(14)-C(22)               1.512(6) 
C(14)-H(14A)              0.9700 
C(14)-H(14B)              0.9700 
  C(15)-C(23)               1.374(6) 
  C(15)-C(20)               1.377(6) 
  C(15)-C(24)               1.491(6) 
  C(16)-C(17)               1.370(7) 
  C(16)-C(18)               1.391(7) 
  C(16)-C(26)               1.516(7) 
  C(17)-C(19)               1.394(7) 
C(17)-H(17)               0.9300 
C(18)-H(18)               0.9300 
C(19)-H(19)               0.9300 
  C(20)-C(27)               1.382(7) 
C(20)-H(20)               0.9300 
C(21)-H(21A)              0.9600 
C(21)-H(21B)              0.9600 
C(21)-H(21C)              0.9600 
C(22)-H(22)               0.9800 
  C(23)-C(25)               1.363(7) 
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 C(23)-H(23)               0.9300 
 C(24)-H(24A)              0.9700 
  C(24)-H(24B)              0.9700 
    C(25)-C(28)               1.349(7) 
  C(25)-H(25)               0.9300 
  C(26)-H(26A)              0.9600 
  C(26)-H(26B)              0.9600 
  C(26)-H(26C)              0.9600 
    C(27)-C(28)               1.357(7) 
  C(27)-H(27)               0.9300 
  C(28)-H(28)               0.9300 
 
  C(10)-N(1)-C(12)        133.1(5) 
  C(10)-N(1)-C(1)          95.9(5) 
  C(12)-N(1)-C(1)         131.0(5) 
  C(9)-N(2)-C(24)         120.8(5) 
  C(9)-N(2)-C(14)         122.0(5) 
  C(24)-N(2)-C(14)        116.3(5) 
  C(6)-O(1)-C(21)         118.7(4) 
  C(2)-O(2)-C(22)         105.5(4) 
  C(22)-O(4)-C(11)         99.9(4) 
  N(1)-C(1)-C(4)          115.1(4) 
  N(1)-C(1)-C(2)           86.7(4) 
  C(4)-C(1)-C(2)          120.0(5) 
     N(1)-C(1)-H(1)          111.0 
     C(4)-C(1)-H(1)          111.0 
     C(2)-C(1)-H(1)          111.0 
   O(2)-C(2)-C(11)         103.0(4) 
   O(2)-C(2)-C(10)         113.4(4) 
   C(11)-C(2)-C(10)        117.3(5) 
   O(2)-C(2)-C(1)          116.7(5) 
   C(11)-C(2)-C(1)         120.4(5) 
   C(10)-C(2)-C(1)          86.3(4) 
   C(6)-C(3)-C(7)          119.7(4) 
C(6)-C(3)-H(3)          120.2 
C(7)-C(3)-H(3)          120.2 
   C(5)-C(4)-C(7)          117.2(5) 
   C(5)-C(4)-C(1)          122.6(5) 
   C(7)-C(4)-C(1)          120.2(5) 
   C(4)-C(5)-C(8)          122.0(4) 
C(4)-C(5)-H(5)          119.0 
C(8)-C(5)-H(5)          119.0 
   O(1)-C(6)-C(3)          125.7(5) 
   O(1)-C(6)-C(8)          114.9(5) 
   C(3)-C(6)-C(8)          119.4(5) 
   C(4)-C(7)-C(3)          122.1(5) 
C(4)-C(7)-H(7)          119.0 
C(3)-C(7)-H(7)          119.0 
   C(6)-C(8)-C(5)          119.6(4) 
C(6)-C(8)-H(8)          120.2 
C(5)-C(8)-H(8)          120.2 
   O(5)-C(9)-N(2)          123.3(6) 
   O(5)-C(9)-C(11)         120.4(7) 
   N(2)-C(9)-C(11)         116.2(6) 
   O(3)-C(10)-N(1)         132.3(6) 
   O(3)-C(10)-C(2)         136.6(6) 
   N(1)-C(10)-C(2)          91.1(5) 
   O(4)-C(11)-C(2)         101.1(4) 
   O(4)-C(11)-C(9)         110.9(4) 
   C(2)-C(11)-C(9)         110.4(5) 
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O(4)-C(11)-H(11)        111.3 
C(2)-C(11)-H(11)        111.3 
C(9)-C(11)-H(11)        111.3 
   C(19)-C(12)-C(13)       120.2(6) 
   C(19)-C(12)-N(1)        119.4(6) 
   C(13)-C(12)-N(1)        120.4(6) 
   C(12)-C(13)-C(18)       119.2(6) 
C(12)-C(13)-H(13)       120.4 
C(18)-C(13)-H(13)       120.4 
   N(2)-C(14)-C(22)        110.3(4) 
N(2)-C(14)-H(14A)       109.6 
C(22)-C(14)-H(14A)      109.6 
N(2)-C(14)-H(14B)       109.6 
C(22)-C(14)-H(14B)      109.6 
H(14A)-C(14)-H(14B)     108.1 
   C(23)-C(15)-C(20)       118.7(6) 
   C(23)-C(15)-C(24)       117.8(7) 
   C(20)-C(15)-C(24)       123.5(7) 
   C(17)-C(16)-C(18)       116.8(6) 
   C(17)-C(16)-C(26)       122.1(8) 
   C(18)-C(16)-C(26)       121.1(7) 
   C(16)-C(17)-C(19)       122.3(6) 
C(16)-C(17)-H(17)       118.9 
C(19)-C(17)-H(17)       118.9 
   C(16)-C(18)-C(13)       121.8(6) 
C(16)-C(18)-H(18)       119.1 
C(13)-C(18)-H(18)       119.1 
   C(12)-C(19)-C(17)       119.7(6) 
C(12)-C(19)-H(19)       120.1 
C(17)-C(19)-H(19)       120.1 
 
   C(15)-C(20)-C(27)       119.8(6) 
C(15)-C(20)-H(20)       120.1 
C(27)-C(20)-H(20)       120.1 
O(1)-C(21)-H(21A)       109.5 
O(1)-C(21)-H(21B)       109.5 
H(21A)-C(21)-H(21B)     109.5 
O(1)-C(21)-H(21C)       109.5 
H(21A)-C(21)-H(21C)     109.5 
H(21B)-C(21)-H(21C)     109.5 
   O(4)-C(22)-O(2)         106.7(5) 
   O(4)-C(22)-C(14)        108.9(5) 
   O(2)-C(22)-C(14)        111.5(5) 
O(4)-C(22)-H(22)        109.9 
O(2)-C(22)-H(22)        109.9 
C(14)-C(22)-H(22)       109.9 
   C(25)-C(23)-C(15)       121.8(7) 
C(25)-C(23)-H(23)       119.1 
C(15)-C(23)-H(23)       119.1 
   N(2)-C(24)-C(15)        117.3(5) 
N(2)-C(24)-H(24A)       108.0 
C(15)-C(24)-H(24A)      108.0 
N(2)-C(24)-H(24B)       108.0 
C(15)-C(24)-H(24B)      108.0 
H(24A)-C(24)-H(24B)     107.2 
   C(28)-C(25)-C(23)       118.0(7) 
C(28)-C(25)-H(25)       121.0 
C(23)-C(25)-H(25)       121.0 
C(16)-C(26)-H(26A)      109.5 
C(16)-C(26)-H(26B)      109.5 
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H(26A)-C(26)-H(26B)     109.5 
C(16)-C(26)-H(26C)      109.5 
H(26A)-C(26)-H(26C)     109.5 
H(26B)-C(26)-H(26C)     109.5 
   C(28)-C(27)-C(20)       118.9(8) 
C(28)-C(27)-H(27)       120.5 
C(20)-C(27)-H(27)       120.5 
   C(25)-C(28)-C(27)       122.7(8) 
C(25)-C(28)-H(28)       118.6 
C(27)-C(28)-H(28)       118.6 
 
 
Table 4. Anisotropic displacement parameters (A^2x10^3) for   12. 
The anisotropic displacement factor exponent takes the    
form:   -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ] 
  _______________________________________________________________________ 
  
            U11     U22      U33     U23     U13     U12 
    _____________________________________________________________________ 
 
N(1)   77(4)   71(3)    70(4)    8(3)  -11(3)    0(3) 
N(2)   75(4)  101(4)    92(4)   -9(3)   -5(4)  -11(3) 
O(1)   77(2)   78(3)   116(3)   13(2)  -18(2)    2(2) 
O(2)   80(2)   86(3)    79(2)  -11(2)   14(2)  -12(2) 
O(3)   72(2)  115(3)   109(3)   -3(2)  -16(3)    9(2) 
O(4)   69(3)  113(3)   128(4)  -25(3)   -2(3)    6(2) 
O(5)   88(3)   91(3)   141(4)    0(2)    0(3)  -25(2) 
C(1)   72(4)   55(3)    85(4)    3(3)    6(4)   -6(3) 
C(2)   61(4)   78(4)    72(4)    2(4)    0(4)   -5(3) 
C(3)   53(3)   74(4)    87(4)    0(4)  -12(3)   -5(4) 
C(4)   53(4)   66(4)    67(4)    1(3)    2(3)  -14(3) 
C(5)   48(3)   92(4)    86(4)    7(4)   -8(3)   -6(4) 
C(6)   61(4)   74(4)    75(4)   -3(3)   -5(3)    5(4) 
C(7)   74(4)   64(4)    77(4)   -7(3)   -1(3)  -11(3) 
C(8)   63(4)   63(4)   107(5)    4(4)  -16(4)  -11(3) 
C(9)   65(5)   73(4)   103(5)  -18(4)    1(5)    2(3) 
C(10)  62(4)   77(4)   101(6)   -1(4)   -1(5)    0(3) 
C(11)  70(4)   80(4)   100(5)   -3(3)    6(4)   -6(4) 
C(12)  79(5)   74(4)    70(5)   15(4)  -18(5)   -1(4) 
C(13)  84(5)   84(4)    88(5)   10(4)    0(4)    4(4) 
C(14)  95(5)  118(5)    88(5)  -20(4)   10(5)  -14(4) 
C(15)  76(4)   87(5)    73(5)    1(4)    2(4)  -11(4) 
C(16) 131(7)   84(5)    72(6)    8(4)   14(6)  -12(5) 
C(17) 106(6)  115(5)    70(5)    7(4)  -20(5)    0(4) 
C(18) 115(6)   81(4)    90(5)    8(4)   32(6)    3(4) 
C(19) 106(5)   98(5)    74(4)    4(4)   -4(5)   14(4) 
C(20) 117(5)   94(5)    76(4)  -14(5)   10(4)    0(5) 
C(21)  85(4)  108(5)   154(5)   22(4)  -49(4)   16(3) 
C(22)  65(4)  128(6)   101(5)  -20(5)   17(4)  -31(4) 
C(23)  94(5)  100(6)    91(5)   -2(5)    0(4)  -12(5) 
C(24) 105(4)   89(5)   110(5)  -18(4)  -37(4)   -8(4) 
C(25) 118(6)  137(7)   110(6)   -2(7)  -22(5)  -15(6) 
C(26) 204(7)  131(5)    77(4)  -16(4)   30(5)   -1(5) 
C(27) 164(7)  100(6)    96(6)    0(5)   17(5)   -3(6) 
C(28) 135(6)  120(8)   106(6)   26(6)   -4(6)   24(6) 
____________________________________________________________________ 
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(1’R,2R,3R,5’S)-3’-benzyl-2-(4-bromophenyl)-1-p-tolyl-6’,8’-dioxa-3’-
azaspiro[azetidine-3,7’-bicyclo[3.2.1]octane]-2’,4-dione 
 
N
O
OO
N
O
Bn
Br cis major
3.13  
 
Yellow solid, 152 mg, 33% yield. M.p. 96–99°C. [α]25D = –123.02 (c = 0.95, 
CH2Cl2). 
1H NMR (200 MHz, CDCl3): δ = 7.42–7.16 (m, 9 H, Ph), 7.05–
6.99 (m, 4 H, Ph), 5.68 (d, J = 2.6 Hz, 1 H, 5-H), 5.37 (s, 1 H, PhCHN), 
5.09 (s, 1 H, 1-H), 4.87 (d, J = 14.6 Hz, 1 H, CH2Ph), 4.14 (d, J = 13.2 Hz, 
1 H, CH2Ph), 3.26 (dd, J = 12.4 Hz, J = 2.6 Hz, 1 H, 4-H), 2.69 (d, J = 12.1 
Hz, 1 H, 4-H), 2.25 (s, 3 H, CH3) ppm. 
13C NMR (50 MHz, CDCl3): δ = 
164.5 (s, C=O), 163.5 (s, C=O), 134.7 (s, Ph), 134.6 (s, Ph), 133.8 (s, Ph), 
132.1 (s, Ph), 131.8 (d, Ph), 129.7 (d, Ph), 129.0 (d, Ph), 128.9 (d, Ph), 128.7 
(d, Ph), 128.1 (d, Ph), 122.8 (s, Ph), 117.6 (d, Ph), 100.3 (d, C-5), 92.2 (s, C-
7), 76.9 (d, PhCHN), 61.9 (d, C-1), 50.9 (t, C-4), 48.9 (t, CH2Ph), 21.2 (q, 
CH3) ppm. MS: m/z (%) = 520 (5) [M + 1]
+, 518 (5) [M – 1]+, 387 (13), 385 
(13), 275 (22), 273 (22), 240 (15), 238 (15). IR (CDCl3): ν = 3054, 2991, 
1762, 1672, 1515, 1488 cm–1. C27H23BrN2O4 (519.4): calcd. C 62.44, H 4.46, 
N 5.39; found C 62.41, H 4.44, N 5.39. 
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8.4. Experimental Section of 
Chapter 4 
 
Methyl (R)-[(S)-2,2-Dimethyl-1,3-dioxolan-4-
yl](trifluoromethansulfonyloxy)acetate 
 
OO
CO2Me
TfO
4.2  
 
A solution of 4.1 (5.00 g, 26.3 mmol) in dry CH2Cl2 (45.5 mL) was cooled 
at -10°C, and precooled dry pyridine (4.50 mL) was added under a nitrogen 
atmosphere. Then a solution of Tf2O (7.30 mL, 34.2 mmol) in dry CH2Cl2 
(13.6 mL) was added over 30 min, and the mixture was stirred at r.t. for 
30min. After the organic phase had been washed with a satured NaHCO3 
solution (3×50 mL), the organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo to give a dark oil. Flash chromatography (petroleum 
ether/EtOAc, 2:1) afforded 4.2 as a white solid; yield: 4.98 g, (59%). M.p. 
51-54°C. [α]25D = +38.8 (c = 0.8, CH2Cl2). 
1H-NMR (400 MHz, CDCl3): δ 
= 5.04 (d, J = 5.5 Hz, 1 H, TfOCH), 4.56-4.52 (m, 1 H, ring H-4), 4.18 (dd, 
J = 9.4 Hz, J = 6.7 Hz, 1 H, CH2), 4.06 (dd, J = 9.4 Hz, J = 4.7 Hz, 1 H, 
CH2), 3.88 (s, 3 H, OCH3), 1.45 (s, 3 H, CH3), 1.36 (s, 3 H, CH3) ppm. 
13C-
NMR (100 MHz, CDCl3): δ = 165.1 (s, C=O), 121.5 (s, CF3), 111.1 (s, 
[C(CH3)2], 82.6 (d, TfOCH), 74.1 (d, ring C-4), 65.4 (t, CH2), 53.5 (q, 
OCH3), 25.9 (q, CH3), 25.0 (q, CH3) ppm. MS: m/z (%): 322 (8) [M]
+, 69 
(100), 55 (77). IR (CDCl3): ν = 3052, 2986, 1733, 1265 cm
-1. C9H13F3O7S 
(322.03): calcd. C 33.54, H 4.07; found C 33.46, H 3.99. 
 
 
 
 
 
 
 
 
 
Bicyclic Proline 
analogue from L-
Ascorbic acid 
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Methyl (S)-[(2,2-Dimethoxyethyl)amino][(R)-2,2-dimethyl-1,3-
dioxolan-4-yl]acetate 
 
OO
HN
CO2Me
MeO
MeO
4.4  
 
A solution of 4.2 (1.30 g, 4.01 mmol) in dry CH2Cl2 (20 mL) was cooled to 
0°C, and then a solution of 2,2-dimethoxyethanamine (4.3) (0.50 mL, 4.81 
mmol) and DIPEA (1.40 mL, 8.02 mmol) in dry CH2Cl2 (20 mL) was 
added under a nitrogen atmosphere. The mixture was stirred at r.t. for 15h, 
and then it was extracted with a satured NaHCO3 solution (3×40 mL). The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo to give 
a dark oil. Flash chromatography (petroleum ether/EtOAc, 3:1) afforded 
pure 4.4 as a yellow oil; yield: 1.11 g, (99%). [α]25D = +15.6 (c = 0.9, 
CH2Cl2). 
1H-NMR (400 MHz, CDCl3): δ = 4.41 [(t, J = 4.8 Hz, 1 H, 
(CH3)2CHCH2NH)], 4.18-4.13 (m, 1 H, ring H-4), 4.07-4.00 (m, 2 H, ring 
CH2), 3.76 (s, 3 H, CO2CH3), 3.35 (s, 3 H, OCH3), 3.34 (s, 3 H, OCH3), 
3.27 (d, J = 7.3 Hz, 1 H, CHNH), 2.76 (dd, J = 12.1 Hz, J = 6.3 Hz, 1 H, 
CH2NH), 2.63 (dd, J = 12.1 Hz, J = 4.6 Hz, 1 H, CH2NH), 1.72 (br, 1 H, 
NH), 1.41 (s, 3 H, CH3), 1.31 (s, 3 H, CH3) ppm. 
13C-NMR (100 MHz, 
CDCl3): δ = 173.3 (s, C=O), 109.7 (s), 103.5 [d, CH(OCH3)2], 76.8 [d, 
CHOC(CH3)2], 67.1 (t, CH2NH), 64.4 (d, CHCO2CH3), 53.9 (q, OCH3), 
53.2 (q, OCH3), 51.9 (q, OCH3), 49.5 (t, ring CH2), 26.7 (q, CH3), 25.3 (q, 
CH3) ppm. MS: m/z (%): 277 (4) [M]
+, 177 (79), 144 (100), 75 (96). IR 
(CDCl3): ν = 2991, 2955, 2836, 1733, 1250, 1219 cm
-1. C12H23NO6 (277.15): 
calcd. C 51.97, H 8.36, N 5.05; found C 51.84, H 8.40, N 5.12. 
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Methyl (S)-[(2,2-Dimethoxyethyl)(9H-fluoren-9-ylmethoxy 
carbonyl)amino][(R)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate 
 
OO
N
CO2Me
MeO
MeO
Fmoc
4.5  
 
To a solution of 4.4 (616 mg, 2.22 mmol) in dioxane (44 mL) at 0°C and 
under a nitrogen atmosphere, were added FmocCl (863 mg, 3.33 mmol) 
and 2,6-lutidine (388 µL, 3.33 mmol). The mixture was stirred at r.t. for 
15h. The solution was then concentrated in vacuo, the crude dissolved in 
CH2Cl2 (20 mL), and the solution was washed with 5% citric acid solution 
(3×20 mL). The organic layer was dried (Na2SO4), filtered and concentrated 
in vacuo to give a coulorless oil. Flash chromatography (petroleum 
ether/EtOAc, 5:1) afforded 4.5 as a colorless oil; yield: 1.07 g, (97%). [α]25D 
= -48.1 (c = 1.45, CH2Cl2). 
1H-NMR (400 MHz, CDCl3) mixture of 
rotamers: δ = 7.68 (d, J = 5.4 Hz, 2 H, Ar), 7.51 (d, J = 3.9 Hz, 2 H, Ar), 
7.33-7.22 (m, 4 H, Ar), 4.61 (m, 2 H), 3.62 (s, 3 H, OCH3), 4.56-3.02 (m, 14 
H), 1.28 (s, 3 H, CH3), 1.25 (s, 3 H, CH3) ppm. 
13C-NMR (100 MHz, 
CDCl3) mixture of rotamers: δ = 169.7 (s), 156.1 and 155.9 (s), 143.5 (s, 2 
C), 141.4 and 141.3 (s, 2 C), 127.7 (d, 2 C), 127.1 (d, 2 C), 124.8 and 124.5 
(d, 2 C), 120.1 and 119.9 (d, 2 C), 110.1 and 109.9 (s), 103.4 and 102.9 (d), 
74.9 and 74.6 (d), 67.2 and 66.6 (d), 66.1 (q), 62.2 and 61.9 (d), 55.3 and 
55.1 (t), 54.4 and 54.1 (t), 52.2 (q, 2 C), 49.6 (d), 47.4 and 47.1 (t), 26.8 and 
25.4 (q), 26.6 and 25.4 (q) ppm. MS: m/z (%): 499 (0.3) [M]+, 178 (99), 75 
(100). IR (CDCl3): ν = 2958, 1794, 1709 cm
-1. C27H33NO8 (499.22): 
calcd. C 64.92, H 6.66, N 2.80; found C 64.91, H 6.62, N 2.75. 
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(1R,2S,5S)-3-(9fluorenylmethoxycarbonyl)-6,8-dioxa-3-
azabicyclo[3.2.1]octane-2-endo-carboxylic Acid 
 
O
N O
HO2C
Fmoc
4.6  
 
Compound 4.5 (1.02 g, 2.00 mmol) was dissolved in TFA (4.20 mL), and 
then the solution was stirred at 25°C overnight. The solution was then 
concentrated in vacuo to give a dark oil. Flash chromatography 
(CH2Cl2/MeOH, 20:1, buffered with 0.1% TFA) afforded 4.6 as a white 
solid; yield: 0.351 g, (46%). M.p. 198-201°C. [α]25D = -78.1 (c = 1, CH2Cl2-
1% TFA). 1H-NMR (400 MHz, CDCl3) 2:1 mixture of rotamers: δ = 7.69 
(d, J = 7.1 Hz, 2 H, Ar), 7.50 (d, J = 7.8 Hz, 2 H, Ar), 7.33-7.22 (m, 4 H, 
Ar), 5.16 (s, 2/3 H, H-5, rot A), 5.11 (d, J = 2.7 Hz, 1/3 H, H-5, rot B), 
4.68-4.21 (m, 7 H), 3.95 (d, J = 13.4 Hz, 1/3 H, H-4, rot B), 3.85 (d, J = 
13.6 Hz, 2/3 H, H-4, rot A), 3.06 (d, J = 13.6 Hz, 2/3 H, H-4, rot A), 2.99 
(d, J = 13.4 Hz, 1/3 H, H-4, rot B) ppm. 13C-NMR (100 MHz, CDCl3) 
mixture of rotamers: δ = 173.0 (s, O-C=O), 158.6 (s, N-C=O), 143.2 (s, 2 
C, Ar), 141.0 (s, 2 C, Ar), 127.9 (d, 2 C, Ar), 127.4 and 127.3 (d, 2 C, Ar), 
124.9 (d, 2 C, Ar), 120.1 and 119.8 (d, 2 C, Ar), 88.7 and 88.6 (d, C-5), 72.2 
and 71.2 (t, C-7), 70.9 and 69.8 (t), 65.4 and 65.0 (d, C-1), 53.9 and 53.8 (d, 
C-2), 47.0 and 46.7 (d), 44.4 and 43.7 (t, C-4) ppm. MS: m/z (%): 381 (1.3) 
[M]+, 178 (100). IR (CDCl3): ν = 3691, 2958, 1794, 1602 cm
-1. C21H19NO6 
(381.12): calcd. C 66.13, H 5.02, N 3.67; found C 65.94, H 4.94, N 3.55. 
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Methyl (S)-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl](trifluoromethan 
sulfonyloxy)acetate 
 
OO
CO2Me
TfO
4.9  
 
A solution of 4.8 (150 mg, 0-79 mmol) in dry CH2Cl2 (1.4 mL) was cooled 
to -10°C, precooled dry pyridine (4.50 mL) was added under a nitrogen 
atmosphere, followed by the addition of a solution of Tf2O (219 µL, 1.02 
mmol) in dry CH2Cl2 (0.4 mL) over 30min. The mixture was stirred at r.t. 
for 30 min and the neutralized with a satured NaHCO3 solution. The 
organic layer was separated, dried (Na2SO4), filtered and concentrated in 
vacuo to give a dark oil. Flash chromatography (petroleum ether/EtOAc, 
2:1) afforded 4.9 as a yellow oil; yield: 136 mg, (53%). 1H-NMR (200 MHz, 
CDCl3): δ = 5.24 (d, J = 3.6 Hz, 1 H, TfOCH), 4.58-4.50 (m, 1 H, ring H-
4), 4.10-3.94 (m, 2 H, ring CH2), 3.84 (s, 3 H, OCH3), 1.43 (s, 3 H, CH3), 
1.34 (s, 3 H, CH3) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 165.0 (s, C=O), 
121.5 (s, CF3), 110.9 (s, [C(CH3)2], 81.0 (d, TfOCH), 74.0 (d, ring C-4), 65.4 
(t, CH2), 53.5 (q, OCH3), 25.8 (q, CH3), 24.9 (q, CH3) ppm. MS: m/z (%): 
322 (3) [M]+, 75 (100), 55 (62).  
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Methyl (R)-[(2,2-Dimethoxyethyl)amino][(R)-2,2-dimethyl-1,3-
dioxolan-4-yl]acetate 
 
OO
HN
CO2Me
MeO
MeO
4.10  
 
A solution of 4.9 (136 mg, 0.42 mmol) in dry CH2Cl2 (2.1 mL) was cooled 
to 0°C, and then a solution of 2,2-dimethoxyethanamine (4.3) (56 µL, 0.51 
mmol) and DIPEA (144 µL, 0.84 mmol) in dry CH2Cl2 (2.1 mL) was added 
under a nitrogen atmosphere. The mixture was stirred at r.t. for 15h, and 
then neutralized with a satured NaHCO3 solution. The organic layer was 
separated, dried (Na2SO4), filtered and concentrated in vacuo to give a dark 
oil. Flash chromatography (petroleum ether/EtOAc, 3:1) afforded pure 
4.10 as a colourless oil; yield: 101 mg, (86%). [α]25D = +19.3 (c = 0.7, 
CH2Cl2). 
1H-NMR (200 MHz, CDCl3): δ = 4.41 [(t, J = 5.4 Hz, 1 H, 
(CH3)2CHCH2NH)], 4.23 (q, J = 6.5 Hz, 1 H, ring H-4), 4.01-3.86 (m, 2 H, 
ring CH2), 3.71 (s, 3 H, CO2CH3), 3.31 (s, 7 H, OCH3, CHNH), 2.80 (dd, J 
= 12.1 Hz, J = 5.9 Hz, 1 H, CH2NH), 2.57 (dd, J = 12.4 Hz, J = 5.1 Hz, 1 
H, CH2NH), 1.36 (s, 3 H, CH3), 1.29 (s, 3 H, CH3) ppm. 
13C-NMR (50 
MHz, CDCl3): δ = 172.7 (s, C=O), 109.6 (s), 103.9 [d, CH(OCH3)2], 76.2 
[d, CHOC(CH3)2], 66.4 (t, CH2NH), 62.9 (d, CHCO2CH3), 54.0 (q, OCH3), 
53.2 (q, OCH3), 52.1 (q, OCH3), 49.5 (t, ring CH2), 26.5 (q, CH3), 25.4 (q, 
CH3) ppm. MS: m/z (%): 277 (6) [M]
+, 177 (75), 144 (89), 75 (100). IR 
(CDCl3): ν = 2990, 2954, 2834, 1739, 1271, 1261 cm
-1. C12H23NO6 (277.15): 
calcd. C  51.97, H 8.36, N 5.05; found C 52.10, H 8.55, N 5.14. 
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Methyl (R)-[(2,2-Dimethoxyethyl)(9H-fluoren-9-ylmethoxy 
carbonyl)amino][(R)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate 
 
OO
N
CO2Me
MeO
MeO
Fmoc
4.11  
 
To a solution of 4.10 (136 mg, 0.29 mmol) in dioxane (5.8 mL) at 0°C and 
under a nitrogen atmosphere, were added FmocCl (122 mg, 0.43 mmol) 
and 2,6-lutidine (50 µL, 0.43 mmol). The mixture was stirred at r.t. for 15h. 
The solution was then concentrated in vacuo, the crude dissolved in 
CH2Cl2 and the solution was washed with 5% citric acid solution (3×10 
mL). The organic layer was dried (Na2SO4), filtered and concentrated in 
vacuo to give a clear oil. Flash chromatography (petroleum ether/EtOAc, 
5:1) afforded 4.11 as a colorless oil; yield: 115 mg, (80%). [α]25D = +48.4 (c 
= 0.95, CH2Cl2). 
1H-NMR (200 MHz, CDCl3) mixture of rotamers: δ = 
7.81-7.74 (m, 2 H, Ar), 7.63-7.53 (m, 2 H, Ar), 7.44-7.31 (m, 4 H, Ar), 4.77-
3.55 (m, 10 H), 3.68 (s, 3 H, OCH3), 3.37 and 3.32 (s, 6 H, OCH3), 1.41 (s, 
3 H, CH3), 1.36 (s, 3 H, CH3) ppm. 
13C-NMR (50 MHz, CDCl3) mixture of 
rotamers: δ = 169.4 and 168.7 (s), 155.5 and 155.3 (s), 143.7 and 143.6 (s, 2 
C), 141.6 and 141.3 (s, 2 C), 127.6 and 127.0 (d, 2 C), 124.8 (d, 2 C), 124.3 
and 124.1 (d, 2 C), 120.1 and 119.9 (d, 2 C), 108.9 and 108.6 (s), 104.4 and 
104.3 (d), 73.6 and 73.5 (d), 68.6 and 68.5 (d), 67.1 (q), 65.0 and 64.5 (d), 
55.8 and 55.6 (t), 55.5 and 55.4 (t), 52.3 and 51.9 (q), 51.8 and 51.3 (q), 47.4 
and 47.1 (t), 26.8 and 26.7 (q), 25.2 and 25.1 (q) ppm. MS: m/z (%): 499 
(0.3) [M]+, 178 (100), 75 (60). IR (CDCl3): ν = 2988, 1739, 1701, 1261, 1066 
cm-1. C27H33NO8 (499.22): calcd. C 64.92, H 6.66, N 2.80; found C 64.90, H 
6.51, N 2.70. 
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Methyl (1R,2R,5S)-3-(9fluorenylmethoxycarbonyl)-6,8-dioxa-3-
azabicyclo[3.2.1]octane-2-exo-carboxylate 
 
O
N O
MeO2C
Fmoc
4.12  
 
Compound 4.11 (226 mg, 0.45 mmol) was dissolved in TFA (950 µL), and 
then the solution was stirred at 25°C for 48h. The solution was then 
concentrated in vacuo to give a dark oil. Flash chromatography 
(CH2Cl2/MeOH, 20:1, buffered with 0.1% TFA) afforded 4.12 as a white 
solid; yield: 145 mg, (81%). M.p. 56-59°C. [α]25D = +48.5 (c = 0.35, CH2Cl2-
1% TFA). 1H-NMR (400 MHz, CDCl3) 3:2 mixture of rotamers: δ = 7.69 
(m, 2 H, Ar), 7.51 and 7.41 (m, 2 H, Ar), 7.36-7.21 (m, 4 H, Ar), 5.45 (s, 1 
H, H-5), 4.92 (d, J = 3.9 Hz, 3/5 H, H-1, rot A), 4.78 (d, J = 3.9 Hz, 2/5 
H, H-1, rot B) 4.52-3.64 (m, 7 H), 3.74 and 3.64 (s, 3 H, OCH3), 3.30 (d, J 
= 12.5 Hz, 3/5 H, H-4, rot A), 3.14 (d, J = 13.0 Hz, 2/5 H, H-4, rot B) 
ppm. 13C-NMR (100 MHz, CDCl3) mixture of rotamers: δ = 168.9 (s, O-
C=O), 156.6 (s, N-C=O), 143.5 (s, 2 C, Ar), 141.2 (s, 2 C, Ar), 127.7 and 
127.0 (d, 2 C, Ar), 124.9 (d, 2 C, Ar), 124.6 and 124.5 (d, 2 C, Ar), 120.0 (d, 
2 C, Ar), 98.9 and 98.4 (d, C-5), 72.7 and 72.3 (d, C-1), 68.2 and 67.7 (t), 
67.3 (t, C-7), 59.5 and 58.9 (d, C-2), 52.8 (q), 47.5 and 47.2 (t, C-4), 47.3 (d) 
ppm. MS: m/z (%): 395 (0.7) [M]+, 336 (2), 178 (100), 165 (14), 89 (7), 55 
(8). IR (CDCl3): ν = 2927, 1752, 1708, 1269 cm
-1. C22H21NO6 (395.14): 
calcd. C 66.83, H 5.35, N 3.54; found C 66.34, H 5.30, N 3.46. 
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(1R,2R,5S)-3-(9fluorenylmethoxycarbonyl)-6,8-dioxa-3-azabicyclo 
[3.2.1]octane-2-exo-carboxylic Acid 
 
O
N O
HO2C
Fmoc
4.13  
 
A solution of 4.12 (55 mg, 0.14 mmol) in MeCN (2 mL) and 4M HCl (3 
mL)  was refluxed for 16h and then the solvent was evaporated in vacuo. 
The white solid was treated with Et2O (10 mL), and the solution was 
filtered and evaporated. This gave a yellow solid which was purified by 
flash chromatography (CH2Cl2/MeOH, 20:1, buffered with 0.1% TFA) to 
give 4.13 as a white solid; yield: 40 g, (75%). M.p. 86-88°C. [α]25D = +62.9 
(c = 0.5, CH2Cl2). 
1H-NMR (200 MHz, CDCl3) 3:2 mixture of rotamers: δ 
= 10.34 (br, 1 H, COOH), 7.75 (m, 2 H, Ar), 7.70-7.27 (m, 6 H, Ar), 5.55 
and 5.53 (s, 1 H, H-5), 5.04 (d, J = 4.6 Hz, 3/5 H, H-1, rot A), 4.86 (m, 2/5 
H, H-1, rot B), 4.66-3.67 (m, 7 H), 3.36 (d, J = 12.8 Hz, 3/5 H, H-4, rot A), 
3.19 (d, J = 13.0 Hz, 2/5 H, H-4, rot B) ppm. 13C-NMR (50 MHz, CDCl3) 
mixture of rotamers: δ = 173.5 and 173.3 (s, O-C=O), 156.5 and 155.4 (s, 
N-C=O), 143.2 (s, 2 C, Ar), 140.9 (s, 2 C, Ar), 128.4 (d, 2 C, Ar), 127.5 (d, 
2 C, Ar), 124.7 and 124.3 (d, 2 C, Ar), 119.7 (d, 2 C, Ar), 98.6 and 98.0 (d, 
C-5), 72.3 and 71.8 (d, C-1), 67.9 (t), 67.3 and 66.9 (t, C-7), 58.7 and 58.4 
(d, C-2), 47.1 and 46.7 (t, C-4), 46.8 (d) ppm. MS: m/z (%): 381 (0.3) [M]+, 
178 (100). IR (CDCl3): ν = 3066, 2960, 2900, 1709, 1451, 1413 cm
-1. 
C21H19NO6 (381.12): calcd. C 66.13, H 5.02, N 3.67; found C 66.05, H 4.92, 
N 3.65. 
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8.5. Experimental Section of 
Chapter 5  
 
(R)-methyl-2-[(2S,4R)-4-(benzyloxy)-2- 
(dimethoxyethyl)pyrrolidin-1-yl]-2-[(R)-2,2- 
dimethyl-1,3-dioxolan-4-yl]acetate 
 
5.3
O
O
N
MeO2C
BnO
O
O
 
 
A solution of 4.2 (see Chapter 8.4) (743 mg, 2.30 mmol) in dry CH2Cl2 (15 
mL) was cooled to 0°C, and then a solution of (2R,4R)-4-(benzyloxy)-2-
(dimethoxymethyl)pyrrolidine (5.1) (579 mg, 2.30 mmol) and DIPEA (0.79 
mL, 4.61 mmol) in dry CH2Cl2 (10 mL) was added under a nitrogen 
atmosphere. The mixture was stirred at r.t. for 15h, and then it was 
extracted with a satured NaHCO3 solution. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to give a dark oil. Flash 
chromatography (petroleum ether/EtOAc, 3:1) afforded pure 5.3 as a 
yellow oil; yield: 654 mg, (65%). 1H-NMR (400 MHz, CDCl3): δ = 7.31-
7.23 (m, 5H, Ar), 4.52-4.36 (m, 3 H, CH2Ph and CH(OMe)2), 4.11-4.01 (m, 
3 H, ring H-4, CHOBn and CHN), 3.94-3.74 (m, 2 H, ring CH2 and CHN 
ring Pro), 3.60 (s, 3 H, CO2CH3), 3.56-3.47 (m, 1 H, CH2 ring Pro), 3.41 (s, 
3 H, OCH3), 3.35 (s, 3 H, OCH3), 3.07-2.97 (m, 1 H, CH2 ring Pro), 1.99-
1.95 (m, 1 H, CH2 ring Pro), 1.81-1.75 (m, 1 H, CH2 ring Pro), 1.38 (s, 3 H, 
CH3), 1.35 (s, 3 H, CH3) ppm. 
13C-NMR (100 MHz, CDCl3): δ = 170.7 
(C=O), 138.2 (Ar), 128.2 (2 C, Ar), 127.5 (2 C, Ar), 127.4 (1 C, Ar), 109.6 
(s), 108.3 (CH(OCH3)2), 76.4 (CHOC(CH3)2), 74.8 (CH2Ph), 70.9 
(CHOBn), 67.1 (CH2NH), 65.3 (CHCH(OCH3)2), 60.5 (CHCO2CH3), 54.5 
(OCH3), 53.5 (OCH3), 52.5 (ring CH2), 51.3 (OCH3), 33.7 (CH2 ring Pro), 
27.0 (CH3), 25.8 (CH3) ppm. MS: m/z (%): 423 (4) [M]
+, 170 (68), 137 (27), 
128 (29), 111 (100), 95 (24), 84 (42), 75 (29), 60 (43), 57 (30). 
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(R)-tert-butyl-3-[(R)-1-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-
methoxy-2-oxoethylamino]-4,4-dimethoxybutanoate  
 
 
 
A solution of 4.2 (see Chapter 8.4) (1.13 g, 3.12 mmol) in dry CH2Cl2 (20 
mL) was cooled to 0°C under a nitrogen atmosphere, then a solution of 
(S)-tert-butyl-3-amino-4,4’-dimethoxybutanoate 5.2 (770 mg, 3.52 mmol) 
and DIPEA (1.20 mL, 7.63 mmol) in dry CH2Cl2 (15 mL) were added. The 
mixture was stirred at room temperature for 15h, then it was extracted with 
a saturated NaHCO3 solution. The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo to give a dark oil. Flash chromatography  
afforded pure 5.4 as a yellow oil (1.00 g, 73%). 1H NMR (200 MHz, 
CDCl3): δ = 4.17 (d, 1 H), 4.12-4.07 (m, 1 H), 3.99 (d, 2 H), 3.73 (s, 3 H), 
3.48 (d, 1 H), 3.38 (s, 3 H), 3.36 (s, 3 H), 3.18-3.09 (m, 1 H), 2.45 (dd, 1 H), 
2.23 (dd, 1 H), 2.03 (br, 1 H), 1.43 (s, 9 H), 1.40 (s, 3 H), 1.30 (s, 3 H) ppm. 
13C NMR (50 MHz, CDCl3): δ = 173.4 (s, 1 C), 170.8 (s, 1 C), 109.4 (s, 1 
C), 106.8 (d, 1 C), 80.4 (s, 1C), 77.1 (d, 1 C), 66.9 (t, 1 C), 62.1 (d, 1 C), 55.2 
(q, 3 C), 51.8 (d, 1 C), 33.6 (t, 1 C), 28.1 (q, 3 C), 26.7 (q, 1 C), 25.2 (q, 1 C) 
ppm. MS: m/z (%): 392 (1) [M+1]+, 316 (26), 260 (50), 203 (15), 202 (100), 
101 (12), 75 (31), 71 (11), 57 (39). 
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(5R/S,3aS,7aR)-5-Hydroxy-hexahydro-2,4-dioxa-7-aza-inden-1-one 
 
O
N
H
O
O
HO
5.5  
 
Compound 4.4 (see Chapter 8.4) (1 eq) is dissolved in HCl 6N (3.5 
mL/mmol). The mixture is left for 2h at 80°C under a nitrogen 
atmosphere. Successively, the mixture is concentrated and filtered on a 
weakly basic resin, giving compound 5.5 as a yellow oil. 1H NMR (200 
MHz, D2O): mixture of epimers δ = 5.19 (s, 1 H), 4.77-4.74 (m, 1 H), 4.52-
4.48 (m, 1 H), 4.42-4.39 (m, 1 H minor), 4.37-4.34 (m, 1 H major), 4.25-
4.23 (d, 1 H major), 4.19-4.17 (d, 1 H minor), 3.04-2.81 (m, 2 H). 13C NMR 
(50 MHz, D2O): mixture of epimers δ = 170.7 and 170.2 (s, 1 C), 86.6 and 
86.9 (d, 1 C), 72.4 and 70.5 (t, 1 C), 64.5 (d, 1 C), 52.3 and 51.5 (d, 1 C), 
43.3 and 43.0 (t, 1 C). MS: m/z (%): 159 (6) [M]+, 142 (10), 135 (13), 114 
(17), 99 (19), 85 (39), 74 (46), 71 (30), 68 (39), 59 (98), 54 (100), 52 (25). 
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(5R/S,3aS,7aR)-5-hydroxy-7-fluorenylmethoxycarbonyl-hexahydro-
2,4-dioxa-7-aza-inden-1-one 
 
O
N
O
O
HO
O O
5.6  
 
To a solution of 5.5 (1 eq) and 2,6-lutidine (2.5 eq) in dioxane (20 
mL/mmol) Fmoc-Cl (1.5 eq) is added at 0°C. The mixture is allowed to 
reach room temperature and is left overnight stirring under a nitrogen 
atmosphere. Successively, the mixture is concentrated, dissolved in EtOAc 
and washed with 5% citric acid and brine. The organic phase is dried 
(Na2SO4) and concentrated. Compound 5.6 is isolated by flash 
chromatography (petroleum ether/EtOAc, 1:2). White solid, yield: 58%. 1H 
NMR (200 MHz, DMSO): mixture of epimers and rotamers δ = 7.68-7.61 
(m, 2 H), 7.58-7.45 (m, 2 H), 7.32-7.14 (m, 4 H), 5.11 (s, 1 H major), 5.05 
(d, 1 H minor), 4.81 (d, 1 H minor), 4.72-4.55 (m, 1 H major), 4.47-4.23 (m, 
6 H), 4.00-3.81 (m, 1 H), 2.97 (dd, 1 H major), 2.79-2.42 (m, 1 H minor). 
13C NMR (50 MHz, DMSO): mixture of epimers and rotamers δ = 171.9 
(s, 1 C), 155.4 and 154.7 (s, 1 C), 143.0 and 142.9 (s, 2 C), 140.4 (s, 2 C), 
127.1 (d, 2 C), 126.5 (d, 2 C), 124.5 (d, 2 C), 119.3 (d, 2 C), 91.0 (d, 1 C 
minor), 88.1 and 87.8 (d, 1 C major), 70.5 and 70.1 (t, 1 C), 67.8 (t, 1 C), 
64.1 and 63.8 (d, 1 C), 55.3 and 52.8 (d, 1 C), 46.4 (d, 1 C), 44.6 and 43.9 (t, 
1 C). MS: m/z (%): 381 (1) [M]+, 179 (23), 178 (100), 166 (9), 165 (18), 89 
(4), 76 (3), 63 (3), 54 (9). 
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(5R/S,3aS,7aR)-5-hydroxy-7-carbobenzyloxy-hexahydro-2,4-dioxa-7-
aza-inden-1-one 
 
O
N
O
O
HO
O O
5.7  
 
To a solution of 5.5 (1 eq) and NaHCO3 (2 eq) in H2O-EtOAc (1.7 
mL/mmol-2 mL/mmol) benzylchloroformate (1 eq) is added at 0°C. The 
mixture is allowed to reach room temperature and is left overnight stirring 
under a nitrogen atmosphere. Successively, the mixture is washed with 1N 
HCl and brine. The organic phase is dried (Na2SO4) and concentrated. 
Compound 5.7 is isolated by flash chromatography (petroleum 
ether/EtOAc, 1:2). White solid, yield: 53%. 1H NMR (200 MHz, CDCl3): 
mixture of epimers and rotamers δ = 7.31 (s, 5 H), 5.15 (s, 2 H major), 5.12 
(s, 2 H minor), 4.90-4.64 (m, 2 H), 4.30-4.23 (m, 3 H), 4.03-3.87 (m, 1 H), 
3.03-2.88 (m, 1 H major), 2.75-2.56 (m, 1 H minor). 13C NMR (50 MHz, 
CDCl3): mixture of epimers and rotamers δ = 172.8 and 172.5 (s, 1 C), 
156.3 and 155.8 (s, 1 C), 135.7 and 135.5 (s, 1 C), 128.5 (d, 1 C), 128.3 (d, 1 
C), 128.1 (d, 1 C), 127.9 (d, 1 C), 127.7 (d, 1 C), 91.8 and 91.4 (d, 1 C 
minor), 88.9 and 88.5 (d, 1 C major), 71.2 and 70.7 (t, 1 C), 68.3 (t, 1 C), 
64.9 and 64.5 (d, 1 C), 53.9 (d, 1 C minor), 53.4 and 52.8 (d, 1 C, major), 
45.9 and 45.4 (t, 1 C minor), 44.7 and 44.1 (t, 1 C major). MS: m/z (%): 294 
(1) [M]+, 293 (5), 132 (8), 92 (9), 91 (100), 65 (13). 
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(5R/S,3aS,7aR)-5-methoxy-hexahydro-2,4-dioxa-7-aza-inden-1-one 
 
 
 
Compound 4.4 (see Chapter 8.4) (1 eq) is added to a solution of SOCl2 (2.5 
eq) in MeOH (5 mL/mmol). The mixture is refluxed for 4h under a 
nitrogen atmosphere. Successively the mixture is concentrated and filtered 
on a weakly basic resin giving quantitatively compound 5.8 as a yellow oil. 
1H NMR (200 MHz, CDCl3): mixture of epimers δ = 4.43-4.28 (m, 3 H), 
3.76-3.70 (m, 2 H), 3.45 (s, 3 H major),3.40 (s, 3 H minor), 2.94-2.76 (m, 2 
H), 2.44 (br, 1 H). 13C NMR (50 MHz, CDCl3): mixture of epimers δ = 
174.8 (s, 1 C), 95.8 (d, 1 C), 70.8 (t, 1 C), 65.3 (d, 1 C), 55.6 (q, 1 C), 54.8 (d, 
1 C), 44.4 (t, 1 C). MS: m/z (%): 173 (17) [M]+, 115 (10), 113 (12), 85 (59), 
67 (16), 58 (100). 
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(5R/S,3aS,7aR)-7-benzoyl-5-methoxy-hexahydro-2,4-dioxa-7-aza-
inden-1-one 
 
O
N
O
O
O
O
5.9  
 
To a solution of compound 4.4 (see Chapter 8.4) (1 eq) and DIPEA (1.2 
eq) in anhydrous THF (1.8 mL/mmol), benzoyl chloride (1 eq) is added at 
0°C. The mixture is allowed to reach room temperature and is left 
overnight stirring under a nitrogen atmosphere. Successively the mixture is 
concentrated, diluted with EtOAc, and washed with water and brine. The 
organic phase is dried (Na2SO4) and concentrated. Compound 4.4, 
functionalized at the nitrogen atom with Bz group (4.4a), is isolated by 
flash chromatography (petroleum ether/EtOAc, 1:1). Colourless oil, yield: 
99%. 1H NMR (200 MHz, CDCl3): mixture of rotamers δ = 7.50-7.41 (m, 5 
H), 4.79 (br, 1 H), 4.47 (br, 2 H), 4.12-3.96 (m, 2 H), 3.74 (s, 3 H), 3.46-
3.43 (m, 2 H), 3.33 (s, 3 H), 3.23 (s, 3 H), 1.32 (s, 6 H). MS: m/z (%): 381 
(1) [M]+, 366 (5), 249 (16), 144 (3), 105 (55), 101 (11), 77 (33), 75 (100), 58 
(15). 
A solution of compound 4.4a and SOCl2 (1.5 eq) in MeOH (10 mL/mmol) 
is overnight stirred at room temperature under a nitrogen atmosphere. 
Successively, the mixture is concentrated and purified by flash 
chromatography (petroleum ether/EtOAc, 1:1), thus giving product 5.9 as 
a white solid, yield: 66%. 1H NMR (400 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.60-7.53 (m, 2 H), 7.47-7.42 (m, 3 H), 5.68 (d, 1 H), 
4.66-4.28 (m, 4 H), 3.67 (d, 1 H major), 3.46 (s, 3 H minor), 3.41 (s, 3 H 
major), 3.30 (d, 1 H major), 2.99 (d, 1 H minor). 13C NMR (50 MHz, 
CDCl3): mixture of epimers and rotamers δ = 171.9 and 171.7 (s, 2 C), 
133.5 and 133.3 (s, 1 C), 130.3 and 130.1 (d, 1 C), 128.4 and 128.2 (d, 2 C), 
127.2 and 126.9 (d, 2 C), 95.3 and 94.7 (d, 1 C), 70.8 and 70.5 (t, 1 C), 65.3 
and 64.9 (d, 1 C), 56.5 and 56.1 (q, 1 C), 51.3 (d, 1 C), 47.2 (t, 1 C). MS: m/z 
(%): 277 (7) [M]+, 216 (7), 118 (10), 105 (100), 85 (15), 77 (52), 71 (24), 69 
(18), 57 (63), 55 (19), 51 (24). 
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(4aS,7aR)-(9H-fluoren-9-yl)methyl-2-methoxy-5-oxotetrahydro-2H-
furo[3,4-b][1,4]oxazine-4(3H)-carboxylate  
 
O
N
O
O
O
O O
5.10  
 
Compound 4.4 is functionalized at the nitrogen atom with Fmoc group to 
give 4.5 (see Chapter 8.4). A solution of 4.5 and SOCl2 (1.5 eq) in MeOH 
(10 mL/mmol) is overnight stirred at room temperature under a nitrogen 
atmosphere. Successively, the mixture is concentrated and purified by flash 
chromatography (petroleum ether/EtOAc, 1:1), giving product 5.10 as a 
white solid, yield: 86%. 1H NMR (400 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.77-7.73 (m, 2 H, Ar), 7.61-7.56 (m, 2 H, Ar), 7.41-7.37 
(m, 2 H, Ar), 7.32-7.25 (m, 2 H, Ar), 5.12 (d, J = 5.4 Hz, 1 H, CHOCH3), 
4.68-4.30 (m, 7 H), 4.05-3.99 (m, 1 H), 3.45 (s, 3 H, OCH3 major), 3.41 (s, 3 
H, OCH3 minor), 3.17 (dd, J = 14.0 Hz, J = 2.4 Hz, 1 H, major) ppm. 
13C-
NMR (100 MHz, CDCl3) mixture of rotamers: δ = 169.7 (s), 155.8 (s), 
143.5 (s, 2 C), 141.2 (s, 2 C), 127.7 (d, 2 C), 127.2 and 127.0 (d, 2 C), 125.2 
and 125.1 (d, 2 C), 119.9 and 119.8 (d, 2 C), 109.9 (s), 95.6 and 95.1 (d), 
70.6 (t), 68.4 (t), 65.0 and 64.5 (q), 55.3 and 55.1 (d), 532 and 53.1 (d), 46.9 
(d), 43.9 and 43.1 (t) ppm. 
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(5R/S,3aS,7aR)-7-carbobenzyloxy-5-methoxy-hexahydro-2,4-dioxa-7-
aza-inden-1-one 
 
O
N
O
O
O
O O
5.11  
 
To a solution of 4.4 (see Chapter 8.4) (1 eq) and NaHCO3 (2 eq) in H2O-
EtOAc (1.7 mL/mmol - 2 mL/mmol) Cbz-Cl (1 eq) is added at 0°C. The 
mixture is allowed to reach room temperature and is left overnight stirring 
under a nitrogen atmosphere. Successively, the mixture is washed with 
aqueous 1N HCl and brine. The organic phase is dried (Na2SO4) and 
concentrated. Compound 4.4, functionalized at the nitrogen atom with Cbz 
group (4.4b), is obtained after flash chromatography (petroleum 
ether/EtOAc, 1:1) as a colourless oil, yield: 80%. 1H NMR (200 MHz, 
CDCl3): mixture of rotamers δ = 7.35-7.21 (m, 5 H), 5.18-5.14 (m, 1 H), 
4.70-4.42 (m, 3 H), 4.04-3.85 (m, 2 H), 3.73-3.56 (m, 4 H), 3.60 (s, 3 H), 
3.41-3.27 (m, 6 H), 1.39 (s, 3 H), 1.35 (s, 3 H). MS: m/z (%): 412 (1) [M]+, 
279 (8), 162 (11), 101 (10), 91 (36), 75 (100), 65 (4). 
A solution of 4.4b and SOCl2 (1.5 eq) in MeOH (10 mL/mmol) is 
overnight stirred at room temperature under a nitrogen atmosphere. 
Successively, the mixture is concentrated and purified by flash 
chromatography (petroleum ether/EtOAc, 1:1), giving product 5.11 as a 
white solid, yield: 99%. 1H NMR (200 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.36 (s, 5 H), 5.21 (s, 2 H), 4.85-4.60 (m, 2 H), 4.48-4.36 
(m, 3 H), 4.08-3.94 (m, 1 H), 3.44 and 3.41 (s, 3 H), 3.14-2.99 (m, 1 H). 13C 
NMR (50 MHz, CDCl3): mixture of epimers and rotamers δ = 172.3 (s, 1 
C), 155.9 and 155.3 (s, 1 C), 135.9 (s, 1 C), 128.5 (d, 2 C), 128.1 (d, 2 C), 
127.7 (d, 1 C), 95.7 and 95.2 (d, 1 C), 71.2 (t, 1 C), 68.2 (t, 1 C), 65.3 and 
65.0 (d, 1 C), 55.7 (q, 1 C), 53.9 and 53.4 (d, 1 C), 44.1 and 43.4 (t, 1 C). 
MS: m/z (%): 307 (10) [M]+, 132 (13), 91 (100), 65 (15), 58 (13). 
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(5R/S,3aS,7aR)-5-methoxy-7-acetyl-hexahydro-2,4-dioxa-7-aza-
inden-1-one 
 
O
N
O
O
O
O
5.12  
 
To a solution of 4.4 (see Chapter 8.4) (1 eq) and DIPEA (3.5 eq) in 
anhydrous CH2Cl2 (2 mL/mmol) Ac2O (3 eq) and DMAP (0.1 eq) are 
added. The mixture is left overnight stirring under a nitrogen atmosphere. 
Successively the mixture is washed with H2O/ice and 1M KHSO4. The 
organic phase is dried (Na2SO4) and concentrated. Compound 4.4, 
functionalized at the nitrogen atom with Ac group (4.4c), is isolated by 
flash chromatography (petroleum ether/EtOAc, 1:1) as a colourless oil; 
yield: 95%. 1H NMR (200 MHz, CDCl3): mixture of epimers and rotamers 
δ = 4.78-4.71 (m, 1 H), 4.52 (t, 1 H), 4.34 (d, 1 H), 4.08-4.01 (d, 1 H), 3.88-
3.80 (m, 1 H), 3.73 (s, 3 H), 3.55 (d, 1 H), 3.46 (s, 3 H), 3.44 (s, 3 H), 3.36 
(d, 1 H), 2,16 (s, 3 H), 1.39 (s, 3 H), 1.34 (s, 3 H). 
A solution of 4.4c and SOCl2 (1.5 eq) in MeOH (10 mL/mmol) is 
overnight stirred at room temperature under a nitrogen atmosphere. 
Successively the mixture is concentrated and purified by flash 
chromatography (petroleum ether/EtOAc, 1:1) thus giving product 5.12 as 
a yellow oil; yield: 72%. 1H NMR (200 MHz, CDCl3): mixture of epimers 
and rotamers δ = 5.55 (d, 1 H), 4.65 (s, 1 H), 4.43-4.24 (m, 3 H), 3.64 (d, 1 
H), 3.36 (s, 3 H), 3.28 (dd, 1 H), 2.16 (s, 3 H). 13C NMR (50 MHz, CDCl3): 
mixture of epimers and rotamers δ = 172.3 (s, 1 C), 171.7 (s, 1 C), 95.3 and 
94.6 (d, 1 C), 70.7 (t, 1 C), 65.3 and 64.3 (d, 1 C), 55.2 and 55.0 (q, 1 C), 
51.0 (d, 1 C), 46.1 (t, 1 C), 20.3 (q, 1 C). MS: m/z (%): 215 (14) [M]+, 142 
(29), 140 (10), 84 (56), 68 (15), 58 (100), 53 (18). 
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(5R/S,3aS,7aR)-5-methoxy-7-(2-nitrobenzyl)-hexahydro-2,4-dioxa-7-
aza-inden-1-one 
 
O
N
O
O
O
NO2
5.13  
 
To a solution of 4.4 (see Chapter 8.4) (1 eq) and 2-nitrobenzaldehyde (1 eq) 
in THF (0.2M), NaBH(OAc)3 (1.3 eq) is added in small portions. The 
mixture is left overnight stirring at room temperature, then it is 
concentrated, diluted with EtOAc, and washed with water and brine. The 
organic phase is dried (Na2SO4) and concentrated. Compound 4.4, 
functionalized at the nitrogen atom with CH2-o-NO2Ph group (4.4d), is 
obtained after flash chromatography (petroleum ether/EtOAc, 1:1) as a 
colourless oil, yield: 40%. 1H NMR (200 MHz, CDCl3): mixture of epimers 
δ = 8.14 (d, 1 H), 7.78-7.62 (m, 2 H), 7.49-7.38 (m, 2 H), 4.96 (s, 2 H), 
4.38-4.29 (m, 1 H), 4.11-3.98 (m, 1 H), 3.77 (s, 3 H), 3.24 (s, 3 H), 3.19 (s, 3 
H), 2.91-2.57 (m, 2 H), 1.24 (s, 6 H).  
A solution of 4.4d and SOCl2 (1.5 eq) in MeOH (10 mL/mmol) overnight 
stirred at room temperature and under a nitrogen atmosphere. Successively, 
the mixture is concentrated and purified through flash chromatography 
(petroleum ether/EtOAc, 1:1), thus giving compound 5.13 as a yellow oil, 
yield: 43%. 1H NMR (200 MHz, CDCl3): mixture of epimers δ = 7.88-7.38 
(m, 4 H), 4.62 (m, 1 H), 4.60 (d, J = 15.4 Hz, 1 H), 4.5 (m, 1 H), 4.32 (d, J 
= 15.4 Hz, 1 H), 4.35 (d, J = 8 Hz, 1 H), 4.25 (s, 2 H), 3.59 (d, J = 4.0 Hz, 
1 H), 3.38 (s, 3 H), 2.83 (dd, J = 12.5 Hz, J = 2.5 Hz, 1 H), 2.60 (d, J = 12.5 
Hz, 1 H). 
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(5R/S,3aS,7aR)-7-benzyl-5-methoxy-hexahydro-2,4-dioxa-7-aza-
inden-1-one 
 
O
N
O
O
O
5.14  
 
To a solution of 5.8 (1 eq) and benzaldehyde (1 eq) in THF (5 mL/mmol) 
NaBH(OAc)3 (1.3 eq) is added in small portions. The mixture is left 
overnight stirring at room temperature, then is concentrated, diluted with 
EtOAc and washed with H2O and brine. The organic phase is dried 
(Na2SO4) and concentrated. Compound 5.14 is isolated by flash 
chromatography (petroleum ether/EtOAc, 2:1). White solid, yield: 45%. 1H 
NMR (200 MHz, CDCl3): mixture of epimers δ = 7.45-7.29 (m, 5 H), 4.68 
(s, 1 H), 4.49-4.26 (m, 2 H), 4.24 (s, 2 H), 4.11 (d, 1 H), 3.56 (d, 1 H major), 
3.51 (d, 1 H minor), 3.48 (s, 3 H minor), 3.43 (s, 3 H major), 2.94-2.77 (m, 
2 H major), 2.60-2.50 (m, 2 H minor). 13C NMR (50 MHz, CDCl3): mixture 
of epimers δ = 173.8 (s, 1 C), 136.9 (s, 1 C), 129.1 (d, 2 C), 128.3 (d, 1 C), 
127.6 (d, 1 C), 127.4 (d, 1 C), 99.5 and 97.2 (d, 1 C), 70.7 and 70.4 (t, 1 C), 
66.4 (d, 1 C), 58.3 and 57.3 (q, 1 C), 57.8 (t, 1 C), 55.7 (d, 1 C), 51.4 and 
50.3 (t, 1 C). MS: m/z (%): 263 (5) [M]+, 205 (8), 174 (7), 133 (13), 91 (100), 
65 (95), 58 (33), 51 (66). 
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Crystallographic data are reported: only one diastereoisomer crystallizes. 
 
 
Table 1.  Crystal data and structure refinement for exp_229. 
 
Identification code   exp_229 
  
Empirical formula   C14 H17 N O4 
  
Formula weight   263.29 
  
Temperature    293(2) K 
  
Wavelength    1.54178 A 
  
Crystal system, space group Orthorhombic, P 21 21 21 
  
Unit cell dimensions  a = 5.418(1)A   alpha = 90 deg. 
        b = 8.842(1)A   beta = 90 deg. 
          c = 27.603(3)A  gamma = 90 deg. 
  
Volume     1322.3(3) A^3 
  
Z, Calculated density  4,  1.322 Mg/m^3 
  
Absorption coefficient  0.804 mm^-1 
  
F(000)     560 
 
Crystal size    ? x ? x ? mm 
  
Theta range for data collection   5.25 to 62.12 deg. 
  
Limiting indices   -6<=h<=5, -9<=k<=9, -31<=l<=28 
  
Reflections collected/unique 5242 / 1853 [R(int) = 0.0880] 
  
Completeness to theta=62.12 97.4 % 
  
Refinement method   Full-matrix least-squares on F^2 
  
Data/restraints/parameters 1853 / 0 / 172 
O
N
O
O
O
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Goodness-of-fit on F^2  1.069 
  
Final R indices[I>2sigma(I)] R1 = 0.1004, wR2 = 0.2395 
  
R indices (all data)  R1 = 0.1495, wR2 = 0.2639 
  
Absolute structure parameter -0.9(10) 
  
Largest diff. peak and hole 0.364 and -0.308 e.A^-3 
 
Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic 
displacement parameters (A^2 x 10^3) for exp_229. 
U(eq) is defined as one third of the trace of the Orthogonalized 
Uij tensor. 
________________________________________________________________ 
 
x             y             z         
U(eq) 
________________________________________________________________ 
 
N(1)         7619(11)     -1131(7)       1018(2)       50(2) 
O(1)         7426(11)      1877(6)        682(2)       60(2) 
O(2)         8719(10)       214(7)       -202(2)       71(2) 
O(3)         5612(10)      1593(7)       1439(2)       72(2) 
O(4)        11210(10)     -1377(7)        177(2)       69(2) 
C(1)         6031(14)       765(9)        436(3)       56(2) 
C(2)         8255(14)     -3191(9)       1602(3)       54(2) 
C(3)         9253(16)      -720(11)       167(3)       62(2) 
C(4)         6120(15)     -2779(9)       1878(3)       59(2) 
C(5)         6309(15)       973(9)        -98(3)       64(2) 
C(6)         9463(15)     -4780(11)      2285(3)       71(3) 
C(7)         8551(16)     -2660(10)      1103(3)       59(2) 
C(8)         8989(15)        66(9)       1253(3)       59(2) 
C(9)         7335(15)     -4358(11)      2541(3)       72(3) 
C(10)        9865(17)     -4198(11)      1824(3)       69(3) 
C(11)        7113(15)      -797(10)       523(3)       55(2) 
C(12)        7758(16)      1599(11)      1184(3)       69(3) 
C(13)        5722(16)     -3334(10)      2341(3)       62(2) 
C(14)        4500(20)      3092(10)      1455(3)       82(3) 
________________________________________________________________ 
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Table 3.  Bond lengths [A] and angles [deg] for exp_229. 
         
___________________________________________________________ 
  
            N(1)-C(11)                    1.426(9) 
            N(1)-C(8)                     1.446(9) 
            N(1)-C(7)                     1.462(10) 
            O(1)-C(1)                     1.414(9) 
            O(1)-C(12)                    1.419(10) 
            O(2)-C(3)                     1.341(10) 
            O(2)-C(5)                     1.495(10) 
            O(3)-C(12)                    1.359(10) 
            O(3)-C(14)                    1.457(9) 
            O(4)-C(3)                     1.209(9) 
            C(1)-C(5)                     1.492(10) 
            C(1)-C(11)                    1.520(11) 
            C(2)-C(10)                    1.388(11) 
            C(2)-C(4)                     1.433(11) 
            C(2)-C(7)                     1.464(11) 
            C(3)-C(11)                    1.521(11) 
            C(4)-C(13)                    1.385(11) 
            C(6)-C(10)                    1.391(11) 
            C(6)-C(9)                     1.402(11) 
            C(8)-C(12)                    1.523(11) 
            C(9)-C(13)                    1.374(11) 
  
            C(11)-N(1)-C(8)             112.1(6) 
            C(11)-N(1)-C(7)             114.3(6) 
            C(8)-N(1)-C(7)              115.3(6) 
            C(1)-O(1)-C(12)             114.6(6) 
            C(3)-O(2)-C(5)              108.6(6) 
            C(12)-O(3)-C(14)            111.5(7) 
            O(1)-C(1)-C(5)              109.5(7) 
            O(1)-C(1)-C(11)             110.5(6) 
            C(5)-C(1)-C(11)             103.2(7) 
            C(10)-C(2)-C(4)             115.8(8) 
            C(10)-C(2)-C(7)             123.5(8) 
            C(4)-C(2)-C(7)              120.5(7) 
            O(4)-C(3)-O(2)              120.2(7) 
            O(4)-C(3)-C(11)             129.2(9) 
            O(2)-C(3)-C(11)             110.6(8) 
            C(13)-C(4)-C(2)             121.8(8) 
            C(1)-C(5)-O(2)              102.9(6) 
            C(10)-C(6)-C(9)             119.4(9) 
            N(1)-C(7)-C(2)              114.2(7) 
            N(1)-C(8)-C(12)             111.7(7) 
            C(13)-C(9)-C(6)             119.7(9) 
            C(2)-C(10)-C(6)             122.8(9) 
            N(1)-C(11)-C(1)             114.5(7) 
            N(1)-C(11)-C(3)             118.8(7) 
            C(1)-C(11)-C(3)              98.7(7) 
            O(3)-C(12)-O(1)             113.5(7) 
            O(3)-C(12)-C(8)             107.8(8) 
            O(1)-C(12)-C(8)             109.4(7) 
            C(9)-C(13)-C(4)             120.3(8) 
           
_____________________________________________________________ 
 
 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  5  
 
 
 105
Symmetry transformations used to generate equivalent atoms: 
 
    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) 
    for exp_229. 
    The anisotropic displacement factor exponent takes the form: 
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ] 
  
    
_______________________________________________________________________ 
  
             U11       U22      U33       U23      U13      U12 
    
_______________________________________________________________________ 
  
    N(1)    39(4)     58(4)    54(4)     -4(3)    14(3)     1(4) 
    O(1)    54(3)     71(4)    56(4)      2(3)     5(3)    -4(3) 
    O(2)    51(3)    100(5)    61(4)     -3(4)     4(3)    -8(4) 
    O(3)    53(4)     78(5)    86(4)      1(4)     3(3)    -6(4) 
    O(4)    33(3)     92(4)    84(4)    -10(4)     5(3)    10(3) 
    C(1)    27(4)     67(6)    75(6)      4(5)     6(4)    20(5) 
    C(2)    37(5)     55(5)    70(6)     -3(4)     0(4)    18(4) 
    C(3)    51(6)     96(7)    40(5)     -4(5)     8(4)    -6(5) 
    C(4)    46(5)     64(6)    68(6)     -4(5)    -3(4)    11(5) 
    C(5)    43(5)     68(6)    81(7)      1(5)    -5(5)     6(5) 
    C(6)    38(5)     92(7)    83(7)     12(6)    -9(5)    14(5) 
    C(7)    47(5)     70(6)    61(6)     -4(5)    -2(4)    11(4) 
    C(8)    46(5)     72(6)    59(5)     -6(5)     4(4)     0(5) 
    C(9)    47(5)     95(7)    73(6)      8(5)     1(5)     3(6) 
    C(10)   52(5)     89(7)    65(6)     -3(5)    -1(5)    12(5) 
    C(11)   48(5)     76(6)    42(5)     -9(4)    10(4)   -12(5) 
    C(12)   42(5)     81(7)    84(7)     -3(5)     6(5)   -18(6) 
    C(13)   49(5)     70(6)    65(6)     -1(5)     1(4)    17(5) 
    C(14)   96(8)     69(7)    80(7)     -6(5)     2(6)    18(6) 
    
_______________________________________________________________________ 
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(5R/S,3aS,7aR)-7-(2-Bromo-acetyl)-5-methoxy-hexahydro-2,4-dioxa-
7-aza-inden-1-one 
 
O
N
O
O
O
O
Br
5.15  
 
To a solution of 5.8 (1 eq) and TEA (1 eq) in anhydrous CH2Cl2 (1 
mL/mmol) bromoacetyl bromide (1 eq) is added dropwise at 0°C. The 
mixture is allowed to reach room temperature and is left 30min stirring 
under a nitrogen atmosphere. Successively the mixture is diluted with H2O, 
washed with 1N HCl and brine. The organic phase is dried (Na2SO4) and 
concentrated. Compound 5.15 is isolated by flash chromatography 
(petroleum ether/EtOAc, 1:1). White solid, yield: 55%. 1H NMR (200 
MHz, CDCl3): mixture of epimers and rotamers δ = 5.44 (d, 1 H major), 
5.34 (d, 1 H, minor), 4.74-4.22 (m, 5 H), 3.93 (d, 1 H major), 3.90 (d, 1 H 
minor), 3.67 (d, 1 H major), 3.48 (d, 1 H minor), 3.39 (s, 3 H), 3.33 (dd, 1 
H major), 2.81 (dd, 1 H minor). 13C NMR (50 MHz, CDCl3): mixture of 
epimers and rotamers δ = 172.1 (s, 1 C), 167.1 (s, 1 C), 95.8 and 94.8 (d, 1 
C), 70.8 and 70.7 (t, 1 C), 65.7 and 64.8 (d, 1 C), 55.5 (q, 1 C), 51.6 (d, 1 C), 
46.6 (t, 1 C), 25.7 and 25.4 (t, 1 C). MS: m/z (%): 294 (2) [M]+, 293 (13) [M-
1]+, 214 (32), 172 (25), 170 (11), 154 (17), 142 (22), 122 (11), 120 (12), 113 
(25), 112 (20), 68 (15), 57 (100), 54 (31).  
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(5R/S,3aS,7aR)-7-(2-nitrobenzoyl)-5-methoxy-hexahydro-2,4-dioxa-
7-aza-inden-1-one 
 
O
N
O
O
O
NO2
O
5.16  
 
To a solution of 5.8 (1 eq) and TEA (1.5 eq) in anhydrous CH2Cl2 (2.5 
mL/mmol) a solution of 2-nitrobenzoyl chloride (1.2 eq) in anhydrous 
CH2Cl2 (2.5 mL/mmol) is added at 0°C. The mixture is allowed to reach 
room temperature and is left overnight stirring under a nitrogen 
atmosphere. Successively the mixture is washed with NaHCO3, 1N HCl 
and brine. The organic phase is dried (Na2SO4) and concentrated. 
Compound 5.16 is isolated by flash chromatography (petroleum 
ether/EtOAc, 1:2). White solid, yield: 83%.1H NMR (200 MHz, CDCl3): 
mixture of epimers and rotamers δ = 8.15 (d, 1 H major), 8.07 (d, 1 H 
minor), 7.74-7.47 (m, 3 H), 5.59 (d, 1 H), 4.79 (s, 1 H minor), 4.63-4.23 (m, 
4 H), 4.35 (d, 1 H), 3.39 (s, 3 H minor), 3.35 (s, 3 H major), 3.24-3.18 (m, 1 
H major), 2.96 (dd, 1 H minor). 13C NMR (50 MHz, CDCl3): mixture of 
epimers and rotamers δ = 173.9 (s, 1 C), 167.7 (s, 1 C), 134.8 (s, 1 C), 134.5 
and 134.2 (d, 1 C), 130.4 (d, 1 C), 128.7 (d, 1 C), 124.7 (d, 1 C), 116.1 (d, 1 
C), 95.6 and 94.8 (d, 1 C), 70.9 (t, 1 C), 65.5 and 65.0 (d, 1 C), 56.5 and 55.6 
(q, 1 C), 51.4 (d, 1 C), 46.8 (t, 1 C). MS: m/z (%): 322 (2) [M]+, 292 (7), 232 
(51), 215 (24), 151 (20), 150 (100), 133 (20), 104 (17), 84 (13), 76 (34), 68 
(11), 58 (73), 51 (66). 
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(5R/S,3aS,7aR)-7-(2-iodobenzoyl)-5-methoxy-hexahydro-2,4-dioxa-7-
aza-inden-1-one 
 
O
N
O
O
O
I
O
5.17  
 
To a solution of 5.8 (1 eq) and TEA (1.5 eq) in anhydrous CH2Cl2 (2.5 
mL/mmol) a solution of 2-iodobenzoyl chloride (1.2 eq) in anhydrous 
CH2Cl2 (2.5 mL/mmol) is added at 0°C. The mixture is allowed to reach 
room temperature and is left overnight stirring under a nitrogen 
atmosphere. Successively the mixture is washed with NaHCO3, 1N HCl 
and brine. The organic phase is dried (Na2SO4) and concentrated. 
Compound 5.17 is isolated by flash chromatography (petroleum 
ether/EtOAc, 1:1). White solid, yield: 61%. 1H NMR (200 MHz, CDCl3): 
mixture of epimers and rotamers δ = 7.80-7.64 (m, 1 H), 7.38-7.21 (m, 2 
H), 7.11-7.01 (m, 1 H), 5.61 (d, 1 H major), 5.52 (d, 1 H minor), 4.78 (s, 1 
H minor), 4.54-4.25 (m, 4 H), 4.08-3.98 (m, 1 H), 3.38 (s, 3 H minor), 3.32 
(s, 3 H major), 3.22-3.15 (m, 1 H major), 2.91-2.59 (m, 1 H minor). 13C 
NMR (50 MHz, CDCl3): mixture of epimers and rotamers δ = 171.4 (s, 1 
C), 170.6 and 170.3 (s, 1 C), 142.2 (s, 1 C), 139.2 (d, 1 C), 130.8 and 130.6 
(d, 2 C), 128.5 and 128.2 (d, 1 C), 128.0 and 127.6 (d, 1 C), 95.8 and 95.2 (d, 
1 C), 70.9 (t, 1 C), 65.8 and 65.2 (d, 1 C), 56.2 and 55.4 (q, 1 C), 51.2 (d, 1 
C), 47.5 and 46.5 (t, 1 C). MS: m/z (%): 403 (26) [M]+, 276 (18), 230 (100), 
202 (17), 105 (16), 76 (25), 49 (14). 
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(5R/S,3aS,7aR)-7-(2-bromobenzoyl)-5-methoxy-hexahydro-2,4-
dioxa-7-aza-inden-1-one 
 
O
N
O
O
O
Br
O
5.18  
  
To a solution of 5.8 (1 eq) and TEA (1.5 eq) in anhydrous CH2Cl2 (2.5 
mL/mmol) a solution of 2-bromobenzoyl chloride (1.2 eq) in anhydrous 
CH2Cl2 (2.5 mL/mmol) is added at 0°C. The mixture is allowed to reach 
room temperature and is left overnight stirring under a nitrogen 
atmosphere. Successively the mixture is washed with NaHCO3, 1N HCl 
and brine. The organic phase is dried (Na2SO4) and concentrated. 
Compound 5.18 is isolated by flash chromatography (petroleum 
ether/EtOAc, 1:1). White solid, yield: 79%. 1H NMR (200 MHz, CDCl3): 
mixture of epimers and rotamers δ = 7.59-7.52 (m, 1 H), 7.44-7.19 (m ,3 
H), 5.66 (d, 1 H major), 5.55 (d, 1 H minor), 4.78 (s, 1 H minor), 4.57-4.28 
(m ,4 H), 4.13-4.09 (m, 1 H), 3.41 (s, 3 H minor), 3.34 (s, 3 H major), 3.26-
3.18 (m, 1 H major), 2.92 (dd, 1 H minor). 13C NMR (50 MHz, CDCl3): 
mixture of epimers and rotamers δ = 170.9 (s, 1 C), 169.3 and 168.9 (s, 1 
C), 135.8 (s, 1 C), 133.4 and 132.8 (d, 1 C), 130.9 and 130.7 (d, 2 C), 128.8 
(d, 1 C), 127.9 and 127.4 (d, 1 C), 95.7 and 95.2 (d, 1 C), 70.8 (t, 1 C), 65.4 
and 65.2 (d, 1 C), 56.1 and 55.5 (q, 1 C), 51.2 and 50.9 (d, 1 C), 47.3 and 
46.3 (t, 1 C). MS: m/z (%): 355 (26) [M-1]+, 184 (100), 182 (85), 154 (20), 99 
(37), 76 (28), 58 (70), 54 (63), 50 (30). 
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(5R/S,3aS,7aR)-7-(4-chlorobenzenesulfonyl)-5-methoxy-hexahydro-
2,4-dioxa-7-aza-inden-1-one 
 
O
O
O
O
N
S O
O
Cl
5.19  
 
To a solution of 5.8 (1 eq), TEA (2.5 eq) and DMAP (0.2 eq) in anhydrous 
CH2Cl2 (10 mL/mmol) 4-chlorobenzenesulfonyl chloride (2 eq) is added at 
0°C. The mixture is allowed to reach room temperature and is left 
overnight stirring under a nitrogen atmosphere. Successively the mixture is 
washed with NaHCO3, 1N HCl and brine. The organic phase is dried 
(Na2SO4) and concentrated. Compound 5.19 is isolated by flash 
chromatography (petroleum ether/EtOAc, 1:1). White solid, yield: 87%. 1H 
NMR (200 MHz, CDCl3): mixture of epimers δ = 7.96 (d, 2 H minor), 7.82 
(d, 2 H major), 7.58 (d, 2 H minor), 7.45 (d, 2 H major), 4.86 (d, 1 H), 4.61 
(s, 1 H minor), 4.51-4.28 (m, 4 H), 3.64 (d, 1 H), 3.44 (s, 3 H minor), 3.30 
(s, 3 H major), 2.99 (dd, 1 H major), 2.57 (dd, 1 H minor). 13C NMR (50 
MHz, CDCl3): mixture of epimers δ = 171.2 (s, 1 C), 139.3 (s, 1 C), 137.9 
(s, 1 C), 129.3 and 129.2 (d, 2 C), 129.0 and 128.4 (d, 2 C), 94.7 (d, 1 C), 
70.8 and 70.7 (t, 1 C), 64.9 (d, 1 C), 55.6 and 55.4 (q, 1 C), 54.6 and 54.2 (d, 
1 C), 44.8 and 44.3 (t, 1 C).  
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(5R/S,3aS,7aR)-7-(carbomethoxy-4-tolylmethyl)-5-methoxy-
hexahydro-2,4-dioxa-7-aza-inden-1-one 
 
 
 
A solution of 5.8 (1 eq), p-tolylboronic acid (1 eq) and glyoxylic acid (1 eq) 
in EtOH (3.5 mL/mmol) is left overnight stirring at room temperature, 
then is concentrated. The crude acid was dissolved in MeOH/CH2Cl2 (5 
mL/mmol-5mL/mmol) and was added TMSCHN2 (2M in Et2O) dropwise. 
The mixture is left 2h stirring at room temperature successively is 
concentrated. Compound 5.20 is isolated by flash chromatography 
(petroleum ether/EtOAc, 3:2). White solid, yield: 65%. 1H NMR (200 
MHz, CDCl3): mixture of epimers δ = 7.48 (d, 2 H), 7.16 (d, 2 H), 5.16 (s, 1 
H), 4.68 (s, 1 H), 4.47 (s, 1 H), 4.15 (s, 2 H), 3.67 (s, 3 H), 3.48 (s, 3 H), 
3.42 (d, 1 H), 2.99-2.81 (m, 2 H), 2.32 (s, 3 H). 
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(4aS,7aR)-4-benzoyl-7,7a-dihydro-4H-furo[3,4-b][1,4]oxazin-5(4aH)-
one  
O
N
O
O
O
5.21  
A mixture of 4.4a (see molecule 5.9) (1 eq) and p-toluenesulfonic acid (0.1 
eq) in toluene (10 mL/mmol) is refluxed (110°C) for 3h in presence of 4Ǻ 
molecular sieves. Successively, the mixture is filtered over NaHCO3, and 
purified by flash chromatography (petroleum ether/EtOAc, 3:2), giving 
compound 5.21 as a white solid, yield: 20%. 1H NMR (200 MHz, CDCl3): 
mixture of rotamers δ = 7.61-7.58 (m, 2 H), 7.50-7.41 (m, 3 H), 6.04 (s, 1 
H), 5.86 (s, 1 H), 5.71 (s, 1 H), 4.59-4.50 (m, 3 H). 13C NMR (50 MHz, 
CDCl3): mixture of rotamers δ = 186.8 (s, 1 C), 158.1 (s, 1 C), 133.3 (s, 1 C) 
131. (d, 2 C), 128.6 (d, 2 C), 128.2 (d, 1 C), 106.1 (d, 1 C), 101.0 (d, 1 C), 
71.0 (t, 1 C), 70.1 (d, 1 C), 51.8 (d, 1 C). MS: m/z (%): 245 (8) [M]+, 105 
(100), 77 (57), 51 (24). 
 
(4aS,7aR)-benzyl-5-oxo-4a,5,7,7a-tetrahydro-4H-furo[3,4-
b][1,4]oxazine-4-carboxylate  
O
N
O
O
O O
5.22  
A mixture of 4.4b (see molecule 5.11) (1 eq) and p-toluenesulfonic acid (0.1 eq) 
in toluene (10 ml/mmol) is refluxed (110°C) for 3h in presence of 4Å 
molecular sieves. Successively the mixture is filtered on NaHCO3 and purified 
by flash chromatography (petroleum ether/EtOAc, 3:2) giving compound 5.22 
as a white solid yield: 23%.  1H NMR (200 MHz, CDCl3): mixture of rotamers δ 
= 7.37 (s, 5 H minor), 7.34 (s, 5 H major), 6.46 (d, 1 H minor), 6.30 (d, 1 H 
major), 6.02 (d, 1 H minor), 5.89 (d, 1 H major), 5.24 (d, 2 H minor), 5.18 (d, 2 
H major), 5.09-4.47 (m, 2 H), 4.40 (d, 2 H major), 4.35 (d, 2 H minor). 13C 
NMR (100 MHz, CDCl3): mixture of rotamers δ = 185.7 (s, 1 C), 158.3 (s, 1 C), 
129.3 (1 C), 128.5 (1 C), 128.4 (1 C), 128.2 (1 C), 127.9 (1 C), 104.3 and 104.1 
(d, 1 C), 95.5 and 95.2 (d, 1 C), 71.0 and 70.9 (1 C), 68.9 and 68.6 (1 C), 65.1 
and 64.8 (1 C), 53.5 and 53.7 (1 C). MS: m/z (%): 275 (2) [M]+, 231 (7), 91 (100), 
65 (16). 
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(3aR, 5aS, 7R, 9aS)-7-(benzyloxy)-5-methoxyoctahydro-1H-furo[3,4-
b]pyrrolo[1,2-d] [1,4]oxazin-1-one  
 
N
O
O
O
O
BnO
5.23  
 
Compound 5.3 (1 eq) is added to a solution of SOCl2 (2.5 eq) in MeOH (5 
mL/mmol). The mixture is refluxed for 4h under a nitrogen atmosphere. 
Successively the mixture is concentrated and filtered on a weakly basic resin 
giving compound 5.23 as a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 
7.36-7.25 (m, 5 H, Ar), 4.65-4.62 (m, 1 H, CHCH2O), 4.56 (d, J = 6.8 Hz, 1 
H, CHOCH3), 4.47 (q, J = 11.6 Hz, 2 H, CH2Ph), 4.39 (d, J = 3.6 Hz, 2 H, 
CH2O), 4.25-4.20 (m, 1 H, CHOBn), 4.01 (dd, J = 6.4 Hz, J = 3.6 Hz, 1 H, 
CH2N), 3.43 (s, 3 H, OCH3), 3.26 (d, J = 6.0 Hz, 1 H, CHC=O), 2.73-2.67 
(m, 1 H, CHCHOCH3), 2.49 (dd, J = 4.8 Hz, J = 6.5 Hz, 1 H, CH2N), 2.14 
(ddd, J = 13.2 Hz, J = 6.0 Hz, J = 1.6 Hz, 1 H, CH2CHOBn), 1.78-1.70 (m, 
1 H, CH2CHOBn) ppm. 
13C NMR (100 MHz, CDCl3): mixture of epimers 
δ = 174.7 (C=O), 137.9 (C, Ar), 128.4 (CH, 3 C, Ar), 127.6 (CH, 2 C, Ar), 
104.3 (CHOCH3), 76.8 (CHOBn), 71.2 (CH2Ph), 70.5 (CH2O), 67.2 
(CHCH2O), 61.6 (CHC=O), 60.2 (CHCHOCH3), 59.3 (CH2N), 55.6 
(OCH3), 35.2 (CH2CHOBn) ppm. 
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Crystallographic data are reported: only one diastereoisomer crystallizes. 
 
      Table 1.  Crystal data and structure refinement for new. 
  
  
      Identification code  new 
  
      Empirical formula  C34 H42 N2 O10 
  
      Formula weight  638.70 
  
      Temperature   293(2) K 
  
      Wavelength   1.54178 A 
  
      Crystal system,space group Monoclinic, C 2 
  
      Unit cell dimensions    a = 25.827(1)A  alpha=90deg. 
              b = 4.624(1)A beta=135.374(2)deg. 
              c = 19.232(1)A  gamma=90deg. 
  
      Volume    1613.4(4) A^3 
  
      Z, Calculated density 2,  1.315 Mg/m^3 
  
      Absorption coefficient 0.802 mm^-1 
  
      F(000)    680 
  
      Crystal size   ? x ? x ? mm 
  
      Theta range for data collection 4.60 to 71.12 deg. 
  
      Limiting indices  -30<=h<=27, -5<=k<=4, -23<=l<=22 
  
      Reflections collected/unique 3473/2151 [R(int) = 0.0173] 
  
      Completeness to theta=71.12  93.2 % 
  
      Refinement method  Full-matrix least-squares on F^2 
  
      Data/restraints/parameters 2151 / 1 / 208 
N
O
O
O
O
O
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      Goodness-of-fit on F^2   1.058 
  
      Final R indices[I>2sigma(I)] R1 = 0.0355, wR2 = 0.0854 
  
      R indices (all data)   R1 = 0.0469, wR2 = 0.0911 
  
      Absolute structure parameter -0.1(3) 
  
      Largest diff. peak and hole  0.115 and -0.141 e.A^-3 
 
 
 
 
Table 2.  Atomic coordinates ( x 10^4) and equivalent 
isotropic 
       displacement parameters (A^2 x 10^3) for new. 
U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
          ______________________________________________________________ 
  
                       x           y           z         U(eq) 
         ________________________________________________________________ 
  
          N(1)       1823(1)    10307(4)    10705(1)     47(1) 
          O(1)       2267(1)    11781(4)    12365(1)     56(1) 
          O(2)       3683(1)    11194(5)    12850(1)     71(1) 
          O(3)       3277(1)     8503(6)    11587(1)     86(1) 
          O(4)       1135(1)    13948(4)    11548(1)     59(1) 
          O(5)        159(1)    10104(4)     8177(1)     55(1) 
          C(1)       2472(1)    12155(6)    11328(2)     53(1) 
          C(2)       2585(1)    13574(6)    12148(2)     55(1) 
          C(3)       3416(1)    13507(7)    13031(2)     67(1) 
          C(4)       3167(1)    10388(7)    11891(2)     61(1) 
          C(5)       1488(1)    11607(6)    11565(1)     51(1) 
          C(6)       1240(1)    11594(6)    10574(1)     49(1) 
          C(7)        576(1)     9749(6)     9761(1)     55(1) 
          C(8)        700(1)     8783(6)     9126(1)     52(1) 
          C(9)       1482(1)     9808(6)     9699(1)     58(1) 
          C(10)       164(1)     8955(8)     7495(2)     70(1) 
          C(11)      -465(1)    10247(6)     6498(1)     58(1) 
          C(12)     -1184(1)     9717(9)     5988(2)     82(1) 
          C(13)     -1759(2)    10939(11)    5075(2)    103(1) 
          C(14)     -1614(2)    12636(9)     4658(2)    100(1) 
          C(15)      -903(2)    13178(9)     5151(2)    103(1) 
          C(16)      -333(2)    12017(8)     6070(2)     80(1) 
          C(17)      1236(2)    14068(8)    12378(2)     78(1) 
         ________________________________________________________________ 
 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  5  
 
 
 116
Table 3.  Bond lengths [A] and angles [deg] for new. 
           
_____________________________________________________________ 
  
            N(1)-C(1)                     1.454(3) 
            N(1)-C(9)                     1.465(2) 
            N(1)-C(6)                     1.465(2) 
            O(1)-C(5)                     1.421(3) 
            O(1)-C(2)                     1.423(3) 
            O(2)-C(4)                     1.348(3) 
            O(2)-C(3)                     1.444(3) 
            O(3)-C(4)                     1.192(3) 
            O(4)-C(5)                     1.400(3) 
            O(4)-C(17)                    1.424(2) 
            O(5)-C(8)                     1.422(2) 
            O(5)-C(10)                    1.425(3) 
            C(1)-C(4)                     1.514(3) 
            C(1)-C(2)                     1.532(3) 
            C(2)-C(3)                     1.517(3) 
            C(5)-C(6)                     1.519(3) 
            C(6)-C(7)                     1.516(3) 
            C(7)-C(8)                     1.536(3) 
            C(8)-C(9)                     1.533(3) 
            C(10)-C(11)                   1.496(3) 
            C(11)-C(16)                   1.363(4) 
            C(11)-C(12)                   1.372(4) 
            C(12)-C(13)                   1.377(4) 
            C(13)-C(14)                   1.351(5) 
            C(14)-C(15)                   1.362(5) 
            C(15)-C(16)                   1.369(4) 
  
            C(1)-N(1)-C(9)              115.98(16) 
            C(1)-N(1)-C(6)              110.13(18) 
            C(9)-N(1)-C(6)              104.93(15) 
            C(5)-O(1)-C(2)              112.57(16) 
            C(4)-O(2)-C(3)              110.90(19) 
            C(5)-O(4)-C(17)             114.0(2) 
            C(8)-O(5)-C(10)             112.09(18) 
            N(1)-C(1)-C(4)              110.9(2) 
            N(1)-C(1)-C(2)              111.29(17) 
            C(4)-C(1)-C(2)              103.47(18) 
            O(1)-C(2)-C(3)              108.12(19) 
            O(1)-C(2)-C(1)              109.0(2) 
            C(3)-C(2)-C(1)              103.04(18) 
            O(2)-C(3)-C(2)              106.4(2) 
            O(3)-C(4)-O(2)              121.6(2) 
            O(3)-C(4)-C(1)              128.2(2) 
            O(2)-C(4)-C(1)              110.2(2) 
            O(4)-C(5)-O(1)              112.2(2) 
            O(4)-C(5)-C(6)              106.73(18) 
            O(1)-C(5)-C(6)              111.47(16) 
            N(1)-C(6)-C(7)              102.72(18) 
            N(1)-C(6)-C(5)              108.81(16) 
            C(7)-C(6)-C(5)              116.87(18) 
            C(6)-C(7)-C(8)              105.02(17) 
            O(5)-C(8)-C(9)              112.28(19) 
            O(5)-C(8)-C(7)              108.92(17) 
            C(9)-C(8)-C(7)              104.62(17) 
            N(1)-C(9)-C(8)              104.22(15) 
            O(5)-C(10)-C(11)            108.6(2) 
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            C(16)-C(11)-C(12)           117.9(2) 
            C(16)-C(11)-C(10)           120.3(2) 
            C(12)-C(11)-C(10)           121.8(3) 
            C(11)-C(12)-C(13)           121.4(3) 
            C(14)-C(13)-C(12)           119.5(3) 
            C(13)-C(14)-C(15)           120.0(3) 
            C(14)-C(15)-C(16)           120.3(3) 
            C(11)-C(16)-C(15)           120.9(3) 
           
_____________________________________________________________ 
  
 
 
 
 
 Symmetry transformations used to generate equivalent atoms: 
  
 
Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 
new. 
The anisotropic displacement factor exponent takes the form: 
-2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
_______________________________________________________________________ 
  
            U11      U22      U33      U23      U13      U12    
_______________________________________________________________________ 
  
    N(1)   47(1)    53(1)    42(1)     5(1)    32(1)     7(1) 
    O(1)   56(1)    66(1)    43(1)     6(1)    34(1)     2(1) 
    O(2)   51(1)    80(1)    62(1)     2(1)    34(1)     7(1) 
    O(3)   62(1)   107(2)    90(1)   -16(1)    54(1)     6(1) 
    O(4)   68(1)    64(1)    65(1)    -3(1)    53(1)     3(1) 
    O(5)   56(1)    67(1)    39(1)     6(1)    32(1)    14(1) 
    C(1)   55(1)    58(2)    50(1)     8(1)    39(1)     4(1) 
    C(2)   57(1)    52(1)    53(1)     5(1)    38(1)     5(1) 
    C(3)   61(1)    68(2)    58(1)    -3(1)    38(1)    -3(1) 
    C(4)   52(1)    70(2)    64(1)    -2(1)    42(1)    -3(1) 
    C(5)   55(1)    54(1)    48(1)     3(1)    38(1)     2(1) 
    C(6)   53(1)    53(1)    48(1)    14(1)    38(1)    14(1) 
    C(7)   46(1)    75(2)    45(1)    12(1)    33(1)    15(1) 
    C(8)   51(1)    60(2)    41(1)     9(1)    31(1)    13(1) 
    C(9)   54(1)    79(2)    47(1)     7(1)    38(1)    13(1) 
    C(10)  71(2)    89(2)    45(1)     2(1)    40(1)    19(2) 
    C(11)  61(1)    65(2)    41(1)    -5(1)    35(1)     2(1) 
    C(12)  69(2)   111(3)    55(1)     6(2)    40(1)    -8(2) 
    C(13)  62(2)   152(4)    53(2)    -5(2)    26(1)     2(2) 
    C(14)  98(2)   109(3)    48(1)    16(2)    36(2)    25(2) 
    C(15) 119(3)    98(3)    80(2)    24(2)    67(2)     5(2) 
    C(16)  78(2)    88(2)    64(2)     0(2)    47(1)    -7(2) 
    C(17)  82(2)   103(2)    72(2)   -28(2)    63(1)   -21(2)    
______________________________________________________________________ 
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(5R/S,3aS,7aR)-6-carbomethoxymethyl-5-methoxy-hexahydro-2,4-
dioxa-7-aza-inden-1-one 
 
 
 
Compound 5.4 (1 eq) is added to a solution of SOCl2 (2.5 eq) in MeOH (5 
mL/mmol). The mixture is refluxed for 4h under a nitrogen atmosphere. 
Successively the mixture is concentrated and filtered on a weakly basic resin 
giving compound 5.24 as a yellow oil. 1H NMR (200 MHz, CDCl3): mixture 
of epimers δ = 4.49-4.13 (m, 3 H), 3.64 (s, 3 H minor), 3.59 (m, 3 H 
major), 3.53-3.41 (m, 3 H), 3.35 (s, 3 H major), 3.33 (s, 3 H minor), 3.16-
3.02 (m, 1 H), 2.57-2.32 (m 2 H). 13C NMR (50 MHz, CDCl3): mixture of 
epimers δ = 176.5 and 173.1 (s, 1 C), 172.1 and 171.6 (s, 1 C), 106.6 (d, 1 
C), 98.9 (d, 1 C), 71.8 (d, 1 C), 70.8 (t, 1 C), 64.7 and 62.9 (d, 1 C), 63.8 and 
62.7 (t, 1 C), 55.4 and 55.9 (q, 1 C), 52.5 and 52.2 (q, 1 C). MS: m/z (%): 
246 (12) [M+1]+, 245 (7) [M]+, 234 (25), 214 (21), 202 (46), 186 (12), 172 
(17), 170 (24), 158 (20), 154 (18), 130 (21), 112 (14), 85 (100), 75 (90), 71 
(74), 55 (22). 
 
 
(2R,3R)- methyl-2-(hydroxymethyl)-6-methoxymorpholine-3-
carboxylate  
 
 
 
Compound 4.10 (see Chapter 8.4) (1 eq) is added to a solution of SOCl2 
(2.5 eq) in MeOH (5 mL/mmol). The mixture is refluxed for 4h under a 
nitrogen atmosphere. Successively the mixture is concentrated and filtered 
on a weakly basic resin giving quantitatively compound 5.25 as a yellow oil. 
1H NMR (200 MHz, CDCl3): mixture of epimers δ = 4.52 (s, 1 H), 3.79-
3.71 (m, 3 H), 3.72 (s, 3 H, OCH3), 3.66-3.61 (m, 3 H), 3.48-3.42 (m, 2 H), 
3.37 (s, 3 H, OCH3), 2.91 (br, 1 H). 
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General Procedure for the Synthesis of Compounds of general 
formula III A 5.26-5.31. 
To a solution of IIB (1 eq) and and amine (1 eq) in dry CHCl3 (0.5 
ml/mmol) was added under a nitrogen atmosphere LiNTf2 (0.5 eq). The 
mixture was stirred in sealed vial at 85°C (oil bath) for 40h, then it was 
washed with a sat. NaHCO3 solution, and the organic phase was dried 
(Na2SO4), filtered and concentrated, and purified by flash chromatography 
(petroleum ether/EtOAc, 1:1), thus giving product IIIA.  
 
 
Benzyl-(5R/S,3aS,7aR)-4-benzoyl-2-hydroxymethyl-6-methoxy-
morpholin-3-carboxamide 
 
 
 
Compound 5.9 reacted with benzylamine thus giving product 5.26 as a 
white solid, yield: 93%. 1H NMR (400 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.50-7.28 (m, 10 H), 7.01 (br, 1 H), 5.15 (d, 1 H), 4.70 (s, 
1 H), 4.49 (dq, 2 H), 4.36-4.32 (m, 1 H), 4.03 (dd, 1 H), 3.84 (br, 1 H), 3.71 
(dd, 2 H) 3.41 (s, 3 H). 13C NMR (50 MHz, CDCl3): mixture of epimers and 
rotamers δ = 172.3 (s, 1 C), 168.0 (s, 1 C), 137.9 (s, 1 C), 134.1 (s, 1 C), 
130.3 (d, 1 C), 128.6 (d, 2 C), 128.4 (d, 2 C), 127.7 (d, 2 C), 127.6 (d, 2 C), 
127.3 (d, 1 C), 95.7 (d, 1 C), 68.2 (d, 1 C), 61.9 (t, 1 C), 54.9 (q, 1 C), 53.3 
(d, 1 C), 48.0 (t, 1 C), 43.5 (t, 1 C). MS: m/z (%): 384 (1) [M]+, 352 (60), 250 
(53), 219 (15), 128 (22), 104 (100), 91 (54), 77 (74), 67 (12), 58 (14), 51 (23). 
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Allyl-(5R/S,3aS,7aR)-4-benzoyl-2-hydroxymethyl-6-methoxy-
morfolin-3-carboxamide 
 
 
 
Compound 5.9 reacted with allylamine thus giving product 5.27 as a white 
solid, yield: 97%. 1H NMR (400 MHz, CDCl3): mixture of epimers and 
rotamers δ = 7.53-7.49 (m, 2 H), 7.42-7.39 (m, 3 H), 6.83 (br, 1 H), 5.88-
5.81 (m, 1 H), 5.25-5.14 (m, 3 H), 4.70 (s, 1 H major), 4.61 (s, 1 H minor), 
4.33 (q, 1 H), 4.03-3.75 (m, 7 H)  3.75 (s), 3.41 (s, 3 H). 13C NMR (50 MHz, 
CDCl3): mixture of epimers and rotamers δ = 172.2 (s, 1 C), 168.0 (s, 1 C), 
134.2 (s, 1 C), 133.6 (d, 1 C), 130.3 (d, 2 C), 128.4 (d, 2 C) 127.7 (d, 1 C), 
116.4 (t, 1 C), 95.7 (d, 1 C), 68.1 (d, 1 C), 61.8 (t, 1 C), 54.9 (q, 1 C), 53.2 (d, 
1 C), 48.0 and 47.6 (t, 1 C), 41.9 (t, 1 C). MS: m/z (%): 334 (1) [M]+, 302 
(44), 250 (32), 128 (15), 106 (16), 105 (100), 96 (14), 77 (60), 58 (13), 51 
(16).  
 
Propargyl-(5R/S,3aS,7aR)-4-benzoyl-2-hydroxymethyl-6-methoxy-
morfolin-3-carboxamide 
 
 
 
Compound 5.9 reacted with propargylamine thus giving product 5.28 as a 
yellow solid, yield: 93%. 1H NMR (400 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.56-7.52 (m, 2 H), 7.41-7.38 (m, 3 H), 7.15 (br, 1 H), 
5.18 (d, 1 H), 4.69 (s, 1 H), 4.61 (s, 1 H), 4.34 (q, 1 H), 4.14-4.04 (m, 2 H), 
4.00-3.96 (m, 1 H), 3.84-3.69 (m, 3 H), 3.50 (s, 3 H minor), 3.40 (s, 3 H 
major), 2.23 (s, 1 H). 13C NMR (50 MHz, CDCl3): mixture of epimers and 
rotamers  δ = 172.1 (s, 1 C), 167.7 (s, 1 C), 133.9 (s, 1 C), 130.0 (d, 1 C), 
128.4 and 128.2 (d, 2 C), 127.4 and 126.8 (d, 2 C), 95.4 (d, 1 C), 71.2 (t, 1 
C), 67.7 (d, 1 C), 61.2 (s, 1 C), 54.5 (q, 1 C), 52.5 (d, 1 C), 47.7 (t, 1 C), 28.7 
(t, 1 C). MS: m/z (%):  332 (1) [M]+, 300 (19), 250 (19), 127 (11), 105 (100), 
77 (62), 57 (18), 51 (14). 
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Cyclopropyl-(5R/S,3aS,7aR)-4-benzoyl-2-hydroxymethyl-6-methoxy-
morfolin-3-carboxamide 
 
 
 
Compound 5.9 reacted with cyclopropylamine thus giving product 5.29 as 
a white solid, yield: 86%. 1H NMR (400 MHz, CDCl3): mixture of epimers 
and rotamers δ = 7.56-7.52 (m, 2 H), 7.41-7.38 (m, 3 H), 7.21 (br, 1 H), 
5.16 (d, 1 H), 4.67 (d, 1 H), 4.33 (q, 1 H), 3.98 (dd, 1 H), 3.87-3.82 (m, 1 
H), 3.67-3.64 (m, 2 H), 3.37 (s, 3 H), 2.78 (m, 1 H), 0.88 (d, 2 H), 0.49 (d, 2 
H). 13C NMR (50 MHz, CDCl3): mixture of epimers and rotamers δ = 
172.2 (s, 1 C), 169.5 (s, 1 C), 134.3 (s, 1 C), 130.3 (d, 1 C), 128.4 (d, 2 C), 
127.6 (d, 2 C), 95.7 (d, 1 C), 68.1 (d, 1 C), 61.7 (t, 1 C), 54.9 (q, 1 C), 52.9 
(d, 1 C), 48.1 (t, 1 C), 22.7 (d, 1 C), 6.6 (t, 1 C), 6.4 (t, 1 C). MS: m/z (%):  
334 (1) [M]+,  302 (2), 105 (100), 85 (14), 77 (60), 71 (25), 69 (19), 58 (21), 
57 (87), 56 (26), 55 (24), 51 (19). 
 
Piperidinyl-(5R/S,3aS,7aR)-4-benzoyl-2-hydroxymethyl-6-methoxy-
morfolin-3-carboxamide 
 
 
 
Compound 5.9 reacted with piperidine thus giving product 5.30 as a yellow 
solid, yield: 85%. 1H NMR (400 MHz, CDCl3): mixture of epimers and 
rotamers δ = 7.56-7.52 (m, 2 H), 7.41-7.38 (m, 3 H), 5.56 (d, 1 H), 4.69 (d, 
1 H), 4.31 (q, 1 H), 4.02 (dd, 1 H), 3.87-3.64 (m, 5 H), 3.55-3.48 (m, 2 H), 
3.36 (s, 3 H), 2.60-2.56 (m, 1 H), 1.64 (m, 6 H). 13C NMR (50 MHz, 
CDCl3): mixture of epimers and rotamers δ = 171.7 (s, 1 C), 167.0 (s, 1 C), 
134.8 (s, 1 C), 129.9 (d, 1 C), 128.3 (d, 2 C), 127.5 (d, 2 C), 95.8 (d, 1 C), 
68.5 (d, 1 C), 62.5 (t, 1 C), 54.7 (q, 1 C), 48.2 (d, 1 C), 47.2 (t, 1 C), 43.3 (t, 1 
C), 26.9 (t, 1 C), 25.9 (t, 1 C), 24.7 (t, 1 C). MS: m/z (%): 362 (1) [M]+, 330 
(15), 250 (15), 128 (14), 105 (100), 84 (27), 77 (53), 69 (18), 56 (19), 51 (12).   
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(2R/3S)-N-benzyl-2-hydroxymethyl-4-(2-iodobenzoyl)-6-
methoxymorpholine-3-carboxamide  
 
 
 
Compound 5.17 reacted with benzylamine thus giving product 5.31 as a 
white solid, yield: 97%. 1H NMR (200 MHz, CDCl3): mix of epimers and 
rotamers δ = 7.70 (d, 1 H), 7.42-7.35 (m, 2 H), 7.28 (s, 5 H), 7.09-7.03 (m, 
2 H), 5.36 (d, 1 H major), 5.18 (d, 1 H minor), 4.60 (s, 1 H), 4.51 (t, 2 H), 
4.32-4.25 (m, 1 H), 4.01-3.83 (m, 2 H), 3.63-3.38 (m, 1 H), 3.31 (s, 3 H) 
3.26-3.19 (m, 1 H). 13C NMR (50 MHz, CDCl3): mix of epimers and 
rotamers δ = 170.9 and 170.7 (s, 1 C), 167.4 and 167.2 (s, 1 C), 141.1 and 
140.9 (s, 1 C), 139.5 and 138.8 (d, 1C), 138.0 (s, 1 C), 137.5 (s, 1 C), 130.6 
(d, 1 C), 128.6 (d, 2 C), 128.4 (d, 2 C), 128.2 (d, 1 C), 127.5 (d, 1 C), 127.2 
and 126.9 (d, 1 C), 96.2 and 95.5 (d, 1 C), 68.6 and 67.8 (d, 1 C), 62.1 and 
61.2 (t, 1 C), 56.2 and 54.8 (q, 1 C), 53.4 and 53.0 (d, 1 C), 48.0 and 46.9 (t, 
1 C), 43.8 and 43.5 (t, 1 C). MS: m/z (%): 511 (1) [M+1]+, 478 (48), 376 
(11), 230 (100), 202 (13), 104 (22), 91 (43), 75 (13).   
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Allyl-(5R/S,3aS,7aR)-4-benzoyl-2-acryloyloxy-6-methoxy-morfolin-3-
carboxamide 
 
 
 
To a solution of 5.27 (1 eq) and TEA (1 eq) in anhydrous CH2Cl2 (5 
mL/mmol) acryloyl chloride (1.1 eq) is added at 0°C. The mixture is 
allowed to reach room temperature and left overnight stirring, then a 
saturated NaHCO3 solution is added. The organic phase is washed with 1N 
HCl, a saturated NaHCO3 solution and brine, and successively dried 
(Na2SO4), filtered and concentrated. Compound 5.32 is obtained after flash 
chromatography (petroleum ether/EtOAc, 1:1) as a colourless oil, yield: 
78%. 1H NMR (400 MHz, CDCl3): mixture of epimers and rotamers δ = 
7.56-7.55 (m, 2 H), 7.46-7.40 (m, 3 H), 6.68 (br, 1 H), 6.45 (d, 1 H), 6.16 
(dd, 1 H), 5.87 (d, 1 H), 5.83-5.79 (m, 1 H), 5.19-5.11 (m, 3 H), 4.70-4.62 
(m, 2 H), 4.55-4.41 (m, 2 H), 3.92-3.87 (m, 2 H), 3.77 (d, 1 H), 3.62 (d, 1 
H), 3.41 (s, 3 H). 13C NMR (50 MHz, CDCl3): mixture of epimers and 
rotamers δ = 172.0 (s, 1 C), 167.0 (s, 1 C), 165.3 (s, 1 C), 137.1 (d, 1 C), 
133.4 (d, 1 C), 133.6 (s, 1 C), 131.1 (t, 1 C), 130.2 (d, 1 C), 128.1 (d, 2 C), 
127.7 (d, 2 C), 115.9 (t, 1 C), 95.1 (d, 1 C), 66.1 (d, 1 C), 63.8 (t, 1 C), 54.4 
(q, 1 C), 52.6 (d, 1 C), 47.2 (t, 1 C), 41.2 (t, 1 C). MS: m/z (%): 388 (1) [M]+, 
356 (18), 232 (23), 106 (13), 105 (100), 96 (10), 77 (51), 58 (11), 57 (22), 55 
(33).  
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(5R/S,3aS,7aR)-2-allyloxymethyl-4-benzoyl-6-methoxy-morpholine-
3-carboxylic acid allyl-prop-2-ynyl-amide 
 
N
OO
O
N
O
5.33
O
 
 
To a solution of 5.28 (1 eq) in anhydrous THF (10 ml/mmol) TBAI (0.01 
eq) and allyl bromide (1 eq) were added. Then NaH (60% suspension in 
mineral oil; 20 mg, 3 eq) was added at 0°C. The mixture was allowed to 
reach room temperature and left overnight stirring, then washed with 
ice/water and exctracted with EtOAc. The organic phase is dried (Na2SO4), 
filtered and concentrated. Compound 5.33 is obtained after flash 
chromatography (petroleum ether/EtOAc, 1:1) as a colourless oil, yield: 
88%. 1H NMR (400 MHz, CDCl3): mix of epimers and rotamers δ = 7.50-
7.38 (m, 5 H), 5.96- 5.75 (m, 2 H), 5.62 (d, 1 H major), 5.50 (d, 1 H minor), 
5.30-5.15 (m, 4 H), 4.66 (m, 1 H), 4.53-4.42 (m, 2 H), 4.24-3.92 (m, 6 H), 
3.72-3.57 (m, 3 H), 3.37 (s, 3 H, minor), 3.35 (s, 3 H, major), 2.28 (s, 1 H 
minor), 2.20 (s, 1 H major). 13C NMR (50 MHz, CDCl3): mix of epimers 
and rotamers δ = 171.4 (s, 1 C), 168.0 and 167.5 (s, 1 C), 134.9 (s, 1 C), 
134.4 and 134.2 (d, 1 C), 133.0 and 132.1 (d, 1 C), 129.9 (d, 1 C), 128.3 (d, 2 
C), 127.5 (d, 2 C), 118.4 and 118.0 (t, 1 C), 117.2 and 116.5 (t, 1 C), 95.6 (d, 
1 C), 73.0 and 72.4 (t, 1 C), 69.9 and 69.8 (t, 1 C), 67.5 and 67.0 (d, 1 C), 
54.7 (q, 1 C), 50.1 and 49.8 (t, 1 C), 48.7 and 48.5 (d, 1 C), 47.7 and 47.4 (t, 
1 C), 36.9 (s, 1 C) 33.8 (t, 1 C). MS: m/z (%): 412 (1) [M]+, 380 (35), 318 
(19), 290 (50), 232 (21), 105 (100), 77 (45). 
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[(2R,3S)-3-(benzylcarbomoyl)-4-(2-iodobenzoyl)-6-
methoxymorpholin-2-yl]methyl acetate 
 
 
 
To a solution of 5.31 (1 eq) in anhydrous CH2Cl2 (2 mL/mmol) Ac2O (3 
eq) and DMAP (0.1 eq) are added. The mixture is left overnight stirring 
under a nitrogen atmosphere. Successively, the mixture is washed with 
H2O/ice and 1M KHSO4. The organic phase is dried (Na2SO4) and 
concentrated, giving compound 5.34 after flash chromatography 
(petroleum ether/EtOAc, 1:1) as colourless oil, yield: 95%. 1H NMR (200 
MHz, CDCl3): mixture of epimers and rotamers δ = 7.71 (d, 1 H), 7.44-
7.36 (m, 2 H), 7.30 (s, 5 H), 7.14-7.04 (m, 1 H), 6.85 (br, 1 H), 5.32 (d, 1 H 
major), 5.21 (d, 1 H minor), 4.75-4.33 (m, 6 H), 3.55-3.40 (m, 1 H), 3.34 (s, 
3 H) 3.27-3.20 (m, 1 H), 2.08 (s, 3 H). 13C NMR (50 MHz, CDCl3): mixture 
of epimers and rotamers δ = 170.7 and 170.3 (s, 1 C), 166.2 (s, 1 C), 140.2 
(s, 1 C), 139.0 and 138.7 (d, 1 C), 137.6 (s, 2 C), 130.6 (d, 1 C), 128.6 (d, 2 
C), 128.4 (d, 2 C), 128.0 (d, 2 C), 127.5 and 127.2 (d, 1 C), 95.3 (d, 1 C), 
66.9 (d, 1 C), 64.3 (t, 1 C), 54.6 (q, 1 C), 52.6 and 52.4 (d, 1 C), 46.7 (t, 1 C), 
43.7 (t, 1 C), 20.9 (q, 1 C). MS: m/z (%): 553 (1) [M+1]+, 520 (24), 358 (18), 
333 (18), 230 (100), 202 (17), 105 (16), 104 (42), 90 (74), 76 (30), 75 (31), 68 
(20), 64 (15), 58 (15), 50 (11). 
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(3aS,5R/S,7aR)-7-fluorenylmethoxycarbonyl-5-trichloroacetimido-
hexahydro-2,4-dioxa-7-aza-inden-1-one 
 
O
N
O
O
Cl3C
NH
5.35
OO
 
 
To a solution of 5.6 (1 eq) in anhydrous CH2Cl2 (5 mL/mmol) 
trichloroacetonitrile (2 eq) is added  dropwise and DBU (0.1 eq) at 0°C. 
The mixture is allowed to reach room temperature and is left 2h stirring 
under a nitrogen atmosphere. Successively the mixture is diluted with Et2O 
and washed with H2O and brine. The organic phase is dried (Na2SO4) and 
concentrated. Compound 5.35 is isolated by flash chromatography 
(petroleum ether/EtOAc, 1:2). White solid, yield: 38%. 1H NMR (200 
MHz, CDCl3): mixture of epimers and rotamers δ = 8.65 (d, 1 H), 7.76 (d, 
2 H), 7.55 (d, 2 H), 7.43-7.29 (m, 4 H), 6.21 (d, 1 H), 5.25 (d, 1 H), 4.87-
4.23 (m, 7 H), 3.35-3.14 (m, 1 H). 13C NMR (50 MHz, CDCl3): mixture of 
epimers and rotamers δ = 171.3 (s, 1 C), 160.1 (s, 1 C) 155.6 (s, 1 C), 143.3 
(s, 2 C), 141.1 (s, 2 C), 127.8 (d, 2 C), 127.1 (d, 2 C), 124.8 (d, 2 C), 120.0 
(d, 2 C), 92.2 (d, 1 C), 77.1 (s, 1 C), 70.5 (t, 1 C), 68.8 (t, 1 C), 67.0 and 66.6 
(d, 1 C), 53.6 and 53.1 (d, 1 C), 47.1 (d, 1 C), 42.7 and 42.0 (t, 1 C). MS: 
m/z (%): 526 (1) [M]+, 179 (37), 178 (100), 165 (8), 152 (3), 89 (3), 81 (1), 
68 (2), 53 (3). 
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(3aS,5R/S,7aR)-7-carbobenzyloxy-5-trichloroacetimido-hexahydro-
2,4-dioxa-7-aza-inden-1-one 
 
O
N
O
O
Cl3C
NH
5.36
OO
 
 
To a solution of 5.7 (1 eq) in anhydrous CH2Cl2 (5 mL/mmol) 
trichloroacetonitrile (2 eq) is added dropwise and DBU (0.1 eq) at 0°C. The 
mixture is allowed to reach room temperature and is left 2h stirring under a 
nitrogen atmosphere. Successively the mixture is diluted with Et2O and 
washed with H2O and brine. The organic phase is dried (Na2SO4) and 
concentrated. Compound 5.36 is isolated by flash chromatography 
(petroleum ether/EtOAc, 1:2). White solid, yield: 46%. 1H NMR (200 
MHz, CDCl3): mixture of epimers and rotamers δ = 8.65 (d, 1 H), 7.33-
7.31 (m, 5 H), 6.18 (d, 1 H), 5.24-4.99 (m, 3 H major and minor), 4.73-4.67 
(m, 1 H), 4.42-4.24 (m, 3 H major and minor), 3.29-3.11 (m, 1 H). 13C 
NMR (50 MHz, CDCl3): mixture of epimers and rotamers δ = 171.4 (1 C), 
160.1 (1 C), 155.5 (1 C), 135.5 (1 C), 128.5 (2 C), 128.3 (1 C), 128.0 (1 C), 
127.9 (1 C), 92.4 and 92.1 (1 C), 77.1 (s, 1 C), 70.5 (1 C), 68.4 (1 C), 67.0 
and 66.7 (1 C), 53.6 and 53.2 (1 C ), 42.8 and 42.1 (1 C). MS: m/z (%): 436 
(1) [M]+, 275 (3), 232 (15), 231 (15), 169 (11), 141 (5), 132 (11), 92 (13), 91 
(100), 82 (3), 65 (17), 51 (4). 
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(3aS,5R/S,7aR)-5-benzyloxy-7-carbobenzyloxy-hexahydro-2,4-dioxa-
7-aza-inden-1-one 
 
O
N
O
O
O
5.37
OO
 
 
To a solution of 5.36 (1 eq) and benzyl alcohol (1 eq) in anhydrous CH2Cl2-
Cyclohexane (2.2 mL/mmol-4.4 mL/mmol) BF3
.2Et2O (0.1 eq) is added 
dropwise at 0°C. The mixture is allowed to reach room temperature and is 
left 2h stirring under a nitrogen atmosphere. Successively the mixture is 
concentrated, dissolved in EtOAc and washed with NaHCO3 and brine. 
The organic phase is dried (Na2SO4) and concentrated. Compound 5.37 is 
isolated by flash chromatography (petroleum ether/EtOAc, 1:1). White 
solid, yield: 93%. 1H NMR (200 MHz, CDCl3): mixture of epimers and 
rotamers δ = 7.34-7.31 (m, 10 H), 5.29-5.12 (m, 3 H), 4.89-4.31 (m, 6 H), 
4.08-3.97 (m, 1 H), 3.16-2.98 (m, 1 H). 13C NMR (50 MHz, CDCl3): 
mixture of epimers and rotamers δ = 171.9 and 171.6 (1 C), 155.8 and 
155.0 (1 C), 136.3 and 136.2 (1 C), 135.6 and 135.4 (1 C), 128.2 (2 C), 127.9 
(2 C), 127.8 (2 C), 127.7 (1 C), 127.6 (1 C), 127.4 (1 C), 127.3 (1 C), 93.1 
and 92.7 (1 C), 70.4 and 70.3 (1 C), 69.1 and 69.0 (1 C), 67.9 and 67.8 (1 C), 
65.0 and 64.6 (1 C), 53.3 and 53.0 (1 C ), 43.8 and 43.1 (1 C). MS: m/z (%): 
383 (1) [M]+, 248 (5), 186 (11), 142 (6), 107 (1), 92 (8), 91 (100), 77 (2), 65 
(8), 51 (3). 
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(1S,3R/S,10R)-8-Benzyl-1-hydroxymethyl-3-methoxy-hexahydro-
pyrazino[2,1-c][1,4]oxazine-6,9-dione 
 
 
 
To a solution of 5.15 (1 eq) and and benzylamine (1 eq) in dry CHCl3 (0.5 
ml/mmol) was added under a nitrogen atmosphere LiNTf2 (0.5 eq). The 
mixture was stirred in sealed vial at 85°C (oil bath) for 40h, then it was 
washed with a sat. NaHCO3 solution, and the organic phase was dried 
(Na2SO4), filtered and concentrated, and purified by flash chromatography 
(petroleum ether/EtOAc, 1:1), thus giving product 5.38 as a white solid, 
yield: 59%. 1H NMR (200 MHz, CDCl3): mixture of epimers and rotamers 
δ = 7.38-7.31 (m, 5 H), 4.84 (t, 1 H), 4.73 (d, 1 H), 4.59 (d, 1 H), 4.51-4.32 
(m, 3 H), 3.98-3.77 (m, 4 H), 3.52 (s, 3 H minor), 3.48 (s, 3 H major), 2.89 
(dd, 1 H). 13C NMR (50 MHz, CDCl3): mixture of epimers and rotamers δ 
= 162.7 and 162.9 (s, 2 C), 134.6 (s, 1 C), 128.8 (d, 2C), 128.4 and 128.2 (s, 
2 C), 128.1 (s, 1 C), 94.9 (d, 1 C), 72.7 (d, 1 C), 61.7 (t, 1 C), 56.2 (q, 1 C), 
55.7 (d, 1 C), 49.3 (t, 1 C), 49.0 (t, 1 C), 45.2 (t, 1 C). MS: m/z (%): 306 (1) 
[M]+, 288 (12), 260 (27), 120 (8), 91 (81), 65 (11), 58 (100), 56 (10). 
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(1S,3R/S,11aR)-10-Benzyl-1-hydroxymethyl-3-methoxy-1,3,4,11a-
tetrahydro-10H-2-oxa-4a,10-diaza-dibenzo[a,d]cycloheptene-5,11-
dione 
 
O
N
O
OH
N
O
O
5.39  
 
A solution of 5.34 (1 eq) in anhydrous DMSO (50 mL/mmol) was added 
under argon to a solution of K2CO3 (2 eq), CuI (0.1 eq) and sarcosine (0.2 eq) in 
anhydrous DMSO. The mixture is left overnight stirring at 110°C, successively 
the mixture is diluted with EtOAc washed with NH4Cl and brine. The organic 
phase is dried (Na2SO4) concentrated and purified by flash chromatography 
(petroleum ether/EtOAc, 1:1), thus giving product 5.39 as a yellow oil, yield: 
30%. 1H NMR (400 MHz, CDCl3): mixture of epimers and rotamers δ = 7.86-
7.07 (m, 9 H), 5.55 (d, J = 4.0 Hz, 1 H, major), 5.16 (d, J = 4.0 Hz, 1 H, minor), 
4.78-4.31  (m, 4 H, CH2Ph, CH2OH), 4.02-3.99 (m, 1 H major), 3.93-3.90 (m, 1 
H, minor), 3.60 (t, J = 6.0 Hz, 1 H), 3.43 (s, 3 H, OCH3 major) and 3.41 (s, 3 H, 
OCH3 major), 3.36 (s, 3 H, OCH3 minor), 3.35-3.13 (m, 2 H).  
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(2R/S,4aR,7aR)-4-Benzoyl-6-cyclopropyl-2-methoxy-hexahydro-
pyrrolo[3,4-b][1,4]oxazin-5-one 
 
 
 
To a solution of 5.29 (1 eq) in anhydrous toluene (10 mL/mmol), 
triphenylphosphine (1 eq) were added. To this stirred solution diisopropyl 
azodicarboxylate (1 eq) was added dropwise. The resulting yellow solution 
is left overnight stirring at room temperature, successively the mixture is 
concentrated. Compound 5.40 is isolated by flash chromatography 
(petroleum ether/EtOAc, 1:1). Yellow solid, yield: 58%. 1H NMR (400 
MHz, CDCl3): mixture of epimers and rotamers δ = 7.65-7.29 (m, 5 H 
major and minor), 5.7 (d, 1 H, CHOCH3, minor), 5.60 (d, 1 H, CHOCH3, 
major), 4.74-4.07 (m, 4 H, CH2NBz, CHCO, CHCHCO), 3.61-3.51 (m, 1H, 
CH2NCyclopropyl), 3.42 (s, 3 H minor), 3.36 (s, 3 H major), 3.30 (br, 1 H, 
CH cyclopropyl), 3.10-3.01 (m, 1H, CH2NCyclopropyl) 0.73-0.58 (m, 4 H, 
CH2 cyclopropyl). 
13C NMR (100 MHz, CDCl3): mixture of epimers and 
rotamers δ = 171.9, 167.4, 134.7, 131.9 (minor), 129.9, 129.8 (minor), 
128.3, 128.2, 127.9 (minor), 125.8, 96.1 (minor), 95.4, 71.7, 71.3 (minor), 
66.4, 65.8 (minor), 56.7, 55.2 and 55.0 (minor), 51.3, 46.5, 40.5, 29.3, 7.81 
and 7.60, 7.46 and 7.24. MS: m/z (%): 316 (2) [M]+, 315 (5), 255 (13), 204 
(9), 151 (24), 105 (100), 77 (72), 70 (20), 68 (12), 58 (29), 54 (11), 51 (25). 
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8.6. Experimental Section of 
Chapter 6 
 
General Procedure for the aminolysis of 
lactones 
To a solution of lactone (1 eq) and amine (1 eq) 
in dry CHCl3 (0.5 ml/mmol) was added under a 
nitrogen atmosphere LiNTf2 (0.5 eq). The 
mixture was stirred in sealed vial at 85°C (oil bath) for 40h, then it was 
washed with a sat. NaHCO3 solution, and the organic phase was 
evaporated to give the title products.  
 
 
N-allyl-4-hydroxybutanamide 
 
 
 
White solid 99% yield. M.p. 78-81°C. 1H NMR (200 MHz, CDCl3): δ = 
6.62 (br, 1 H, NH), 6.03-5.73 (m, 1 H, =CH), 5.23-5.04 (m, 2 H, =CH2), 
4.02 (br, 1 H, OH), 3.88 (t, J = 5.5 Hz, 2 H), 3.72 (t, J = 5.5 Hz, 2 H), 2.40 
(t, J = 6.2 Hz, 2 H), 1.96-1.79 (m, 2 H) ppm. 13C NMR (50 MHz, CDCl3): δ 
= 178.2 (s, 1 C, C=O), 137.1 (d, 1 C, =CH), 119.4 (t, 1 C, =CH2), 65.1 (t, 1 
C, CH2), 45.4 (t, 1 C, CH2), 36.4 (t, 1 C, CH2), 31.5 (t, 1 C, CH2) ppm. MS: 
m/z (%) = 143 (1) [M]+, 99 (28), 84 (10), 69 (14),  57 (100). C7H13NO2 
(143.09): calcd. C 58.72, H 9.15, N 9.78; found C 58.70, H 9.14, N 9.76. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LiNTf2-catalyzed 
aminolysis of lactones 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  6  
 
 
 133
4-hydroxy-1-(piperidin-1-yl)butan-1-one 
 
 
 
Yellow oil 100% yield. 1H NMR (200 MHz, CDCl3): δ = 3.70-3.63 (m, 2 
H), 3.55-3.51 (m, 2 H), 3.43-3.41 (m, 2 H), 3.15 (br, 1 H, OH), 2.50 (t, J = 
6.6 Hz, 2 H), 1.93-1.80 (m, 2 H), 1.60-1.55 (m, 6 H). 13C NMR (50 MHz, 
CDCl3): δ = 171.4 (s, 1 C, C=O), 61.1 (t, 1 C, CH2), 46.3 (t, 1 C, CH2), 44.6 
(t, 1 C, CH2), 42.3 (t, 1 C, CH2), 29.7 (t, 1 C, CH2), 27.6 (t, 1 C, CH2), 25.8 
(t, 1 C, CH2), 21.9 (t, 1 C, CH2). MS: m/z (%) = 171 (1) [M]
+, 127 (14), 86 
(27), 85 (47), 84 (100), 70 (15), 69 (67) 57 (47), 56 (67), 55 (20). C9H17NO2 
(171.13): calcd. C 63.13, H 10.01, N 8.18; found C 63.13, H 10.03, N 8.21. 
 
 
N-benzyl-4-hydroxybutanamide 
 
 
 
Yellow solid 100% yield. M.p. 55-57°C. 1H NMR (200 MHz, CDCl3): δ = 
7.36-7.21 (m, 5 H, Ar), 6.42 (br, 1 H, NH), 4.36 (d, J = 5.9 Hz, 2 H), 3.81 
(br, 1 H, OH), 3.61 (t, J = 5.9 Hz, 2 H), 2.32 (t, J = 5.9 Hz, 2 H), 1.87-1.75 
(m, 2 H). 13C NMR (50 MHz, CDCl3): δ = 173.9 (s, 1 C, C=O), 137.9 (s, 1 
C, Ar), 128.6 (d, 1 C, Ar), 128.2 (d, 1 C, Ar), 128.1 (d, 1 C, Ar), 127.1 (d, 1 
C, Ar), 126.9 (d, 1 C, Ar), 61.2 (t, 1 C, CH2), 43.1 (t, 1 C, CH2), 32.8 (t, 1 C, 
CH2), 28.0 (t, 1 C, CH2). MS: m/z (%) = 193 (37) [M]
+, 162 (13), 149 (45), 
148 (16), 107 (29), 106 (100), 103 (17), 92 (14), 91 (98), 79 (15), 77 (17), 68 
(12), 65 (25), 51 (16). C11H15NO2 (193.11): calcd. C 68.37, H 7.82, N 7.25; 
found C 68.38, H 7.82, N 7.27. 
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N-butyl-4-hydroxybutanamide 
 
 
 
Yellow oil 99% yield. 1H NMR (200 MHz, CDCl3): δ = 6.54 (br, 1 H, NH), 
3.60 (td, J = 5.9, 1.5 Hz, 2 H), 3.16 (q, J = 5.5 Hz 2 H), 2.29 (t, J = 6.6 Hz, 
2 H), 1.86-1.73 (m, 2 H), 1.50-1.21 (m, 4 H), 0.87 (t, J = 6.9 Hz, 3 H, CH3). 
13C NMR (50 MHz, CDCl3): δ = 173.6 (s, 1 C, C=O), 61.4 (t, 1 C, CH2), 
39.1 (t, 1 C, CH2), 33.2 (t, 1 C, CH2), 31.1 (t, 1 C, CH2), 28.1 (t, 1 C, CH2), 
19.7 (t, 1 C, CH2), 13.4 (q, 1 C, CH3). MS: m/z (%) = 159 (5) [M]
+, 129 (16), 
117 (43), 115 (67), 100 (47), 87 (77), 86 (34), 73 (100), 69 (45), 58 (44), 57 
(86). C8H17NO2 (159.13): calcd. C 60.35, H 10.76, N 8.80; found C 60.37, H 
10.77, N 8.80. 
 
 
4-hydroxy-N-(4-methoxyphenyl)butanamide 
 
 
 
Brown solid 11% yield. M.p. 90-93°C. 1H NMR (200 MHz, CDCl3): δ = 
7.39 (d, J = 8.8 Hz, 3 H, Ar and NH), 6.85 (d, J = 6.8 Hz, 2 H, Ar), 3.79 (s, 
3 H, OCH3), 3.76-3.73 (m, 2 H), 2.52 (t, J = 6.6 Hz, 2 H), 2.04-1.91 (m, 2 
H). 13C NMR (50 MHz, CDCl3): δ = 171.9 (s, 1 C, C=O), 155.9 (s, 1 C, Ar), 
130.8 (s, 1 C, Ar), 121.7 (d, 1 C, Ar), 121.6 (d, 1 C, Ar), 113.7 (d, 2 C, Ar), 
61.4 (t, 1 C, CH2), 55.1 (q, 1 C, OCH3), 33.8 (t, 1 C, CH2), 27.9 (t, 1 C, 
CH2). MS: m/z (%) = 209 (17) [M]
+, 123 (100), 108 (80), 80 (14), 52 (13). 
C11H15NO3 (209.11): calcd. C 63.14, H 7.23, N 6.69; found C 63.12, H 7.23, 
N 6.67. 
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1-(4-methoxyphenyl)pyrrolidin-2-one 
 
N
O
O
6.7bis  
 
Brown solid 12% yield. M.p. 99-102°C. 1H NMR (200 MHz, CDCl3): δ = 
7.47-7.41 (m, 2 H, Ar), 6.89-6.83 (m, 2 H, Ar), 3.80-3.69 (m, 2 H), 3.75 (s, 3 
H, OCH3), 2.53 (t, J = 8.1 Hz, 2 H), 2.16-2.05 (m, 2 H). 
13C NMR (50 
MHz, CDCl3): δ = 173.5 (s, 1 C, C=O), 156.1 (s, 1 C, Ar), 132.3 (s, 1 C, 
Ar), 121.4 (d, 1 C, Ar), 121.1 (d, 1 C, Ar), 113.6 (d, 2 C, Ar), 55.1 (q, 1 C, 
OCH3), 48.8 (t, 1 C, CH2), 32.2 (t, 1 C, CH2), 17.6 (t, 1 C, CH2). MS: m/z 
(%) = 191 (51) [M]+, 190 (16), , 176 (12), 149 (25), 136 (100), 134 (11), 123 
(61), 122 (11), 121 (13), 108 (39), 99 (12), 92 (10), 80 (14), 77 (16), 69 (29), 
62 (16), 60 (45), 57 (29), 55 (36), 52 (19). C11H13NO2 (191.09): calcd. C 
69.09, H 6.85, N 7.32; found C 69.08, H 6.86, N 7.32. 
 
 
N-allyl-3-hydroxypropanamide 
 
 
 
Yellow solid 100% yield. M.p. 89-91°C. 1H NMR (200 MHz, CD3OD): δ = 
7.61 (br, 1 H, NH), 5.96-5.73 (m, 1 H, =CH), 5.27-5.08 (m, 2 H, =CH2), 
3.85 (t, J = 5.5 Hz, 1 H), 3.31 (d, J = 6.2 Hz, 1 H), 2.97-2.85 (m, 2 H), 2.43 
(t, J = 5.5 Hz, 2 H). 13C NMR (50 MHz, CD3OD): δ = 174.2 (s, 1 C, C=O), 
132.9 (d, 1 C, =CH), 116.1 (t, 1 C, =CH2), 42.7 (t, 1 C, CH2), 29.9 (t, 1 C, 
CH2), 20.1 (t, 1 C, CH2), 21.6 (t, 1 C, CH2). MS: m/z (%) = 129 (1) [M]
+, 
127 (10), 98 (18), 84 (22), 70 (66), 69 (66), 68 (36), 58 (24), 57 (41), 56 (100), 
55 (30). C6H11NO2 (129.08): calcd. C 55.80, H 8.58, N 10.84; found C 
55.80, H 8.56, N 10.83. 
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N-allyl-5-hydroxypentanamide 
 
H
N
O
OH
6.11  
 
Yellow oil 95% yield. 1H NMR (200 MHz, CDCl3): δ = 5.93-5.74 (m, 2 H, 
=CH and NH), 5.22-5.10 (m, 2 H, =CH2), 3.85 (t, J = 5.9 Hz, 2 H), 3.64 (t, 
J = 5.9 Hz, 2 H), 2.43 (br, 1 H, OH), 2.26 (t, J = 6.9 Hz, 2 H), 1.82-1.56 
(m, 4 H). 13C NMR (50 MHz, CDCl3): δ = 173.8 (s, 1 C, C=O), 133.5 (d, 1 
C, =CH), 115.6 (t, 1 C, =CH2), 61.1 (t, 1 C, CH2), 41.5 (t, 1 C, CH2), 35.4 (t, 
1 C, CH2), 31.3 (t, 1 C, CH2), 21.6 (t, 1 C, CH2). MS: m/z (%) = 157 (2) 
[M]+, 98 (10), 84 (21), 83 (11), 70 (33), 69 (13), 68 (15), 58 (23), 57 (100), 56 
(94), 55 (82). C8H15NO2 (157.11): calcd. C 61.12, H 9.62, N 8.91; found C 
61.13, H 9.64, N 8.93. 
 
 
N-allyl-6-hydroxyhexanamide 
 
 
 
Yellow oil 53% yield. 1H NMR (200 MHz, CDCl3): δ = 5.91-5.72 (m, 2 H, 
=CH and NH), 5.29-5.09 (m, 2 H, =CH2), 4.05 (br, 1 H, OH), 3.86 (t, J = 
5.5 Hz, 2 H), 3.63 (t, J = 6.2 Hz, 2 H), 2.21 (t, J = 7.3 Hz, 2 H), 1.73-1.51 
(m, 4 H), 1.45-1.34 (m, 2 H). 13C NMR (50 MHz, CDCl3): δ = 173.4 (s, 1 C, 
C=O), 133.8 (d, 1 C, =CH), 115.6 (t, 1 C, =CH2), 61.7 (t, 1 C, CH2), 41.5 (t, 
1 C, CH2), 36.0 (t, 1 C, CH2), 31.8 (t, 1 C, CH2), 25.1 (t, 1 C, CH2), 25.0 (t, 1 
C, CH2). MS: m/z (%) = 171 (3) [M]
+, 99 (40), 98 (18), 84 (16), 69 (38), 68 
(11), 57 (100), 56 (83), 55 (87). C9H17NO2 (171.13): calcd. C 63.13, H 10.01, 
N 8.18; found C 63.13, H 9.99, N 8.17. 
 
 
 
 
 
 
 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  6  
 
 
 137
N-allyl-4-hydroxydecanamide 
 
 
 
White solid 80% yield. M.p. 65-67°C. 1H NMR (200 MHz, CDCl3): δ = 
5.93-5.73 (m, 2 H, =CH and NH), 5.22-5.10 (m, 2 H, =CH2), 3.87 (t, J = 
5.9 Hz, 2 H), 3.62 (d, J = 5.9 Hz, 1 H), 2.75 (br, 1 H, OH), 2.37 (t, J = 6.9 
Hz, 2 H), 1.94-1.57 (m, 2 H), 1.42-1.27 (m, 10 H), 0.87 (t, J = 6.9 Hz, 3 H, 
CH3). 
13C NMR (50 MHz, CDCl3): δ = 173.8 (s, 1 C, C=O), 133.8 (d, 1 C, 
=CH), 115.5 (t, 1 C, =CH2), 70.6 (d, 1 C, CH), 41.5 (t, 1 C, CH2), 37.3 (t, 1 
C, CH2), 32.6 (t, 2 C, CH2), 31.5 (t, 1 C, CH2), 29.0 (t, 1 C, CH2), 25.4 (t, 1 
C, CH2), 22.3 (t, 1 C, CH2), 13.7 (q, 1 C, CH3). MS: m/z (%) = 227 (1) [M]
+, 
142 (30), 99 (57), 97 (26), 85 (15), 84 (15), 69 (13), 58 (60), 57 (100), 56 (43), 
54 (39). C13H25NO2 (227.19): calcd. C 68.68, H 11.08, N 6.16; found C 
68.66, H 10.09, N 6.14. 
 
 
N-allyl-5-hydroxydecanamide 
 
 
 
White solid 64% yield. M.p. 63-65°C. 1H NMR (200 MHz, CDCl3): δ = 
5.93-5.74 (m, 1 H, =CH), 5.61 (br, 1 H, NH), 5.22-5.10 (m, 2 H, =CH2), 
3.89 (t, J = 5.9 Hz, 2 H), 3.62-3.49 (m, 1 H), 2.24 (t, J = 6.9 Hz, 2 H), 1.84-
1.69 (m, 4 H), 1.53-1.29 (m, 10 H), 0.91-0.85 (m, 3 H, CH3). 
13C NMR (50 
MHz, CDCl3): δ = 173.3 (s, 1 C, C=O), 133.9 (d, 1 C, =CH), 115.3 (t, 1 C, 
=CH2), 70.5 (d, 1 C, CH), 41.4 (t, 1 C, CH2), 37.1 (t, 1 C, CH2), 36.2 (t, 1 C, 
CH2), 35.7 (t, 1 C, CH2) 31.6 (t, 1 C, CH2), 25.1 (t, 1 C, CH2), 22.3 (t, 1 C, 
CH2), 21.5 (t, 1 C, CH2), 13.7 (q, 1 C, CH3). MS: m/z (%) = 209 (2) [M -
H2O]
+, 156 (21), 99 (69), 98 (20), 84 (18), 71 (12), 69 (17), 58 (73), 57 (100), 
56 (45), 55 (46) C13H25NO2 (227.19): calcd. C 68.68, H 11.08, N 6.16; found 
C 68.69, H 10.09, N 6.15. 
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N-allyl-2,4-dihydroxybutanamide 
 
 
 
Yellow oil 46% yield. 1H NMR (200 MHz, CDCl3): δ = 7.35 (br, 1 H, NH), 
5.88-5.69 (m, 1 H, =CH), 5.19-5.06 (m, 2 H, =CH2), 4.24 (dd, J = 8.4, 3.3 
Hz, 1 H), 3.85-3.72 (m, 4 H), 2.09-1.94 (m, 1 H), 1.81-1.65 (m, 1 H). 13C 
NMR (50 MHz, CDCl3): δ = 174.9 (s, 1 C, C=O), 133.2 (d, 1 C, =CH), 
115.9 (t, 1 C, =CH2), 69.4 (d, 1 C, CH), 58.6 (t, 1 C, CH2), 41.1 (t, 1 C, 
CH2), 36.3 (t, 1 C, CH2). MS: m/z (%) = 159 (4) [M]
+, 115 (59), 114 (25), 85 
(25), 84 (24), 75 (26), 58 (69), 57 (100), 56 (53), 55 (13). C7H13NO3 (159.09): 
calcd. C 52.82, H 8.23, N 8.80; found C 52.81, H 8.24, N 8.82. 
 
 
(2R,3R)-N-allyl-2,3,4-trihydroxybutanamide 
 
 
 
White solid 6% yield. M.p. 73-76°C. 1H NMR (200 MHz, CD3OD): δ = 
6.83 (br, 1 H, NH), 5.94-5.75 (m, 1 H, =CH), 5.26-5.06 (m, 2 H, =CH2), 
4.12 (d, J = 4.8 Hz, 1 H), 3.89-3.82 (m, 3 H), 3.63 (d, J = 5.1 Hz, 2 H). 13C 
NMR (50 MHz, CD3OD): δ = 172.9 (s, 1 C, C=O), 132.9 (d, 1 C, =CH), 
115.9 (t, 1 C, =CH2), 72.5 (d, 1 C, CH), 71.5 (d, 1 C, CH), 62.0 (t, 1 C, 
CH2), 41.0 (t, 1 C, CH2). MS: m/z (%) = 175 (1) [M]
+, 144 (11), 115 (31), 
114 (13), 84 (22), 74 (73), 73 (14), 69 (10), 61 (26), 60 (11), 58 (29), 57 (43), 
56 (100), 55 (20). C7H13NO4 (175.08): calcd. C 47.99, H 7.48, N 8.00; found 
C 48.00, H 7.48, N 8.02. 
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(4R,5R)-N-allyl-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane-4-
carboxamide 
 
H
N
O
O
O
HO
6.23  
 
Yellow oil 93% yield. 1H NMR (200 MHz, CDCl3): δ = 6.86 (br, 1 H, NH), 
5.93-5.74 (m, 1 H, =CH), 5.24-5.14 (m, 2 H, =CH2), 4.67-4.49 (m, 2 H), 
3.97-3.87 (m, 1 H), 3.82-3.75 (m, 1 H), 3.64-3.55 (m, 2 H), 1.54 (s, 3 H, 
CH3), 1.39 (s, 3 H, CH3). 
13C NMR (50 MHz, CDCl3): δ = 169.9 (s, 1 C, 
C=O), 132.8 (d, 1 C, =CH), 116.1 (t, 1 C, =CH2), 109.7 (s, 1 C, Cquat), 76.9 
(d, 1 C, CH), 75.8 (d, 1 C, CH), 60.7 (t, 1 C, CH2), 40.8 (t, 1 C, CH2), 26.3 
(q, 1 C, CH3), 23.8 (q, 1 C, CH3). MS: m/z (%) = 215 (1) [M]
+, 131 (16), 115 
(11), 59 (100), 57 (22), 56 (21), 55 (13). C10H17NO4 (215.12): calcd. C 55.80, 
H 7.96, N 6.51; found C 55.79, H 7.96, N 6.50. 
 
 
N-allyl-2-(benzyloxy)-4-hydroxybutanamide 
 
 
 
Brown oil 99% yield. 1H NMR (200 MHz, CDCl3): δ = 7.37-7.34 (m, 5 H, 
Ar), 6.82 (br, 1 H, NH), 5.91-5.72 (m, 1 H, =CH), 5.21-5.11 (m, 2 H, 
=CH2), 4.58 (s, 2 H, CH2-Ph), 4.07 (t, J = 6.2 Hz, 1 H), 3.89 (t, J = 5.9 Hz, 
2 H), 3.74 (t, J = 5.9 Hz, 2 H), 2.84 (br, 1 H, OH) 2.10-1.96 (m, 2 H). 13C 
NMR (50 MHz, CDCl3): δ = 172.5 (s, 1 C, C=O), 136.5 (s, 1 C, Ar), 133.4 
(d, 1 C, =CH), 128.3 (d, 2 C, Ar), 127.9 (d, 1 C, Ar), 127.7 (d, 2 C, Ar), 
116.1 (t, 1 C, =CH2), 78.0 (d, 1 C, CH), 72.7 (t, 1 C, CH2), 58.8 (t, 1 C, 
CH2), 41.0 (t, 1 C, CH2), 35.4 (t, 1 C, CH2). MS: m/z (%) = 143 (13) [M -
PhCH2O]
+, 112 (12), 92 (23), 91 (100), 75 (11), 65 (16), 57 (10), 55 (8). 
C14H19NO3 (249.14): calcd. C 67.45, H 7.68, N 5.62; found C 67.43, H 7.69, 
N 5.61. 
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Methyl-2-(allylcarbamoyl)-4-hydroxybutanoate 
 
 
 
Yellow oil 80% yield. 1H NMR (200 MHz, CDCl3): δ = 6.08 (br, 1 H, NH), 
5.90-5.70 (m, 1 H, =CH), 5.20-5.08 (m, 2 H, =CH2), 4.26-4.20 (m, 1 H), 
3.84 (t, J = 5.9 Hz, 2 H), 3.75 (s, 3 H, OCH3), 2.41-2.10 (m, 3 H), 2.02-1.84 
(m, 1 H). 13C NMR (50 MHz, CDCl3): δ = 175.1 (s, 1 C, C=O), 173.3 (s, 1 
C, C=O), 133.2 (d, 1 C, =CH), 115.8 (t, 1 C, =CH2), 69.5 (d, 1 C, CH), 52.1 
(q, 1 C, OCH3), 41.6 (t, 1 C, CH2), 31.4 (t, 1 C, CH2), 29.3 (t, 1 C, CH2). 
MS: m/z (%) = 201 (1) [M]+, 142 (10), 113 (8), 99 (10), 85 (45), 58 (52), 57 
(100), 56 (55), 55 (14). C9H15NO4 (201.10): calcd. C 53.72, H 7.51, N 6.96; 
found C 53.72, H 7.50, N 6.98. 
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8.7. Experimental Section of 
Chapter 7 
 
General Procedure for the synthesis of 
isocyanoacetate 
To a solution of ethyl isocyanoacetate 7.1 (1 
eq) in dry DMSO (0.2 M) was added Cs2CO3 
(1.5 eq) and the mixture was stirred 10min at 
room temperature under an argon atmosphere. 
Then fluoro derivative (1-fluoro-4-nitrobenzene I, methyl-4-fluoro-
benzoate II, 4-fluorobenzonitrile III, 4-fluoropyridine HCl IV, 1-fluoro-2-
nitrobenzene V) (1.05 eq) was added and stirring was continued for 16h at 
room temperature. The mixture was washed with water extracted with 
EtOAc, then the organic layer was dried with Na2SO4, filtered and 
concentrated in vacuo. The crude was purified by column chromatography 
on silica gel (heptanes/EtOAc, 2:1) to give the desired compound. 
 
 
Methyl 2-isocyano-2-(4-nitrophenyl)acetate  
 
CN CO2Me
NO2
7.3  
 
Yellow solid, yield: 63%. 1H NMR (300 MHz, CDCl3): δ 3.85 (3H, s, 
OCH3), 5.53 (1H, s, CH), 7.72 (2H, d, J = 5.1 Hz, Ar-H), 8.32 (2H, d, J = 
5.1 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 53.4 (CH), 54.3 (CH3), 
124.4 (2 × CH), 127.8 (2 × CH), 137.9 (C), 148.7 (C), 163.6 (C), 164.8 (C) 
ppm. MS: m/z (ES+) 221 [M+H]+. IR (neat): ν = 2957, 2149, 1753, 1523, 
1347, 1212 cm-1. 
 
 
 
 
 
 
Novel four-component 
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Methyl 4-(2-ethoxy-1-isocyano-2-oxoethyl)benzoate  
 
CN CO2Et
CO2Me
7.4  
 
Yellow solid, yield: 58%. M.p. 65-67°C. 1H NMR (300 MHz, CDCl3): δ 
1.26 (3H, t, J = 7.1 Hz, CH3), 3.94 (3H, s, OCH3), 4.25 (2H, q, J = 7.1 Hz, 
CH2), 5.43 (1H, s, CH), 7.58 (2H, d, J = 8.4 Hz, Ar-H), 8.11 (2H, d, J = 8.4 
Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.8 (CH3), 52.4 (CH3), 60.1 
(CH), 63.4 (CH2), 126.7 (2 × CH), 130.3 (2 × CH), 131.3 (C), 136.2 (C), 
162.2 (C), 164.9 (C), 166.1 (C) ppm. MS: m/z (ES+) 248 [M+H]+. IR (neat): 
ν = 2993, 2152, 1754, 1708, 1271, 1210, 1190, 1112, 1013, 753 cm-1. 
 
 
Ethyl 2-(4-cyanophenyl)-2-isocyanoacetate  
 
CN CO2Et
CN
7.5  
 
Yellow oil, yield: 53%. 1H NMR (300 MHz, CDCl3): δ 1.25 (3H, t, J = 7.2 
Hz, CH3), 4.24 (2H, q, J = 7.2 Hz, CH2), 5.45 (1H, s, CH), 7.63 (2H, d, J = 
8.4 Hz, Ar-H), 7.73 (2H, d, J = 8.4 Hz, Ar-H) ppm. 13C NMR (75 MHz, 
CDCl3): δ 13.8 (CH3), 59.9 (CH), 63.6 (CH2), 113.6 (C), 117.9 (C), 127.5 (2 
× CH), 132.9 (2 × CH), 136.5 (C), 162.8 (C), 164.4 (C) ppm. MS: m/z (ES+) 
215 [M+H]+. IR (neat): ν = 2983, 2359, 2230, 2147, 1746, 1725, 1697, 1263, 
1205, 1018, 697 cm-1. 
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Ethyl 2-isocyano-2-(pyridin-4-yl)acetate 
 
N
CN CO2Et
7.6  
 
Purple solid, yield: 72%. The crude was used without further purification. 
1H NMR (300 MHz, CDCl3): δ 1.31 (3H, t, J = 7.0 Hz, CH3), 4.30 (2H, q, J 
= 7.0 Hz, CH2), 5.40 (1H, s, CH), 7.46 (2H, d, J = 5.8 Hz, Ar-H), 8.73 (2H, 
d, J = 5.8 Hz, Ar-H) ppm. 
 
 
Ethyl 2-isocyano-2-(2-nitrophenyl)acetate  
 
CN CO2Et
O2N
7.7  
 
Yellow oil, yield: 66%. 1H NMR (300 MHz, CDCl3): δ 1.22 (3H, t, J = 7.2 
Hz, CH3), 4.20 (2H, q, J = 7.2 Hz, CH2), 6.31 (1H, s, CH), 7.57 (1H, td, J = 
8.4 Hz, J = 1.5 Hz, Ar-H), 7.72 (1H, td, J = 8.1 Hz, J = 1.5 Hz, Ar-H), 7.80 
(1H, dd, J = 8.1 Hz, J = 1.5 Hz, Ar-H), 8.11 (1H, dd, J = 8.1 Hz, J = 1.5 
Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.8 (CH3), 57.4 (CH), 63.7 
(CH2), 125.7 (CH), 127.3 (C), 129.1 (CH), 130.5 (CH), 134.4 (CH), 147.8 
(C), 158.9 (C), 164.0 (C) ppm. MS: m/z (ES+) 235 [M+H]+. IR (neat): ν = 
2985, 2147, 1725, 1643, 1525, 1346, 1199, 1016 cm-1. 
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General Procedure for the three-component synthesis of 5-
ethoxyoxazoles 
To a solution of morpholine (1 eq) in dry toluene (1 M) was added the 
aldehyde (i-vi) (1 eq) and the mixture was stirred 10min at room 
temperature under an argon atmosphere. Ethyl-2-isocyano-2-(pyridin-4-
yl)acetate 7.6 (1 eq) was then added and stirring was continued for 16h at 
60°C. The solvent was removed in vacuo. The crude was purified by 
column chromatography on silica gel (EtOAc) to give the desired 
compound. 
 
 
4-(Cyclohexyl(5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)methyl) 
morpholine 
N
O
N
H
O
N
O
7.8
 
 
yellow oil, 81% yield. 1H NMR (300 MHz, CDCl3): δ 0.86-0.97 (2H, m, 
CH2), 1.14-1.37 (4H, m, 2 × CH2), 1.42 (3H, t, J = 6.9 Hz, OCH2CH3), 
1.63-1.93 (4H, m, 2 × CH2), 2.01-2.05 (1H, m, CHCHN), 2.36-2.55 (4H, m, 
2 × CH2N), 3.25 (1H, d, J = 10.5 Hz, CHN), 3.58-3.78 (4H, m, 2 × CH2O), 
4.34 (2H, q, J = 6.9 Hz, OCH2CH3), 7.62 (2H, d, J = 6.0 Hz, Ar-H), 8.48 
(2H, d, J = 6.0 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 15.1 
(OCH2CH3), 25.9 (CH2), 26.6 (CH2), 30.2 (2 × CH2), 30.5 (CH2), 36.6 (CH), 
49.9 (2 × CH2N), 67.3 (2 × CH2O), 68.5 (CHN), 69.4 (OCH2CH3), 111.7 
(C), 119.1 (2 × CH), 139.5 (C), 149.4 (2 × CH), 153.4 (C), 155.7 (C) ppm. 
MS: m/z (ES+) 372 [M+H]+. IR (neat): ν = 2922, 2849, 1631, 1602, 1114, 
1028, 1005, 829 cm-1. 
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4-(1-(5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)heptyl)morpholine  
 
N
O
N
H
O
N
O
7.9  
 
yellow oil, 54% yield. 1H NMR (300 MHz, CDCl3): δ 0.82-0.78 (3H, m, 
CH3), 1.18-1.25 (8H, m, 4 × CH2), 1.43 (3H, t, J = 7.2 Hz, OCH2CH3), 
1.77-1.86 (2H, m, CH2CHN), 2.43-2.59 (4H, m, 2 × CH2N), 3.54 (1H, t, J 
= 6.9 Hz, CHN), 3.61-3.66 (4H, m, 2 × CH2O), 4.37 (2H, q, J = 7.2 Hz, 
OCH2CH3), 7.63 (2H, d, J = 6.3 Hz, Ar-H), 8.49 (2H, d, J = 6.3 Hz, Ar-H) 
ppm. 13C NMR (75 MHz, CDCl3): δ 14.0 (CH3), 15.1 (OCH2CH3), 22.5 
(CH2), 26.2 (CH2), 29.0 (CH2), 29.7 (CH2CHN), 31.6 (CH2), 50.0 (2 × 
CH2N), 63.1 (CHN), 67.2 (2 × CH2O), 69.4 (OCH2CH3), 119.1 (2 × CH), 
128.5 (C), 139.6 (C), 149.3 (2 × CH), 153.9 (C), 155.7 (C) ppm. MS: m/z 
(ES+) 374 [M+H]+. IR (neat): ν = 2924, 2853, 1631, 1602, 1188, 1114, 1029, 
830 cm-1. 
 
 
4-((5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)(phenyl)methyl)morpholine 
 
N
O
N
H
O
N
O
7.10  
 
yellow oil, 50% yield. 1H NMR (300 MHz, CDCl3): δ 1.39 (3H, t, J = 6.9 
Hz, OCH2CH3), 2.32-2.50 (4H, m, 2 × CH2N), 3.66 (4H, m, 2 × CH2O), 
4.34 (2H, q, J = 6.9 Hz, OCH2CH3), 4.46 (1H, s, CHN), 7.24-7.31 (3H, m, 
Ar-H), 7.46 (2H, d, J = 6.6 Hz, Ar-H), 7.62 (2H, d, J = 5.4 Hz, Ar-H), 8.47 
(2H, d, J = 5.4 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 15.0 
(OCH2CH3), 51.8 (2 × CH2N), 66.9 (2 × CH2O), 69.4 (OCH2CH3), 69.5 
(CHN), 112.0 (C), 119.0 (2 × CH), 128.3 (C), 128.6 (3 × CH), 128.7 (2 × 
CH), 136.5 (C), 149.1 (2 × CH), 152.8 (C), 156.7 (C) ppm. MS: m/z (ES+) 
366 [M+H]+. IR (neat): ν = 2958, 2853, 2358, 1622, 1601, 1185, 1113, 1029, 
1003, 829, 698 cm-1. 
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4-(1-(5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)-2-phenylethyl) 
morpholine 
 
 
yellow oil, 53% yield. 1H NMR (300 MHz, CDCl3): δ 1.37 (3H, t, J = 6.9 
Hz, OCH2CH3), 2.49-2.69 (4H, m, 2 × CH2N), 3.11-3.27 (2H, m, CH2Ph), 
3.63-3.67 (4H, m, 2 × CH2O), 3.81 (1H, dd, J = 5.7 Hz, J = 3.6 Hz, CHN), 
4.29 (2H, q, J = 6.9 Hz, OCH2CH3), 7.09-7.16 (5H, m, Ar-H), 7.61 (2H, d, J 
= 6.3 Hz, Ar-H), 8.48 (2H, d, J = 5.7 Hz, Ar-H) ppm. 13C NMR (75 MHz, 
CDCl3): δ 15.1 (OCH2CH3), 36.1 (CH2Ph), 50.1 (2 × CH2N), 64.9 (CHN), 
67.1 (2 × CH2O), 69.5 (OCH2CH3), 119.1 (2 × CH), 126.5 (C), 128.3 (3 × 
CH), 129.1 (2 × CH), 138.6 (CH), 140.1 (C) 149.2 (2 × CH) 151.9 (C), 
156.2 (C) ppm. MS: m/z (ES+) 380 [M+H]+. IR (neat): ν = 2957, 2852, 
2359, 1625, 1602, 1186, 1112, 1028, 997, 830, 699 cm-1. 
 
 
4-(1-(5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)-2-methylpropyl) 
morpholine  
N
O
N
H
O
N
O
7.12  
 
yellow oil, 61% yield. 1H NMR (300 MHz, CDCl3): δ 0.79 (3H, d, J = 6.3 
Hz, CH3), 1.01 (3H, d, J = 6.3 Hz, CH3), 1.43 (3H, t, J = 7.2 Hz, 
OCH2CH3), 2.15-2.24 (1H, m, CH(CH3)2), 2.36-2.55 (4H, m, 2 × CH2N),  
3.12 (1H, d, J = 10.5 Hz, CHN), 3.60-3.66 (4H, m, 2 × CH2O), 4.36 (2H, q, 
J = 7.2 Hz, OCH2CH3), 7.64 (2H, d, J = 6.3 Hz, Ar-H), 8.49 (2H, d, J = 6.3 
Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 15.1 (OCH2CH3), 19.8 
(CH3), 19.9 (CH3), 27.4 (CH(CH3)2), 50.0 (2 × CH2N), 67.3 (2 × CH2O), 
69.4 (OCH2CH3), 69.7 (CHN), 109.8 (C), 119.1 (2 × CH), 127.7 (C), 149.2 
(2 × CH), 153.2 (C), 157.6 (C) ppm. MS: m/z (ES+) 332 [M+H]+. IR (neat): 
ν = 2959, 2852, 1604, 1529, 1187, 1113, 1011, 830 cm-1. 
 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  7  
 
 
 147
 (E)4-(1-(5-ethoxy-4-(pyridin-4-yl)oxazol-2-yl)-3-phenylallyl) 
morpholine  
N
O
N
H
O
N
O
7.13  
 
yellow oil, 54% yield. 1H NMR (300 MHz, CDCl3): δ 1.43 (3H, t, J = 6.9 
Hz, OCH2CH3), 2.42-2.65 (4H, m, 2 × CH2N), 3.67-3.70 (4H, m, 2 × 
CH2O), 4.12 (1H, d, J = 8.4 Hz, CHN), 4.40 (2H, q, J = 6.9 Hz, 
OCH2CH3), 6.33 (1H, d, J = 15.9 Hz, J = 8.4 Hz, CHCHN), 6.63 (1H, d, J 
= 15.9 Hz, CHPh), 7.20-7.35 (5H, m, Ar-H), 7.65 (2H, d, J = 6.0 Hz, Ar-
H), 8.49 (2H, d, J = 6.0 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 
15.1 (OCH2CH3), 51.3 (2 × CH2N), 66.9 (2 × CH2O), 67.1 (CHN), 69.7 
(OCH2CH3), 98.4 (CHCHN), 119.1 (2 × CH), 124.4 (C), 126.6 (3 × CH), 
128.3 (C), 128.7 (2 × CH), 135.1 (CHPh), 135.2 (C) 149.0 (2 × CH) 151.7 
(C), 154.3 (C) ppm. MS: m/z (ES+) 392 [M+H]+. IR (neat): ν = 2959, 2853, 
2359, 1633, 1602, 1185, 1112, 1028, 830, 697 cm-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E x p e r i m e n t a l  S e c t i o n  o f  C h a p t e r  7  
 
 
 148
General Procedure for the synthesis of acyl chloride 
To a solution of carboxylic acid (1 eq) in dry CH2Cl2 (0.32 M) oxalyl 
chloride (1.2 eq) and one drop of DMF were added. The reaction mixture 
was stirred for 1h at room temperature. The excess of reagent and solvent 
were distilled off and the acyl chloride was used without further 
purification. 
 
(E)-ethyl 4-chloro-4-oxobut-2-enoate   
 
 
 
78% yield. 1H NMR (300 MHz, CDCl3): δ 1.36 (3H, t, J = 7.2 Hz, CH3), 
4.32 (2H, q, J = 7.2 Hz, CH2), 7.01 (2H, d, J = 3.6 Hz, CH=CH), ppm. 
 
Cinnamoyl chloride   
 
 
81% yield. 1H NMR (300 MHz, CDCl3): δ 6.68 (1H, d, J = 15.6 Hz, CH), 
7.49-7.46 (3H, m, Ar-H), 7.60 (2H, d, J = 6.3 Hz, Ar-H), 7.85 (1H, d, J = 
15.6 Hz, CH), ppm. 
 
(Z)-ethyl 4-chloro-4-oxobut-2-enoate   
 
 
A solution of maleic anhydride (1 eq) in ethanol (0.77 M), was heated for 
1h to reflux. The solvent was distilled and the residue was dissolved in 
CH2Cl2 (0.32 M), then oxalyl chloride (1.2 eq) and one drop of DMF were 
added. The reaction mixture was stirred for 1h at room temperature. The 
excess of reagent and solvent were distilled off and the (Z)-ethyl-4-chloro-
4-oxobut-2-enoate was used without further purification (80% yield). 
1H NMR (300 MHz, Acetone-d6): δ = 1.33 (t, J = 7.2 Hz, 3 H, CH3), 4.2 (q, 
J = 7.2 Hz, 2 H, CH2), 6.41 (d, J = 11.4 Hz, 1 H, CH), 6.88 (d, J = 11.4 Hz, 
1 H, CH) ppm. 
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General Procedure for the four-component synthesis with 
methyl 4-(2-ethoxy-1-isocyano-2-oxoethyl)benzoate 7.4 
To a solution of amine (1 eq) in dry toluene (1 M) was added the aldehyde 
(1 eq) and the mixture was stirred 10min at room temperature under an 
argon atmosphere. Methyl 4-(2-ethoxy-1-isocyano-2-oxoethyl)benzoate (1 
eq) was then added and stirring was continued for 7h at r.t, then the 
mixture was cooled at 0°C and TEA (5 eq) followed by a solution of  acyl 
chloride (2.2 eq) in dry toluene (0.15M) were added. The reaction was 
allowed to warm up to room temperature and then it was heated to reflux 
for 20 min. The solvent was removed in vacuo. The crude was purified by 
column chromatography on silica gel (heptanes/EtOAc, 1:2) to give the 
desired compound. 
 
 
 
 
yellow solid, 68% yield, 13:1 mixture of diastereomers. 1H NMR (300 MHz, 
CDCl3): δ 1.04 (3H, t, J = 7.2 Hz, COCH2CH3), 1.29-1.32 (2H, m, CH2), 
1.35 (3H, t, J = 7.2 Hz, OCH2CH3), 1.74-1.98 (8H, m, 4 × CH2), 2.02-2.04 
(1H, m, CHCHN), 3.28 (1H, d, J = 4.2 Hz, CHCHCO2Et), 3.55 (1H, d, J = 
4.2 Hz, CHCHCO2Et), 3.63 (1H, d, J = 3.6 Hz, CHN), 3.72-3.77 (1H, m, 
OCH2CH3), 3.92-3.96 (2H, m, COCH2CH3), 3.95 (3H, s, OCH3), 3.97-4.04 
(1H, m, OCH2CH3), 4.19 (1H, d, J = 15.3 Hz, CH2Ph), 5.10 (1H, d, J = 
15.3 Hz, CH2Ph), 7.27-7.34 (5H, m, Ar-H), 8.07 (4H, br, Ar-H) ppm. 
13C 
NMR (75 MHz, CDCl3): δ 13.9 (COCH2CH3), 15.2 (OCH2CH3), 26.3 
(CH2), 26.5 (CH2), 26.7 (CH2), 27.6 (CH2), 28.4 (CH2), 38.8 (CHCHN), 45.5 
(CH2Ph), 46.2 (CHCHCO2Et), 52.3 (OCH3), 53.7 (CHCHCO2Et), 61.2 
(COCH2CH3), 63.7 (OCH2CH3), 64.1 (CHN), 99.7 (C), 113.6 (C), 127.6 (3 
× CH), 127.9 (2 × CH), 128.6 (2 × CH), 129.5 (2 × CH), 132.5 (C), 134.5 
(C), 135.9 (C), 166.4 (C), 168.5 (C), 171.5 (C), 172.0 (C) ppm. MS: m/z 
(ES+) 597 [M+Na]+. IR (neat): ν = 2928, 2854, 1723, 1693, 1272, 1180, 
1104, 1018, 699 cm-1. 
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With (E)-ethyl 4-chloro-4-oxobut-2-enoate (1.8:1) and (Z)-ethyl 4-chloro-4-
oxobut-2-enoate (1.8:1) 
yellow oil, 58% yield, 1.8:1 mixture of diastereomers. 1H NMR (300 MHz, 
CDCl3): δ 1.04-1.15 (3H, m, COCH2CH3 major and minor), 1.27 (3H, t, J = 
7.2 Hz, OCH2CH3 minor), 1.36 (3H, t, J = 6.9 Hz, OCH2CH3 major), 3.31 
(1H, d, J = 4.2 Hz, CHCHCO2Et minor), 3.36 (1H, d, J = 3.9 Hz, 
CHCHCO2Et major), 3.51 (1H, d, J = 14.7 Hz, CH2Ph minor), 3.56-3.59  
(2H, m, CHCHCO2Et and OCH2CH3), 3.66-3.72 (2H, COCH2CH3), 3.78-
3.80 (1H, m, CH2Ph major), 3.82 (3H, s, OCH3), 3.92-3.98 (1H, m, 
OCH2CH3), 4.75 (1H, s, CHN), 5.13-5.23 (2H, m, CH2Ph major and 
minor), 6.90-6.91 (1H, m, Ar-H, minor), 7.11 (2H, d, J = 6.0 Hz, Ar-H, 
major and minor), 7.18-7.24 (6H, m, Ar-H major and minor), 7.30-7.31 
(2H, m, Ar-H major and minor), 7.38-7.41 (2H, m, Ar-H major and minor), 
7.83-7.95 (5H, m, Ar-H major and minor) ppm. 13C NMR (75 MHz, 
CDCl3): δ 13.8 (COCH2CH3 minor), 13.9 (COCH2CH3 major), 15.1 
(OCH2CH3 minor), 15.2 (OCH2CH3 major), 44.2 (CH2Ph minor), 44.7 
(CH2Ph major), 46.0 (CHCHCO2Et minor), 46.1 (CHCHCO2Et major), 
52.1 (CHCHCO2Et major), 52.3 (OCH3), 54.0 (CHCHCO2Et minor), 61.6 
(COCH2CH3), 63.4 (CHN minor), 63.5 (CHN major), 63.9 (OCH2CH3 
major), 64.0 (OCH2CH3 minor), 99.3 (C minor), 99.7 (C major), 114.3 (C 
major), 114.5 (C minor), 127.4 (CH), 127.6 (CH), 127.7 (CH), 127.8 (CH), 
128.0 (CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 128.8 (CH), 129.0 (CH), 
129.4 (CH), 129.5 (CH), 131.6 (C minor), 132.6 (C major), 132.7 (C minor), 
133.6 (C major), 134.2 (C major), 135.3 (C major), 135.5 (C minor), 166.2 
(C minor), 166.3 (C major), 168.1 (C minor), 168.2 (C major), 171.4 (C 
minor), 171.5 (C major), 172.0 (C major), 172.5 (C minor) ppm. MS: m/z 
(ES+) 591 [M+Na]+. IR (neat): ν = 2981, 1722, 1697, 1273, 1181, 1108, 
1018, 729, 698 cm-1. 
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65% yield, 2:1 mixture of separated diastereomers. 
Major, white solid 
M.p. 86-89°C. 1H NMR (300 MHz, CDCl3): δ 0.94-0.98 (6H, m, 2 × CH3), 
1.10 (3H, t, J = 7.2 Hz, COCH2CH3), 1.33 (3H, t, J = 7.2 Hz, OCH2CH3), 
1.35-1.39 (6H, m, 3 × CH2), 1.54-1.61 (6H, m, 3 × CH2), 1.90-2.11 (2H, m, 
NCHCH2), 2.97-3.06 (1H, m, NCH2), 3.21 (1H, d, J = 4.2 Hz, 
CHCHCO2Et), 3.48 (1H, d, J = 4.2 Hz, CHCHCO2Et), 3.66-3.77 (2H, m, 
NCH2 and OCH2CH3), 3.83-3.86 (1H, m, CHN), 3.88-3.93 (2H, m, 
COCH2CH3), 3.95 (3H, s, OCH3), 3.97-4.07 (1H, m, OCH2CH3), 8.07 (4H, 
br Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.7 (CH3), 13.8 (CH3), 14.0 
(COCH2CH3), 15.2 (OCH2CH3), 19.9 (CH2), 22.5 (CH2), 25.1 (CH2), 29.2 
(NCHCH2), 29.3 (2 × CH2), 31.6 (CH2), 41.0 (CH2N), 45.7 (CHCHCO2Et), 
52.3 (OCH3), 52.7 (CHCHCO2Et), 59.9 (CHN), 61.5 (COCH2CH3), 63.7 
(OCH2CH3), 99.7 (C), 114.1 (C), 127.6 (2 × CH), 129.5 (2 × CH), 134.6 
(C), 166.4 (C), 168.5 (C), 170.8 (C), 170.9 (C), 182.3 (C) ppm. 
Minor, colourless oil 
1H NMR (300 MHz, CDCl3): δ 0.78-0.82 (3H, m, CH3), 0.88 (3H, t, J = 7.2 
Hz, CH3), 0.96 (3H, t, J = 7.2 Hz, COCH2CH3), 1.18-1.22 (6H, m, 3 × 
CH2), 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 1.53-1.54 (6H, m, 3 × CH2), 
1.73-1.84 (2H, m, NCHCH2), 2.84-2.93 (1H, m, NCH2), 3.13 (1H, d, J = 
4.5 Hz, CHCHCO2Et), 3.41 (1H, d, J = 4.5 Hz, CHCHCO2Et), 3.66-3.83 
(4H, m, OCH2CH3, COCH2CH3 and NCH2), 3.87 (3H, s, OCH3), 3.94-3.97 
(1H, m, OCH2CH3), 4.32 (1H, dd, J = 3.9 Hz, J = 10.8 Hz, CHN), 8.07 
(4H,br, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.8 (2 × CH3), 14.0 
(COCH2CH3), 15.2 (OCH2CH3), 20.0 (CH2), 22.5 (CH2), 24.8 (CH2), 27.4 
(NCHCH2), 29.3 (CH2), 29.4 (CH2), 31.5 (CH2), 39.3 (CH2N), 44.5 
(CHCHCO2Et), 52.4 (OCH3), 53.4 (CHCHCO2Et), 58.4 (CHN), 61.5 
(COCH2CH3), 63.7 (OCH2CH3), 99.5 (C), 114.4 (C), 127.5 (2 × CH), 129.6 
(2 × CH), 132.6 (C), 134.5 (C), 166.3 (C), 168.3 (C), 170.7 (C), 171.2 (C) 
ppm. 
MS: m/z (ES+) 565 [M+Na]+. IR (neat): ν = 2928, 2858, 1725, 1692, 1273, 
1183, 1108, 1032, 1015, 980, 958, 927 cm-1. 
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yellow solid, 61% yield, 2.5:1 mixture of diastereomers. 1H NMR (300 
MHz, CDCl3): δ 1.13 (3H, t, J = 6.9 Hz, OCH2CH3 minor), 1.21 (3H, t, J = 
6.9 Hz, OCH2CH3 major), 3.34 (1H, d, J = 3.9 Hz, CHCHPh minor), 3.36-
3.37 (1H, m, OCH2CH3 minor), 3.40 (1H, d, J = 3.9 Hz, CHCHPh major), 
3.45-3.50 (1H, m, OCH2CH3 major), 3.64 (1H, d, J = 14.7 Hz, CH2Ph 
minor), 3.64-3.70 (1H, m, OCH2CH3 minor), 3.81-3.85 (2H, m, CH2Ph 
major and OCH2CH3 major), 3.86 (3H, s, OCH3), 3.96 (2H, d, J = 3.9 Hz, 
CHCHPh major and minor), 4.91 (1H, s, CHN), 5.25-5.38 (2H, m, CH2Ph 
major and minor), 7.05-7.10 (8H, m, Ar-H major and minor), 7.20 (2H, d, J 
= 8.1 Hz, Ar-H major), 7.26-7.41 (13H, m, Ar-H major and minor), 7.48-
7.53 (4H, m, Ar-H major and minor), 7.70-7.76 (3H, m, Ar-H major) ppm. 
13C NMR (75 MHz, CDCl3): δ 15.1 (OCH2CH3 minor), 15.2 (OCH2CH3 
major), 44.2 (CH2Ph minor), 44.7 (CH2Ph major), 48.1 (CHCHPh minor), 
48.3 (CHCHPh major), 52.2 (OCH3), 53.4  (CHCHPh major), 55.4 
(CHCHPh minor), 63.6 (CHN), 64.0 (OCH2CH3 major), 64.1 (OCH2CH3 
minor), 99.4 (C minor), 100.0 (C major), 116.1 (C major), 116.3 (C minor), 
127.0 (CH), 127.1 (CH), 127.5 (CH), 127.7 (CH), 128.0 (CH), 128.2 (CH), 
128.3 (CH), 128.6 (CH), 128.7 (CH), 128.8 (CH), 128.9 (CH), 129.1 (CH), 
129.7 (CH), 131.9 (C major), 132.0 (C minor), 134.0 (C), 134.4 (C minor), 
134.6 (C major), 134.8 (C minor), 135.0 (C major), 135.6 (C major), 135.8 
(C minor), 166.2 (C minor), 166.3 (C major), 172.3 (C minor), 172.5 (C 
major), 174.9 (C major), 175.0 (C minor) ppm. MS: m/z (ES+) 595 
[M+Na]+. IR (neat): ν = 2949, 1697, 1273, 1109, 729, 696 cm-1. 
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General Procedure for the four-component synthesis with ethyl 
2-(4-cyanophenyl)-2-isocyanoacetate 7.5 
To a solution of amine (1 eq) in dry toluene (1 M) was added the aldehyde 
(1 eq) and the mixture was stirred 10min at room temperature under an 
argon atmosphere. Ethyl 2-(4-cyanophenyl)-2-isocyanoacetate (1 eq) was 
then added and stirring was continued for 4h at r.t, then the mixture was 
cooled at 0°C and TEA (5 eq) followed by a solution of  acyl chloride (2.2 
eq) in dry toluene (0.15M) were added. The reaction was allowed to warm 
up to room temperature and then it was heated to reflux for 20 min. The 
solvent was removed in vacuo. The crude was purified by column 
chromatography on silica gel (heptanes/EtOAc, 1:2) to give the desired 
compound. 
 
 
N
O
O
O O
N
O
CN
7.19  
 
yellow oil, 54% yield, 20:1 mixture of diastereomers. 1H NMR (300 MHz, 
CDCl3): δ 1.05 (3H, t, J = 7.2 Hz, COCH2CH3), 1.18 (2H, m, CH2), 1.27 
(3H, t, J = 6.9 Hz, OCH2CH3), 1.40-1.81 (8H, m, 4 × CH2), 1.81-1.97 (1H, 
m, CHCHN), 3.16 (1H, d, J = 4.2 Hz, CHCHCO2Et), 3.48 (1H, d, J = 4.2 
Hz, CHCHCO2Et), 3.54 (1H, d, J = 3.3 Hz, CHN), 3.62-3.72 (1H, m, 
OCH2CH3), 3.86 (2H, q, J = 7.2 Hz,  COCH2CH3), 3.91-3.99 (1H, m, 
OCH2CH3), 4.11 (1H, d, J = 15.3 Hz, CH2Ph), 5.02 (1H, d, J = 15.3 Hz, 
CH2Ph), 7.17-7.28 (5H, m, Ar-H), 7.62 (2H, d, J = 8.4 Hz, Ar-H), 8.04 (2H, 
d, J = 8.4 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.9 
(COCH2CH3), 15.2 (OCH2CH3), 26.4 (CH2), 26.7 (CH2), 27.6 (CH2), 28.4 
(CH2), 29.2 (CH2), 38.8 (CHCHN), 45.5 (CH2Ph), 45.8 (CHCHCO2Et), 
53.7 (CHCHCO2Et), 61.7 (COCH2CH3), 63.6 (OCH2CH3), 64.1 (CHN), 
99.8 (C), 113.4 (C), 114.9 (C), 118.2 (C), 127.6 (CH), 127.9 (2 × CH), 128.3 
(2 × CH), 128.6 (2 × CH), 132.1 (2 × CH), 134.5 (C), 135.8 (C), 168.6 (C), 
171.0 (C), 171.7 (C) ppm. MS: m/z (ES+) 564 [M+Na]+. IR (neat): ν = 2928, 
2854, 2229, 1731, 1693, 1272, 1181, 1041, 699 cm-1. 
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O
O
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N
O
MeO2C
CN
7.20  
 
yellow solid, 45% yield, 6:1 mixture of diastereomers. 1H NMR (300 MHz, 
CDCl3): δ 0.97 (3H, t, J = 7.2 Hz, COCH2CH3 minor), 1.04 (3H, t, J = 7.2 
Hz, COCH2CH3 major), 1.18 (2H, m, CH2), 1.26 (3H, t, J = 6.9 Hz, 
OCH2CH3), 1.42-1.89 (8H, m, 4 × CH2), 1.93-1.97 (1H, m, CHCHN), 3.12 
(1H, d, J = 4.2 Hz, CHCHCO2Et major), 3.19 (1H, d, J = 4.5 Hz, 
CHCHCO2Et minor), 3.39 (1H, d, J = 4.5 Hz, CHCHCO2Et minor), 3.43 
(1H, d, J = 4.2 Hz, CHCHCO2Et major), 3.54 (1H, d, J = 18.0 Hz, NCH2 
minor), 3.68-3.71 (1H, m, OCH2CH3), 3.71 (3H, s, OCH3), 3.75 (1H, d, J = 
3.3 Hz, CHN), 3.85 (2H, q, J = 7.2 Hz, COCH2CH3), 3.92-4.02 (2H, m, 
OCH2CH3 and NCH2 major), 4.19 (1H, d, J = 17.4 Hz, NCH2 major), 4.70 
(1H, d, J = 18.0 Hz, NCH2 minor), 7.63 (2H, d, J = 8.4 Hz, Ar-H), 8.06 
(2H, d, J = 8.4 Hz, Ar-H) ppm. 13C NMR (75 MHz, CDCl3): δ 13.9 
(OCH2CH3), 15.1 (COCH2CH3), 26.3 (CH2), 26.5 (CH2 minor), 26.6 (CH2), 
27.5 (CH2), 28.2 (CH2), 29.2 (CH2 minor), 29.3 (CH2), 29.7 (CH2 minor), 
31.7 (CH2 minor), 39.1 (CHCHN), 41.9 (NCH2 minor), 44.0 (NCH2 major), 
44.6 (CHCHCO2Et minor), 45.6 (CHCHCO2Et major), 52.3 (OCH3 
major), 52.4 (OCH3 minor), 53.1 (CHCHCO2Et major), 53.9 
(CHCHCO2Et minor), 61.7 (OCH2CH3), 63.6 (COCH2CH3), 66.4 (CHN), 
99.6 (C), 113.4 (C), 114.7 (C), 118.2 (C), 128.3 (2 × CH), 132.1 (2 × CH), 
134.5 (C), 168.4 (C), 168.6 (C), 171.1 (C), 171.8 (C) ppm. MS: m/z (ES+) 
546 [M+Na]+. IR (neat): ν = 2928, 2853, 2229, 1733, 1701, 1275, 1205, 
1179, 1017, 845 cm-1. 
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General Procedure for the four-component synthesis with ethyl 
2-isocyano-2-(2-nitrophenyl)acetate 7.7 
To a solution of amine (1 eq) in dry toluene (1 M) was added the aldehyde 
(1 eq) and the mixture was stirred 10min at room temperature under an 
argon atmosphere. Ethyl 2-isocyano-2-(2-nitrophenyl)acetate (1 eq) was 
then added and stirring was continued for 1h at r.t, then the mixture was 
cooled at 0°C and TEA (5 eq) followed by a solution of  acyl chloride (2.2 
eq) in dry toluene (0.15M) were added. The reaction was allowed to warm 
up to room temperature and then it was heated to reflux for 20 min. The 
solvent was removed in vacuo. The crude was purified by column 
chromatography on silica gel (heptanes/EtOAc, 1:2) to give the desired 
compound. 
 
 
N
O
O
O O
N
O
O2N
7.21  
 
White solid, 57% yield. M.p. 82-84°C.  1H NMR (300 MHz, CDCl3): δ 0.91 
(3H, t, J = 7.2 Hz, COCH2CH3), 1.18-1.19 (2H, m, CH2), 1.20 (3H, t, J = 
6.9 Hz, OCH2CH3), 1.39-1.73 (8H, m, 4 × CH2), 1.85-1.94 (1H, m, 
CHCHN), 3.21 (1H, d, J = 4.2 Hz, CHCHCO2Et), 3.43 (1H, d, J = 4.2 Hz, 
CHCHCO2Et), 3.61 (1H, d, J = 3.3 Hz, CHN), 3.67-3.72 (1H, m, 
OCH2CH3), 3.78-3.82 (2H, m, COCH2CH3), 3.88-3.93 (1H, m, OCH2CH3), 
4.09 (1H, d, J = 15.3 Hz, CH2Ph), 4.99 (1H, d, J = 15.3 Hz, CH2Ph), 7.16-
7.28 (5H, m, Ar-H), 7.47-7.56 (2H, m, Ar-H), 7.63-7.70 (2H, m, Ar-H) 
ppm. 13C NMR (75 MHz, CDCl3): δ 13.7 (COCH2CH3), 14.9 (OCH2CH3), 
26.1 (CH2), 26.5 (CH2), 26.6 (CH2), 27.3 (CH2), 28.0 (CH2), 38.7 (CHCHN), 
44.3 (CHCHCO2Et), 45.4 (CH2Ph), 52.9 (CHCHCO2Et), 61.4 
(COCH2CH3), 63.0 (OCH2CH3), 64.2 (CHN), 100.1 (C), 112.9 (C), 123.6 
(CH), 124.5 (C), 127.5 (CH), 127.9 (2 × CH), 128.6 (2 × CH), 130.9 (CH), 
131.4 (CH), 131.7 (CH), 135.8 (C), 149.7 (C), 168.4 (C), 170.4 (C), 171.7 (C) 
ppm. MS: m/z (ES+) 584 [M+Na]+. IR (neat): ν = 2926, 2853, 1730, 1692, 
1536, 1357, 1280, 1181, 1030, 699 cm-1. 
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yellow oil, 54% yield. 1H NMR (300 MHz, CDCl3): δ 0.84-0.92 (6H, m, 
CH3 and COCH2CH3), 1.17-1.27 (9H, m, OCH2CH3 and 3 × CH2), 1.34-
1.50 (4H, m, 2 × CH2), 1.50-1.78 (4H, m, 2 × CH2), 1.91-1.97 (1H, m, 
CHCHN), 2.91-3.00 (1H, m, NCH2), 3.13 (1H, d, J = 4.2 Hz, 
CHCHCO2Et), 3.35 (1H, d, J = 4.2 Hz, CHCHCO2Et), 3.63-3.80 (5H, m, 
CHN, COCH2CH3, OCH2CH3 and NCH2), 3.87-3.92 (1H, m, OCH2CH3), 
7.50-7.53 (2H, m, Ar-H), 7.70-7.72 (2H, m, Ar-H) ppm. 13C NMR (75 
MHz, CDCl3): δ 13.7 (CH3), 14.8 (COCH2CH3), 19.9 (OCH2CH3), 26.2 
(CH2), 26.6 (2 × CH2), 26.7 (CH2), 27.3 (CH2), 28.1 (CH2), 29.0 (CH2), 38.9 
(CHCHN), 41.5 (NCH2), 44.2 (CHCHCO2Et), 53.0 (CHCHCO2Et), 61.3 
(COCH2CH3), 62.9 (CHN), 64.5 (OCH2CH3), 100.2 (C), 112.9 (C), 123.6 
(CH), 124.5 (C), 130.9 (CH), 131.4 (CH), 131.7 (CH), 149.8 (C), 168.5 (C), 
170.5 (C), 171.3 (C) ppm. MS: m/z (ES+) 550 [M+Na]+. IR (neat): ν = 2926, 
2853, 1731, 1693, 1536, 1356, 1280, 1181, 1030, 699 cm-1. 
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yellow solid, 65% yield, 10:1 mixture of diastereomers. 1H NMR (300 MHz, 
CDCl3): δ 0.88 (3H, t,  J = 7.2 Hz, CH3), 1.11 (3H, t, J = 7.2 Hz, 
OCH2CH3), 1.18-1.78 (14H, m, 7 × CH2), 1.93-1.97 (1H, m, CHCHN), 
2.93-2.98 (1H, m, NCH2), 3.01 (1H, d, J = 4.5 Hz, CHCHPh), 3.44-3.54 
(1H, m, OCH2CH3), 3.59-3.65 (1H, m, NCH2), 3.67-3.69 (1H, m, CHN and 
CHCHPh), 3.79-3.89 (1H, m, OCH2CH3), 6.27 (1H, dd, J = 7.8 Hz, J = 0.9 
Hz, Ar-H), 6.94-7.00 (3H, m, Ar-H), 7.06-7.08 (3H, m, Ar-H), 7.29 (1H, td, 
J = 7.8 Hz, J = 0.9 Hz, Ar-H), 7.42 (1H, dd, J = 7.8 Hz, J = 0.9 Hz, Ar-H) 
ppm. 13C NMR (75 MHz, CDCl3): δ 13.8 (CH3), 15.2 (OCH2CH3), 19.9 
(CH2), 26.2 (CH2), 26.5 (CH2), 26.8 (CH2), 26.9 (CH2), 28.3 (CH2), 29.1 
(CH2) 38.8 (CHCHN), 41.3 (NCH2), 47.9 (CHCHPh), 54.6 (CHCHPh), 
63.9 (OCH2CH3), 64.7 (CHN), 100.1 (C), 115.4 (C), 123.0 (CH), 123.8 (C), 
127.6 (2 × CH), 128.4 (3 × CH), 129.6 (CH), 130.2 (CH), 130.8 (CH), 
135.1 (C), 149.4 (C), 170.7 (C), 172.0 (C) ppm. MS: m/z (ES+) 554 
[M+Na]+. IR (neat): ν = 2929, 2854, 1681, 1537, 1370, 1260, 1036, 848, 
777, 701 cm-1. 
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